Fatigue and prostate cancer by Storey, Dawn Jane
Fatigue and Prostate Cancer
Dawn J. Storey
M.D. The University of Edinburgh - 2007
Declaration
I hereby declare that this thesis is ofmy own composition. I conducted all aspects of
the studies described, including protocol writing, ethics submissions, recruitment,
data collection and analysis, except where acknowledged. This work has not been
submitted previously for a higher degree. It was carried out in the Edinburgh Cancer
Centre, the University of Edinburgh Cancer Research Centre and the Queen









Chapter 1 Introduction. Fatigue and Cancer 1
Chapter 2 Introduction. Prostate Cancer and Fatigue 16
Chapter 3 Aims 31
Chapter 4 General Methods. Measurement of Fatigue 33
Chapter 5 General Methods. Other Measures 45
Chapter 6 Study A. Fatigue In Men Undergoing Treatment For
Localised Prostate Cancer:
A Prospective Observational Study 52
Chapter 7 Study B Fatigue In Men Undergoing Brachytherapy
For Localised Prostate Cancer:
A Prospective Observational Study 85
Chapter 8 Study C Fatigue In Recurrence Free Prostate
Cancer Survivors:
A Cross Sectional Study 120
Chapter 9 Study D Fatigue In Men With Hormone Controlled
Prostate Cancer:
A Cross Sectional Study 141





Fatigue is increasingly recognised as one of the most common, debilitating and
distressing symptoms experienced by cancer patients. As an oncologist I became
acutely aware of this, especially as it was often associated with the treatments I
administered. Some patients complained that their fatigue severely impeded their
ability to carry out self care, fulfil their responsibilities or interact with their family
and friends. This often led to feelings of frustration, inadequacy and isolation. In an
attempt to find something that would help these patients, I started searching the
literature. It quickly became clear that fatigue was poorly understood and research
was in its early stages. In comparison twenty five years ago, nausea, vomiting and
pain were the most troublesome symptoms that affected cancer patients. Thankfully
however, due to improved understanding of the underlying mechanisms and
subsequent development of new treatments, these symptoms are much better
controlled. In the hope that similar advances will be made with fatigue, I was
inspired to embark on this research project.
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Fatigue is a common and debilitating problem for cancer patients. It is associated
with cancer or its treatment. Evidence suggests fatigue may be prolonged after
treatment for some cancers and could be associated with a host systemic
inflammatory response. Prostate cancer is the commonest male cancer however little
is known about fatigue and its associations in this population.
Aims
To explore the incidence of fatigue and its associations during and after treatment for
prostate cancer.
Methods
Four studies were conducted: Study A, was a pilot study which examined fatigue
over 3 months after different treatments for localised prostate cancer (radiotherapy,
brachytherapy and androgen deprivation, n=45). Study B focussed on fatigue over 12
months after brachytherapy (n=51). Two cross sectional postal surveys explored
fatigue in recurrence free prostate cancer survivors (Study C, n=443) and hormone
controlled prostate cancer (Study D, n=198). Throughout, fatigue was assessed using
the Brief Fatigue Inventory and a case definition of clinically significant fatigue
(CSF) was also constructed and applied in Studies A and B.
Results
Study A found CSF increased after treatment but returned to baseline 3 months after
radiotherapy, whereas it appeared to be prolonged after brachytherapy. CSF was not
associated with C reactive protein or interleukin-6. Study B found CSF increased
between baseline and 1 month after brachytherapy (6 vs. 29%, p=0.001) and was
higher than the non-cancer comparison group (29 vs. 4% p=0.001). CSF returned
towards baseline levels by 6 months. There were no baseline predictors of
developing CSF. Study C found 29% of recurrence free prostate cancer survivors had
fatigue after radiotherapy or radical prostatectomy (33 vs. 22% p=0.024) but it was
not independently associated with treatment received after controlling for other
factors. 43% ofmen with hormone controlled prostate cancer had fatigue in Study D.
v
Conclusions
Fatigue is an important symptom in men treated for prostate cancer but resolves
within months of brachytherapy. Almost one third of recurrence free survivors have
fatigue but it does not appear to be related to the type of treatment received. Fatigue
is most prevalent in men with hormone controlled prostate cancer.
vi
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Chapter 1 2
Fatigue and Cancer
1.1 WHAT IS FATIGUE?
Fatigue is a subjective experience which can be normal or abnormal. For healthy
people, fatigue can be a protective, even pleasant response to physical or
psychological stress. It disappears after a good nights' rest and appears to regulate a
healthy balance between rest and activity. When fatigue is abnormal, the individual
finds it a problem and it becomes a symptom. Many medical conditions are
associated with fatigue (Belza et al. 1993;Ream & Richardson 1997;Chaudhuri &
Behan 2004;Theander & Unosson 2004;Appels 2004) and cancer patients describe a
longer lasting, more intense, unpleasant, distressing experience that limits life
activities and tends to be present throughout the day (Holley 2000a;Servaes et al.
2002a). In this thesis I am going to address this important topic.
1.1.1 The definition of fatigue for research
There is currently no universally agreed definition of fatigue. It has many synonyms
including tiredness, lethargy, weakness, exhaustion or lack of energy. For research
purposes, in order to define when fatigue is abnormal there have been attempts to
make distinctions between the concepts of fatigue and normal tiredness. Criteria used
include severity and duration (overwhelming and sustained) and its lack of response
to actions that typically provide relief from tiredness (not relieved by rest). Others
simply view normal fatigue as acute, and pathological fatigue as chronic (Piper
1989;Carpenito 1992;Woo 1995;Ream & Richardson 1996;Tiesinga et al.
1996;Krishnasamy 2000;Trendall 2000). The lack of definition is not a new problem;
almost a century ago Muscio was of the strong opinion that "the term fatigue be
absolutely banished from scientific discussion" (Muscio 1921)
Perhaps one of the factors contributing to this confusion is that different researchers
have approached fatigue according to their own research specialty. Fatigue has been
of interest in the fields of ergonomics, physiology, psychology and medicine.
Physiologists refer to functional organ failure or poor physical performance, viewing
physical insufficiencies as indicators of neuromuscular or metabolic disorders
(Gibson & Edwards 1985;Lewis & Haller 1991). Psychologists tend to refer to
suboptimal mental performance including poor concentration and decreased
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motivation (Lee et al. 1991). In medicine, there is also and added layer of complexity
because of a tendency for disease specialists to appropriate fatigue as a disease
specific entity. In the oncology literature the term 'Cancer Related Fatigue' is
commonly used. The National Comprehensive Cancer Network uses the following
definition:
Cancer related fatigue is a persistent, subjective sense of
tiredness related to cancer and cancer treatment that
interferes with usualfunctioning (NCCN 2006)
This definition has the characteristics of emphasising the subjectivity of the
sensation, the chronicity and interference with usual functioning. It also involves
attributing the cause of fatigue to cancer or its treatment. In practice this can be very
difficult and perhaps premature. It does not include features that some imply may be
characteristic, such as the fatigue being disproportionate to exertion or not relieved
by rest.
1.2 MEASUREMENT OF FATIGUE
1.2.1 Objective measurement of fatigue
Like all other symptoms by definition, fatigue is subjective. However when patients
are asked to describe it, they often find it difficult and instead describe the
consequences of fatigue, such as the way it impairs their ability to function
(Magnusson et al. 1999). There have been attempts to objectively measure what
patients describe as fatigue (or its consequences) by using methods such as
physiological muscle testing, actigraphy, or physical exercise performance (Dimeo et
al. 1997;Monga et al. 1997;Stone et al. 1999;Servaes et al. 2002b;Brown et al.
2005). However, the relationship between these and patients' subjective reports of
fatigue are notoriously poor. The physiological or relatively objective tests that are
currently available do not help. A symptom cannot be measured by an observer and
can only be assessed by self report.
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1.2.2 Subjective measurement of fatigue
1.2.2.1 Continuous scale measures
There are a multitude of self report fatigue measurement instruments available and
no commonly accepted 'gold standard'. To cover them all is beyond the scope of this
thesis but they are listed in Chapter 4 and helpful reviews have been published (Wu
& McSweeney 2001;Dittner et al. 2004). Broadly speaking, measures are classed as
uni or multidimensional but in general they all calculate a continuous numerical
fatigue score. From a clinical perspective it is not clear at what point along these
continuous scale measures that fatigue becomes abnormal or worthy of further
assessment or intervention i.e. the individual becomes a 'case' of clinically
significant fatigue. Typically a patient need only say they are experiencing fatigue to
be considered as having cancer related fatigue, therefore current prevalence estimates
may be high and misleading. Additionally the use of different scales makes it
difficult to compare studies using different scales.
1.2.2.2 Case definition approach to fatigue
In order to remedy this, diagnostic criteria for cancer related fatigue were proposed
(Cella et al. 1998). This has been a helpful step forward and will be covered in more
detail in Chapter 4. At the time of starting my research it had only been used in two
studies, one of which did not apply all the criteria (Cella et al. 2001;Sadler et al.
2002). One of the key points is that by definition cancer related fatigue has to be
attributed to cancer or its treatment. Cause is inherently difficult to attribute and is
perhaps premature. It is also far from clear whether the experience of fatigue in
cancer patients is different to that with other medical conditions (Paterson et al.
2003). A more useful case definition would be for clinically significant fatigue which
could be applied to all conditions with fatigue, not just cancer.
1.3 FATIGUE IN CANCER PATIENTS
Fatigue is the most frequently reported symptom in cancer patients. Prevalence
estimates vary from 15-99% depending on the population studied, measurement
instrument used and the criteria for recording fatigue as present (Stone et al.
2000b;Stone et al. 2000c;Cella et al. 2002;Servaes et al. 2002a). Many patients
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regard their fatigue as inevitable and untreatable and so it tends to be underreported
by patients and underestimated b}/ clinicians (Vogelzang et al. 1997;Stone et al.
2000c).
Fatigue can be associated with cancer or its treatment. It may be the first
manifestation of an underlying malignancy or be induced or worsened by subsequent
treatment with surgery, radiotherapy, chemotherapy or biological agents. There is the
clinical perception that fatigue severity varies according to the primary cancer
diagnosis, stage of disease and type of treatment. There is little research to support
this (Stone et al. 2000b;Glaus 2001) and the relationship between fatigue and
treatment related factors has seldom been investigated (Servaes et al. 2002a).
1.3.1 Consequences of fatigue
Fatigue has a negative impact on quality of life, affects compliance with cancer
treatments and can impair patients' self care abilities (Rhodes et al. 1988;Vogelzang
et al. 1997;Irvine et al. 1998;Curt et al. 2000). Many patients report that fatigue is
more distressing than pain and nausea and particularly interferes with role
performance and ability to meet their own needs and those of their families (Knobf
1986;Cella et al. 2001;Servaes et al. 2002a). A telephone survey of patients who had
received chemotherapy, reported fatigue had detrimental physical, psychosocial and
financial consequences. Of those who were fatigued, 91% reported that it had
prevented 'a normal life' and 75% had to change their work conditions due to fatigue
(Curt et al. 2000).
1.3.2 Fatigue during cancer treatment
Until recently there has been relatively little systematic study of fatigue in cancer
patients. Much of this research has focused on fatigue associated with chemotherapy
and combined chemo-radiation treatment (Servaes et al. 2002a). What has received
less attention is fatigue in patients who have received radiotherapy alone.
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1.3.2.1 Fatigue during chemotherapy or combined chemo-radiotherapy
Many of the fatigue studies to date have been cross sectional. Of the few prospective
studies of fatigue during chemotherapy, most have examined breast cancer patients.
Some studies found fatigue significantly increased during chemotherapy (Irvine et al.
1994;Andrykowski et al. 1998;Jacobsen et al. 1999;Wang et al. 2001;de Jong et al.
2004;Donovan et al. 2004) but not others did not confirm this (Hann et al. 1999;de
Jong et al. 2002;Jacobsen et al. 2004a). In many studies, some patients have also
received concurrent radiotherapy making it difficult to attribute fatigue to specific
treatment modalities. There is the suggestion that the pattern of fatigue may vary
with different chemotherapy regimens but there is limited literature addressing this
(Richardson et al. 1998;de Jong et al. 2002).
1.3.2.2 Fatigue during radiotherapy
There are fewer studies specifically examining fatigue during radiotherapy alone.
There is evidence to suggest that fatigue increases during radiotherapy but this does
not seem to be the case for all patients (Wratten et al. 2004;Hickok et al. 2005) and
there are differing findings about its trajectory. Contrary to expectations some studies
found fatigue did not increase linearly with cumulative doses. Instead it reached a
maximum part way through the course and plateaued. (Greenberg et al. 1992;Irvine
et al. 1998). Results also seem to vary according to the measurement instrument
used. A study of 41 early breast cancer patients who received 50Gy over 5-6 weeks
found fatigue measured by a visual analogue scale increased until week 4 and
remained elevated, whereas when measured on the Fatigue Assessment
Questionnaire showed a decline in week one and never significantly increased
(Geinitz et al. 2001). A larger study of patients with mixed cancer diagnoses found a
gradual increase in fatigue over the course of radiotherapy. They also found a
reduction of fatigue on radiotherapy free days. (Smets et al. 1998a). Researchers
have found the degree of fatigue in radiotherapy patients differs by cancer diagnosis
though whether this is due to differences in biology, gender, tumour or irradiation
site is not clear (Smets et al. 1998a;Jereczek-Fossa et al. 2002). Some suggest that
fatigue correlates with the size of radiotherapy field or dose though this has been
contradicted by others (Smets et al. 1998a;Smets et al. 1998b).
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1.3.3 Fatigue after cancer treatment
Due to the potentially life threatening nature of being diagnosed with cancer, many
patients seem willing to accept the trade off between undesirable acute side effects
of treatment such as hair loss, fatigue, nausea and vomiting, so long as they are
temporary and the potential result is either cure of their cancer or enables them to
live much longer with it. In this situation, quality of life after cancer treatment is of
major importance and the question arises whether persistent fatigue may have an
adverse effect.
Few studies have addressed fatigue after cancer treatment though there is the
suggestion that it may be an important issue for cancer survivors (Cella et al.
2001;Arndt et al. 2005). Bearing in mind that not all 'survivors' are recurrence free,
cancer may contribute to their fatigue rather than be the long term effect of treatment
alone. However, studies that have focussed specifically on recurrence free survivors
show fatigue is prevalent in patients with a history of Hodgkins lymphoma, breast
and testicular cancer (Andrykowski et al. 1998;Bower et al. 2000;Servaes et al.
2002c;Fossa et al. 2003;Ruffer et al. 2003;Hjermstad et al. 2005). Most studies are
cross sectional and so do not have pre-treatment fatigue data to refer to. However one
prospective study assessed breast cancer patients before treatment then at one, two
and three years afterwards and found fatigue remained around the same level of 20%
(Nieboer et al. 2005). Some studies have compared to a non-cancer population and
generally higher levels of fatigue are found in recurrence free survivors
(Andrykowski et al. 1998;Servaes et al. 2002c;Fossa et al. 2003;Ruffer et al.
2003;Hjermstad et al. 2006).
1.3.3.1 Fatigue after radiotherapy
Although there is the clinical impression that fatigue increases during radiotherapy,
there is conflicting evidence as to how long it lasts. Some small prospective studies
with short follow up showed that fatigue recovered to pre-treatment levels within
several weeks (Greenberg et al. 1992;Geinitz et al. 2001) but not for others (Monga
et al. 1999;Wratten et al. 2004). A cross sectional study of prostate cancer patients
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showed that 'severe fatigue' was present in 18.7% of patients approximately two
years post radiotherapy (Vordermark et al. 2002). Another compared fatigue scores
between healthy controls and a group of 154 patients with heterogeneous cancers
treated with radiotherapy nine months previously and found there was no difference
in fatigue (Smets et al. 1998b). It is unclear whether a proportion of recurrence free
survivors in specific cancer groups may experience prolonged fatigue and there is a
need for longer prospective studies to address this.
1.4 ASSOCIATIONS AND MECHANISMS OF FATIGUE IN
CANCER PATIENTS
A number of demographic, psychological and physiological factors have been
reported to contribute to fatigue and are shown in figure 1.
1.4.1 Fatigue and cancer related factors
Fatigue can be caused by the presence of cancer. This can occur in several ways: it
can depend on the site of the primary tumour (in the lungs causing mechanical
obstruction and hypoxia); the site and size of metastatic tumours impairing organ
function (such as liver metastases); substances released by the tumour cells (such as
polypeptides from small cell lung cancer) and the body's physiological response to
those substances or the tumour (such as the host systemic inflammatory response).
There is the clinical assumption that fatigue increases with greater tumour burden
and most commonly it is associated with metastatic disease. In fact there have been
no studies that systematically examine fatigue in patients with different stages of a
single cancer diagnosis. It is not clear whether small localised tumours themselves
cause fatigue or whether psychological and treatment factors are more important. It is
recognised that surgery, radiotherapy, chemotherapy, endocrine and biological
therapies are often associated with fatigue but there are few studies comparing
fatigue in the same tumour type with different treatments (Woo et al. 1998). There is
speculation that tumour growth factors and symptoms associated with cancer and its
treatment may have a shared biologic mechanism (Cleeland et al. 2003).
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1.4.2 Fatigue and demographic factors
There are conflicting findings as to whether marital status, social support, race and
working status are associated with fatigue during treatment (Servaes et al. 2002a).
Many people assume that as age increases then so does fatigue. In fact some studies
show no relationship but Woo et al found a significant negative correlation in breast
cancer patients. They suggested that this may be because more aggressive
chemotherapy regimens were given to women under 60 years old or that younger
women were more likely to have jobs and responsibilities of caring for their families,
giving them fewer opportunities to save energy (Woo et al. 1998). Fatigue is thought
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to be most common in women but whether this is due to gender or confounded by the
site and type of tumour is unclear. The associations of fatigue in men have not
received much attention and are deserving of future study.
1.4.3 Fatigue and psychological factors
Some studies have focussed on the possible psychological mechanisms of fatigue and
show a correlation between anxiety, somatisation, catastrophizing coping style and
especially depression (Hann et al. 1998;Stone et al. 2001;Jacobsen et al. 2004b).
Fatigue is one of the symptoms of the syndrome of Major Depressive Disorder so
perhaps this is not surprising. Because of this relationship, there is an assumption that
depression and fatigue may follow a similar course but it is not clear whether fatigue
causes depression or vice versa. It is worthy of note however, that in three studies,
although correlations between fatigue and depression were moderate, depression
scores either decreased or did not change while fatigue scores rose over the course of
radiotherapy and hormonal therapy (Visser & Smets 1998;Monga et al. 1999;Stone
et al. 2000a).
1.4.4 Fatigue and other factors
Concomitant symptoms and side effects like pain, infection, dehydration,
malnutrition, diarrhoea, sleep disturbance and concurrent medications (i.e. opiods)
have also been found to be associated with fatigue (Jereczek-Fossa et al.
2002;Servaes et al. 2002a;Jacobsen & Thors 2003)
1.4.5 Fatigue and physiological factors
Fatigue during breast cancer treatment has been shown to be associated with less day
time activity (Berger & Farr 1999). This can form a vicious cycle leading to physical
deconditioning which in turn can worsen fatigue and consequently the patient




1.4.5.1 Possible biological mechanisms of fatigue
Biological mechanisms of fatigue in cancer patients are poorly understood. Fatigue is
a self reported sensation which may have objectively measurable correlates yet to be
identified. Anaemia is commonly associated with fatigue and several studies
investigating the use of recombinant human erythropoietin in anaemic chemotherapy
patients have reported a decrease in fatigue or increase in quality of life (Cella
1997;Patrick et al. 2003b). However the relationship between haemoglobin and
fatigue is not strong and has been shown to be confounded by disease stage and
tumour response (Wisloff et al. 2005). Few studies have examined the biological
correlates of fatigue beyond haemoglobin but low Cortisol, hypothalamic-pituitary
dysfunction, disordered ATP (adenosine triphosphate) metabolism and raised
systemic inflammatory response may also play a part (Morrow et al. 2002).
1.4.5.1.1 Systemic inflammatory response
Evidence of a systemic inflammatory response is easily detected by the presence of
raised levels of C - reactive protein (CRP). CRP production is mediated by
proinflammatory cytokines. Cytokines are intercellular signalling polypeptides
produced by a variety of activated cells. The most important of these are
macrophages and monocytes which release substances including Interleukin-6 (IL-6),
IL-ip and Tumour Necrosis Factor (TNF). Hepatic synthesis of CRP in cancer
patients is predominantly under the control of IL-6, its soluble receptor and IL-1
receptor antagonist (Gabay & Kushner 1999).
1.4.5.1.1.1 Radiotherapy and systemic inflammatory response
Fatigue in radiotherapy patients may be related to cytokine activation and consequent
induction of a systemic inflammatory response (Greenberg et al. l993;Kurzrock
2001). In-vitro and in-vivo studies have shown ionizing radiation can induce
production of acute phase response cytokines such as IL-1, IL-6 and TNFa (Beetz et
al. 1997). These cytokines are known to have sleep inducing and malaise inducing
properties (Kurzrock 2001) leading to speculation that cytokine production may be a
cause of fatigue in radiotherapy patients. One study reported an increase in fatigue
and IL-1 levels in prostate radiotherapy patients (Greenberg et al. 1993) but another
Chapter I 12
Fatigue and Cancer
failed to find any relationship between fatigue and IL-1, IL-6 and TNFa (or
haemoglobin) in women having radiotherapy for early breast cancer (Geinitz et al.
2001). The most comprehensive study of inflammatory factors and radiotherapy to
date showed baseline fatigue prior to breast irradiation was associated with variety of
cytokine and coagulation factors including IL-6 and CRP. However, once body mass
index was accounted for, this was no longer the case. Nor was there any relationship
between IL-6, CRP and fatigue during radiotherapy (Wratten et al. 2004).
Breast cancer survivors with persistent fatigue years after treatment have been found
to have elevated levels of proinflammatory cytokines and T-lymphocytes compared
to non fatigued survivors suggesting a chronic inflammatory process. In addition
they show behavioural changes consistent with proinflammatory cytokine activity
including depressed mood, decreased social interest and cognitive difficulties (Bower
et al. 2002;Bower et al. 2003).
1.5 WHY IT IS IMPORTANT TO STUDY FATIGUE IN CANCER
PATIENTS
With the development of new therapeutic approaches, cancer treatments are
becoming increasingly complex and may result in prolonged, more intense therapy
with little or no survival benefit. Consequently patients' quality of life must
increasingly be taken into account. Symptom distress is an important component of
patients' overall evaluation of their well being. Fatigue is now understood to be the
most common symptom associated with cancer and its management and has a major
adverse effect on quality of life (Irvine et al. 1994;Cella 1997;Yellen et al.
1997;Vogelzang et al. 1997;Cella et al. 1998). Patients tend to cope better with
symptoms and side effects of treatment if they are advised about them in advance. It
is therefore important to study fatigue and know more about its trajectory so
clinicians can warn patients about it.
1.6 WHAT RESEARCH IS NEEDED
There have been few studies in cancer patients that examine fatigue using a fatigue
specific measurement instrument. Of those that have, fatigue has often been reported
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as mean fatigue scores rather than the proportion of subjects who have fatigue of a
clinically relevant severity. There is a need for studies using a case definition of
clinically significant fatigue.
Most studies have been cross sectional. Despite a high prevalence of fatigue in
cancer patients, there is a lack of research on its causes and trajectory over time.
Shortly before the start of this research project, the National Institutes for Health
(NIH) in the U.S.A recommended that prospective incidence studies should be
conducted to provide clinicians with information regarding the likelihood of
occurrence, severity and duration of symptoms after a diagnosis of cancer (Patrick et
al. 2003a). Many studies to date have several shortcomings: (a) heterogeneous cancer
populations with different stages of disease and various treatments (b) they have not
used a fatigue specific measurement instrument (c) few have investigated possible
biological correlates of fatigue and (d) there is a lack of information as to whether
fatigue levels are different to that of the non-cancer population.
After reviewing the literature it became clear that there was a need for studies of
homogeneous cancer groups using a fatigue specific measurement instrument to
identify fatigue of a clinically significant severity as well as integrating further
exploration of biological correlates of fatigue and the inclusion of a non-cancer
comparison group.
1.6.1 Why study Prostate Cancer?
Much of the work examining single cancer groups has focused on breast cancer or
Hodgkins Lymphoma. Fatigue is thought to increase during treatment and there is
evidence to suggest that it may still be a problem for patients, years after curative
treatment. Prostate cancer is the commonest male cancer and survival is often in
terms of many years. However little is known about fatigue and its associations in
this population.
When considering the feasibility of which patient group to study, it was important to
have access to a large sample, be able to recruit homogeneous treatment cohorts and
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reduce any confounding factors which may influence fatigue. The prostate cancer
population appeared to have these attributes: early prostate cancer treatment was
unlikely to change during the period of my research (unlike breast cancer treatment
at the time); fatigue assessment was less likely to be complicated by dyspnoea
(unlike lung cancer); the prostate irradiation field was distant from the chest thus
minimising the possibility of fatigue secondary to complications arising from
radiation exposure of the cardiopulmonary system (unlike breast and lung cancer). In
addition, prostate cancer patients were relatively under researched and therefore less
likely to be in a study already (which could have had implications for recruitment). I
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2.1 PROSTATE CANCER
2.1.1 Incidence and presentation of prostate cancer
Prostate cancer is commonest male cancer in the United Kingdom accounting for one
in five of new cancers in men. Only lung cancer kills more men per year (Toms
JR(ed) 2004). The prevalence is highest in men aged over 70 but with the advent of
PSA (prostate specific antigen) testing from the age of 50 onwards, greater numbers
ofmen are being diagnosed and treated with curative intent at a younger age.
Commonly prostate cancer can be asymptomatic and diagnosed as a result of a raised
PSA or be an incidental pathological finding after a TURP (transurethral resection of
prostate). If symptoms are present, they are not specific to cancer but can include
lower urinary tract symptoms (such as frequency, poor flow or nocturia), erectile
dysfunction or haematospermia. Advanced local disease may present with ureteric
obstruction, renal impairment or lower limb oedema. Distant metastatic disease most
often presents with bone pain, malaise and fatigue. The liver can also be involved but
it is uncommon to present with hepatic dysfunction alone.
Most frequently men are referred to a Urologist on the basis of a raised PSA and/or a
suspicious digital rectal examination. The diagnosis is then confirmed by transrectal
ultrasound guided biopsies performed under a local anaesthetic. Then, depending on
the patient's age, fitness and clinical findings, some men will undergo radiological
imaging to fully stage their disease.
2.1.2 Disease Staging
The TNM (tumour, nodes, metastasis) staging of prostate cancer is shown in figure 2.
2.1.3 Pathological Tumour Grading
Prostate cancer is often a multifocal disease and different histological patterns may
be seen within the prostate. The Gleason tumour grade is based on the two most
common patterns of gland architecture and are added together to give the score
ranging between 2 and 10 i.e. 3+4 = 7. A well differentiated tumour will have a score
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Figure 2. TNM definitions of prostate cancer staging (American Joint Committee
on Cancer. 2002)
Primary tumour (T)
TX: Primary tumour cannot be assessed
TO: No evidence of primary tumour
T1: Microscopic tumour confined to prostate and
undetectable by a digital rectal exam or imaging
• T1 a: Tumour incidental histological finding in <5% of
tissue resected
• T1b: Tumour incidental histological finding in >5% of
tissue resected
• T1c: Tumour identified by needle biopsy (e.g.,
because of elevated PSA)
T2: Tumour confined within prostate and can be detected by
digital rectal examination or imaging
• T2a: Tumour involves 50% of one lobe or less
• T2b: Tumour involves >50% of one lobe but not both
lobes
• T2c: Tumour involves both lobes
T3: Tumour extends through the prostate capsule
T3a: Extracapsular extension (unilateral or bilateral)
T3b: Tumour invades seminal vesicle(s)
Rectum
T4: Tumour is fixed or invades adjacent structures other than
seminal vesicles: bladder neck, external sphincter,
rectum, levator muscles, and/or pelvic wall
Regional lymph nodes (N)
NX:Regional lymph nodes were not assessed
NO: No regional lymph node metastasis
N1: Metastasis in regional lymph node(s)
Distant metastasis (M)
MX: Distant metastasis cannot be assessed (not evaluated
by any modality)
MO: No distant metastasis
M1: Distant metastasis
• M1a: Nonregional lymph node(s)
• M1b: Bone(s)
• M1c: Other site(s) with or without bone disease
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up to 6; poorly differentiated 8 or above. The Gleason score has been found to
correlate well with mortality.
2.1.4 Clinical management of prostate cancer
Management depends on a combination of the TNM staging, Gleason score and PSA
level. Broadly, the severity of prostate cancer is split into three groups:
(1) Early localised disease (Tl-2, NO, MO)
(a) Good risk: Gleason score < 6, PSA < 10
(b) Intermediate risk: if PSA >10 but < 20 or PSA < 10 and Gleason 7
(c) Poor risk: ifPSA >10 but < 20 and Gleason 7
(2) Locally advanced disease (T3-4, N0-1, M0, Gleason score > 8, PSA > 20)
(3) Metastatic (Ml, and any combination of T, N, Gleason score and PSA)
2.1.4.1 Early localised disease
Currently there is a lack of randomised clinical trials to indicate which treatment is
best in terms of survival or in fact whether early localised prostate cancer needs to be
treated at all. The choice of treatment is primarily determined on the basis of the
cancer stage, but also with consideration of the patient's age, comorbidities and
treatment preferences (taking into account potential side effects such as incontinence
and erectile dysfunction). For those who are fit enough for a general anaesthetic,
there are a number of different management options: radical prostatectomy;
interstitial brachytherapy; external beam radiotherapy; primary androgen deprivation
or watchful waiting. The latter three options are available to those who are not fit
enough for general anaesthetic (unless there is a contraindication to radiotherapy
such as inflammatory bowel disease).
2.1.4.1.1 Radical prostatectomy
This operation is done with curative intent and the prostate is removed via a
transverse incision in the lower abdominal wall. The surgery requires a 1.5-3 hour
general anaesthetic followed by a minimum four day inpatient stay. Commonly
blood transfusions are required and the patient may have to go home with a urinary
catheter for some time. Increasingly, some radical prostatectomies are being
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performed laparoscopically with a shorter inpatient stay. Common side effects are
urinary incontinence, erectile dysfunction (despite 'nerve sparing' surgery) and
bowel dysfunction.
2.1.4.1.2 Interstitial prostate brachytherapy
This treatment is given with curative intent and offered providing the prostate
volume does not exceed 55cc (measured by ultrasound whilst under a general
anaesthetic). Under a general anaesthetic, radioactive Iodine123 seeds are implanted
throughout the prostate via transperineal needles under ultrasound guidance. The
procedure takes approximately one hour and involves an overnight inpatient stay.
The seeds deliver a minimum dose of 145Gy (the central part receives 220Gy) over
approximately nine months but remain permanently in situ. There is the clinical
impression that this treatment has less of a detrimental effect on erectile function and
men are back to fitness quicker than with radical prostatectomy. If the prostate
measures between 55-70cc, rather than not have brachytherapy, some men undergo
three months of androgen deprivation (see below) to shrink the prostate to enable
successful implantation.
2.1.4.1.3 Radical external beam radiotherapy
At the Edinburgh Cancer Centre, a radiation dose of 55Gy is given in 20 fractions,
Monday to Friday as an outpatient. This treatment is given with curative intent and
each fraction takes about ten minutes to deliver. Common acute side effects are
urinary frequency, dysuria, incontinence, bowel disturbance and rectal bleeding. In
Edinburgh, patients are routinely given three months of neo-adjuvant androgen
deprivation therapy (see below) to reduce the prostate volume and enhance the
apoptotic effects of radiotherapy. The treatment is delivered using conformal
radiotherapy to reduce normal tissue irradiation.
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2.1.4.1.4 Androgen deprivation therapy ("hormonal therapy")
Prostate cancer grows in response to the androgen testosterone and can be controlled
(but not cured) by androgen deprivation. Previously, this was done by performing a
surgical bilateral orchidectomy. Now medical castration is achieved by using LHRH
(lutinising hormone releasing hormone) analogue injections (with an initial three
weeks of oral biclutamide (Casodex) 50mg once a day to prevent 'flare' of the
disease).
»
Some men with high risk tumours are given adjuvant androgen deprivation therapy
(to prevent cancer recurrence) for two years after radiotherapy. However, for those
patients for whom this is the sole treatment then the aim is to control the cancer, not
cure it. Three monthly LHRH analogue injections are administered alone or in
combination with oral anti androgens such as biclutamide (maximal androgen
blockade). PSA is monitored and treatment continues until it rises, indicating the
cancer has become hormone resistant. The main side effects are impotence, loss of
libido, hot flushes and gynaecomastia. The men who have this as their primary
treatment tend to be older and have more comorbidities than those who have surgery,
radiotherapy or brachytherapy.
2.1.4.1.5 Watchful waiting
One option is to do nothing, known as 'watchful waiting' or 'active surveillance'.
This involves regular PSA tests (approximately every six months) and intervening if
and when treatment is indicated. Sometimes younger men choose this option to avoid
the impact of side effects from treatments, in particular erectile dysfunction. More
frequently clinicians advise this for men who are elderly and have other
comorbidities
2.1.4.1.6 Other treatments
There are other treatments available for early localised prostate cancer such as
cyrotherapy or hyperthermia but these are less well established and not available in
Edinburgh.
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2.1.4.2 Locally advanced disease
Locally advanced prostate cancer can often be controlled but cure is uncommon.
These patients are managed with radical external beam radiotherapy, primary
androgen deprivation therapy or less commonly watchful waiting.
2.1.4.3 Metastatic disease
Prostate cancer metastasises to regional lymph nodes, bones and viscera (most
commonly liver). Once the cancer has spread beyond the prostate gland, the aim of
treatment is palliative. In the UK, primarily this is with androgen deprivation therapy
but generally within three to five years the disease becomes hormone resistant. First
line treatment is an LHRU analogue alone (average duration of first line hormone
response is 18 to 24 months) moving on to second line maximal androgen blockade
(average response lasts six months) followed by third line hormonal agents (average
six months response). Chemotherapy is increasingly being employed for patients
who are fit enough and bisphosphonates can be given to maintain the integrity of the
bone. If required, radiotherapy can treat complications from bone metastases such as
pain or spinal cord compression. Diffuse bone metastases can also respond to
OQ
intravenous injections of the radioactive isotope Strontium .
2.1.5 Survival for patients with prostate cancer
More than 90% of all prostate cancers are diagnosed in the early localised and locally
advanced stages. For those with early disease 10 year survival is similar to that of the
normal population but it decreases at 15 years. For locally advanced prostate cancer
the prognosis is worse; about 50% alive at 10 years. (American Cancer Society
2006). If the cancer recurs locally it can seed secondary metastases but with good
local control, many will die with, rather than from their prostate cancer.
Consequently the impact of long term side effects of treatment is of special
relevance.
The prognosis for those with metastatic disease is much poorer but still in terms of
years (34% five year survival). Hence, maximising quality of life and minimising
treatment side effect and symptom burden is also very important for these patients.
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2.2 FATIGUE AND PROSTATE CANCER
The physical side effects most frequently associated with prostate cancer are well
documented. Generally studies have shown that incontinence and sexual difficulties
are reported more frequently by patients who have received radical prostatectomy
than by those who received radiotherapy or brachytherapy while bowel dysfunction
(e.g. diarrhoea, rectal discomfort) is more frequent in patients who have received
radiotherapy or brachytherapy. It is increasingly recognised that the impact of these
treatments on quality of life must also be considered and has become more important
in determining the best approach to treatment, especially since no study has yet
found one of these options to be superior in terms of survival. Studies of American
men with prostate cancer show sexual and urinary function were the most important
factors determining quality of life. In contrast, a study of Norwegian prostate cancer
patients showed that fatigue, physical and emotional function were the only
independent predictors of quality of life (Lilleby et al. 1999). Fatigue may also be an
important consideration in treatment selection for Scottish patients.
2.2.1 Does early prostate cancer cause fatigue?
There is the clinical impression that some cancers intrinsically cause fatigue but that
early localised prostate cancer is not one of them. Currently there is no evidence to
support this. Stone et al found 16% of men with recently diagnosed prostate cancer
had 'severe fatigue' (classed as greater than the 95th percentile of healthy volunteers
scores on the Fatigue Severity Scale), however their disease stage was unclear (Stone
et al. 2000b). It is assumed that more advanced disease is associated with worse
fatigue but there have been no studies comparing fatigue in patients with different
stages of prostate cancer.
2.2.2 Fatigue and prostate cancer treatment - the clinical impression
Prior to embarking on this research project I had come across many patients with
prostate cancer who complained of fatigue that adversely affected their lives. When
discussing this with other health professionals, most agreed that fatigue was
significant problem for men on androgen deprivation therapy (although there is no
published data specifically addressing this). No one was sure whether fatigue was an
Chapter 2 24
Prostate Cancer and Fatigue
issue for brachytherapy patients as this was a relatively new and infrequent treatment
in Edinburgh. However it became clear there was a disparity of opinion amongst
nurses, radiographers and oncologists as to whether fatigue was significant side
effect of radiotherapy. Although most oncologists routinely warned patients about
feeling tired, they did not perceive it as a major side effect during or after treatment.
In contrast, radiographers thought it was a significant problem during radiotherapy
and nurses doing follow up clinics believed it was still an issue for some patients
several months afterwards.
This disparity of perception could be because, by their own admission the
oncologists seldom asked about fatigue after treatment and concentrated their
enquiries on other symptoms such as incontinence and erectile dysfunction. It has
also been suggested that patients are more likely to mention fatigue to their nurse
because they did not want to bother the doctor with symptoms they felt were
inevitable, untreatable, not important enough or because the doctor never raised the
issue (Stone et al. 2003).
Consequently, I began directly asking patients about fatigue. In accordance with the
radiographers and nurses I found many men recalled experiencing fatigue during or
after their treatment and a smaller proportion described themselves as currently
having persistent fatigue that they attributed to their prostate cancer treatment. It
became clear this was an issue deserving ofmore attention. Ifwe were curing men of
their prostate cancer yet leaving them with fatigue that interfered with their lives,
then perhaps this was a significant long term treatment related toxicity that (a) they
should be informed about and (b) we as clinicians should be aware of, understand
better and consequently try to prevent or treat.
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2.2.3 Fatigue and prostate cancer treatment: the research prior to
October 2003
This research project commenced in October 2003, work published after this date is
described in the relevant study discussion sections of this thesis.
2.2.3.1 Studies of fatigue and external beam radiotherapy
When this research project was being designed there were no fully published
prospective data on fatigue beyond six weeks after radiotherapy. Interestingly, a
cross sectional study of 103 men, a median of 2.1 years post radiotherapy (range 0.5-
10 years) found that 18.7% had severe fatigue (Brief Fatigue Inventory 'worst
fatigue' > 7). However this sample had mixed stages of disease, the majority had also
undergone radical prostatectomy and 29% were on androgen deprivation therapy
which may have confounded the findings (Vordermark et al. 2002).
Cross sectional studies only give a snapshot of fatigue at a given point of time, so
prospective studies are more informative about the trajectory of fatigue after
treatment. There are several prospective studies of prostate cancer treatment that
report fatigue as part global quality of life measures (Janda et al. 2000;Egawa et al.
2001;Van Vulpen et al. 2002;Staff et al. 2003) however only those that have
assessed fatigue with a fatigue specific instrument will be reported here.
There have been three published prospective studies that specifically examined
fatigue during radiotherapy for prostate cancer. The largest published report studied
36 men with localised (T1 and T2) prostate cancer undergoing 68-70Gy in 34 to 38
fractions. They found a 17% incidence of fatigue (Piper Fatigue Scale > 6) during
radiotherapy. The mean fatigue score significantly increased during radiotherapy and
was decreasing by five weeks post treatment but not to baseline levels. In addition
they assessed haematocrit and depression scores, neither of which changed
significantly. The five week follow up is short but one of the longest in the
prospective studies published prior to October 2003 (Monga et al. 1999).
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A study of nine men with Tl-2 disease who received 68-70Gy in 34 to 38 fractions,
demonstrated an increase in neuromuscular fatigue after eight weeks of radiotherapy.
The authors commented that this was independent of cardiovascular and
psychological factors though not all subjects completed all the tests. In contrast, the
self reported fatigue scores (Piper Fatigue Scale) did not change (Monga et al. 1997).
The only study to examine cytokines in relation fatigue and prostate cancer
prospectively followed 15 patients (Tl-3) who received 67.2Gy in 36 fractions (over
eight weeks). They found fatigue measured on a visual analogue scale increased to
over the first four weeks, plateaued and then rose again over weeks 6 and 7. There
was no follow up post treatment but worthy of note was that IL-1 tended to increase
as fatigue did (Greenberg et al. 1993).
The largest study sample (n=105) was followed up for eight weeks post radiotherapy
but has only been reported in an abstract so far (Geinitz et al. 2003). Fatigue was
measured using the Fatigue Assessment Questionnaire, EORTC fatigue subscale and
a visual analogue scale for fatigue. No values were reported but fatigue increased in
most measures during radiotherapy but "returned to almost pre-treatment levels"
eight weeks post treatment. However it is not clear what stage of disease these men
had and 25% had adjuvant radiotherapy after radical prostatectomy with consequent
variable radiation doses for the whole sample (55.9-74Gy). Additionally 76 patients
had androgen deprivation therapy which may have confounded the results.
Haemoglobin did not significantly change during radiotherapy, nor did CRP.
However in a personal communication Geinitz informed me they only tested CRP in
60% of the sample.
Most studies of fatigue have been in mixed cancer groups and the results were
collectively reported. However one study that reported fatigue according to tumour
site showed only the urogenital cancer group had a significant increase in fatigue
after radiotherapy (64 prostate, 7 testis, 22 other genitourinary tract cancers) and the
main predictor of fatigue was pre-treatment fatigue (Smets et al. 1998a). Another
study examined 35 men with a range of different stages of non metastatic prostate
Chapter 2 27
Prostate Cancer and Fatigue
cancer before and after radiotherapy (64Gy over six weeks). All had received
androgen deprivation therapy beforehand. As the results were reported together with
34 breast cancer patients so it is not possible to deduce any prostate cancer specific
information (Stone et al. 2001).
None of the prospective studies of fatigue during radiotherapy have accounted for the
effect of neoadjuvant androgen deprivation which is routine treatment in Edinburgh.
Low testosterone levels can be associated with fatigue and LHRH analogues can still
cause castrate levels of testosterone up to eight months after administration (Oefelein
1998). There is a need to see whether this has a significant influence upon the
trajectory of fatigue before and after radiotherapy.
2.2.3.2 Studies of fatigue and brachytherapy
There have been no studies that specifically address fatigue in brachytherapy
patients. Little is known about the effect of brachytherapy on quality of life but there
is the popular perception that patients experience less impairment than with other
treatments even though there are few data to support this (Brandeis et al. 2000).
2.2.3.3 Studies of fatigue and androgen deprivation therapy
Anecdotally fatigue is said to be a common side effect of androgen deprivation
therapy however there is only one study that has prospectively addressed this (Stone
et al. 2000a). They followed 62 mixed stage prostate cancer patients over three
months and found an increase in six out of eight fatigue measures. They compared
these results to their radiotherapy study (Stone et al. 2001) and said the increase in
fatigue was equivalent. However, disease stage may have confounded these results as
some of these men had advanced cancer and were receiving androgen deprivation as
their primary long term treatment not as neoadjuvant treatment prior to radiotherapy.
2.2.3.4 Studies comparing fatigue years after different prostate cancer
treatments
There have been cross sectional studies comparing quality of life in men several
years after different treatments for prostate cancer. However there have been no
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studies that compared fatigue using a fatigue specific measurement instrument.
Those that did reported fatigue as part of a global quality of life scale also included
men who had disease recurrence or were receiving androgen deprivation which may
have confounded the fatigue findings (Potosky et al. 2000;Bacon et al. 2001;Davis et
al. 2001). There is no information specifically addressing the prevalence of long term
fatigue in recurrence free men after different treatments for prostate cancer and
whether treatment modality predicts fatigue.
2.2.4 Questions that need to be addressed
In summary, the trajectory of fatigue after radiotherapy is unclear and there is no
information about fatigue after brachytherapy. These issues are best addressed with
prospective studies. There are some radiotherapy data but follow up is short, disease
stages are mixed, sample numbers are small and decrease with attrition, none take
into account the possible impact of androgen deprivation therapy prior to
radiotherapy or compare to fatigue levels to a non-cancer population. Additionally,
very few have looked at the biological correlates of fatigue and prostate cancer
beyond haemoglobin and routine biochemistry.
In order to address these shortcomings, there needs to be larger and longer
prospective studies of prostate cancer patients receiving radiotherapy or
brachytherapy. To reduce potentially confounding variables, patient groups need to
be homogenous with regard to disease stage and radiotherapy dose and fractionation.
It is important to account for androgen deprivation prior to treatment by measuring
testosterone in case this confounds fatigue findings. Due to the lack of information
about the mechanisms of fatigue development there is a need to build on previous
work and examine possible biological correlates of fatigue such as mediators of the
systemic inflammatory response. Additionally it is important to put fatigue
experienced by prostate cancer patients in context and compare to a male population
of a similar age who do not have cancer.
With the advent of PSA screening after the age of 50, increasingly younger men are
being diagnosed with early prostate cancer and treated with curative intent. It is in
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these men that treatment related toxicity will have the greatest impact. Currently,
there is no information specifically addressing the prevalence and severity of long
term fatigue in recurrence free men and whether treatment modality predicts fatigue.
Another clinically relevant situation where information is lacking is the prevalence
and severity of fatigue in men on long term androgen deprivation for prostate cancer








The overall aim of this thesis was to explore fatigue during and after treatment for
localised prostate cancer.
In order to do this it was planned to:
(1) Devise an interview based case definition of clinically significant fatigue.
(2) Conduct a prospective observational cohort study that would determine the
incidence, associations and' predictors (psychological and biological,
especially proinflammatory cytokines) of clinically significant fatigue in 200
men over the 12 months after receiving either brachytherapy or radiotherapy
for early localised prostate cancer.
In response to preliminary work (Study A) these aims changed slightly and other
research opportunities arose. This led to fatigue in men with prostate cancer being
examined using a combination of approaches including prospective and cross-
sectional studies. In addition, men with more advanced prostate cancer were included
in this research project.
The aims were then expanded to examine fatigue and its associations in:
3) Recurrence free prostate cancer survivors who had undergone treatment more
than one year ago.
4) Men with hormone controlled prostate cancer
A total, of four studies were conducted and the specific aims and hypotheses will be
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4.1 CONTINUOUS FATIGUE MEASUREMENT INSTRUMENTS
Fatigue is a subjective experience and is best assessed by self report. There are a
multitude of self report fatigue measurement instruments available but no commonly
accepted 'gold standard'. In general they all calculate a continuous numerical fatigue
score.
4.1.1 Fatigue scales as part of quality of life measures
Some fatigue measures are subscales of larger measures of quality of life or
psychological wellbeing such as the European Organisation for the Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQc30), the Medical
Outcomes Short Form-36 (SF-36) and the Profile ofMood States (POMS). Although
these are commonly used, they are not viewed as suitable for in depth study of
fatigue as they have a few items and a limited number of possible responses (Stone et
al. 1998). Fatigue specific instruments are more appropriate in this context.
4.1.2 Fatigue specific measurement instruments
There are many fatigue specific measurement instruments. To cover them all is
beyond the scope of this thesis but they are listed in table 4.1 and helpful reviews
have been published (Wu & McSweeney 2001;Dittner et al. 2004). The number of
items in a single instrument range from one to 83. Broadly speaking, measures are
classed according to whether they measure fatigue intensity (unidimensional) or
attempt to measure different fatigue constructs, such as general/mental/physical/
motivational fatigue as well as its severity (multidimensional). There is however, no
agreement amongst researchers about the number of fatigue dimensions (generally
ranging from two to five) and there is little evidence regarding how the measurement
of these different dimensions adds anything to the identification and/or treatment of
fatigue. From the patient's point of view, fatigue becomes a problem when it causes
them difficulty in doing the things they want to (i.e. it impairs function).
Consequently, it was decided that in order to be clinically relevant the instrument for
this project must measure fatigue severity and interference with function, be brief,
easy to understand and have relevant questions (face validity). After reviewing the
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literature and the fatigue measurement instruments available, the Brief Fatigue
Inventory was chosen.
Table 4.1. Fatigue specific measurement instruments that have been used in
cancer patients (arranged in alphabetical order of the authors)
Fatigue Scale Reference
Multidimensional Assessment of Fatigue scale (Belza etal. 1993)
Chalder fatigue scale (also known as the Fatigue
Questionnaire or the Fatigue Scale) (Chalder ef at. 1993)
Fatigue Assessment Questionnaire (Glaus 2001)
Schedule Of Fatigue And Anertia (Hadzi-Pavlovic et at 2000)
Fatigue Symptom Inventory (Hann et al. 1998)
Cancer Related Fatigue Distress Scale (Holley 2000b)
Fatigue Severity Scale (Krupp et al. 1989)
Lee Fatigue scale, also known as Visual Analogue Scale-
Fatigue (Lee etal. 1991)
General Fatigue Scale (Meek ef al. 1997)
Brief Fatigue Inventory (Mendoza et al. 1999)
Fatigue Assessment Scale (Michielsen etal. 2003)
Cancer Fatigue Scale (Okuyama etal. 2000)
Piper Fatigue Scale (Piper ef al. 1989)
Piper Fatigue Scale (revised) (Piper etal. 1998)
Rhoten Fatigue Scale (Rhoten D 1982)
Schwarz Fatigue Scale 6 (revised) (Schwartz & Meek 1999)
Schwarz Cancer Fatigue Scale (Schwartz 1998)
Fatigue Assessment Instrument (Schwartz etal. 1993)
Multidimensional Fatigue Inventory (Smets et al. 1995)
Multidimensional Fatigue Symptom Inventory (Stein et al. 1998)
Multidimensional Fatigue Symptom Inventory Short Form (Stein et al. 2004)
Checklist Individual Strength (Vercoulen etal. 1994)
Wu Cancer Fatigue Scale (Wu & McSweeney 2004)
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4.1.2.1 The BriefFatigue Inventory
This is a nine item instrument. It consists of three fatigue severity items relating to
the present, usual and worst level of fatigue and six items concerning the interference
of fatigue with general activity, mood, walking ability, normal work, relations with
other people and enjoyment of life (see figure 4.1). These are scored by the patient
on an 11 point scale between 0 ("no fatigue'V'does not interfere") and 10 ("as bad as
you can imagine'V'completely interferes"). The global fatigue score is the arithmetic
mean of all nine items providing a score between 0-10. These items refer to fatigue
in the last 24 hours but since I was interested in longer term fatigue this was adjusted
to the last week as suggested by the authors (Mendoza et ol. 1999).
In addition to using a mean global fatigue score of all nine items, cut offs have been
proposed for using just one of the nine items; 'worst fatigue' severity. Based on this,
the NCCN recommends anyone scoring more than 3 out of 10 on a screening
question should receive further clinical evaluation (NCCN 2006). After evaluating
this approach with patients in the Edinburgh Cancer Centre it was clear that 'worst
fatigue' severity scores gave a misleadingly high prevalence of fatigue. For example,
some patients would answer based on recollection of how they felt after a run.
Obviously this severity of fatigue did not interfere with normal functioning which
was what I was interested in. Consequently it was decided to apply the cut off of
greater than 3 to the global fatigue score (referred to as 'Substantial Global Fatigue'
in this thesis). This approach has been used by other authors (Shafqat et al. 2005).
Justification of choice of Brief Fatigue Inventory (BFI)
The BFI was chosen in preference to other fatigue scales because of its brevity and
the items appeared clinically and culturally relevant to the sample population being
studied (good face validity). The authors report that the BFI is internally consistent
with a Cronbach alpha coefficient of 0.96. It has a high correlation with the longer
Functional Assessment of Cancer Therapy-Fatigue (FACT-F) and also the POMS
fatigue scale (Cleeland & Wang 1999). In addition the authors claim that the simple




Figure 4.1 The Brief Fatigue Inventory
Yes No
Throughout our lives most of us have times when we feel tired or
fatigued. Have you felt unusually tired or fatigued in the last
week? WBBBBm
Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your fatigue right NOW
0 1 2 3 4 5 6 7 8 9 10
No fatigue as bad as
you can imagine
Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your USUAL level of fatigue during the past week
0 1 2 3 4 5 6 7 8 9 10
No fatigue as bad as
you can imagine
Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your WORST level of fatigue during the past week
0 1 2 3 4 5 6 7 8 9 10
No fatigue as bad as
you can imagine
Circle the one number that describes how, durinq the oast week, fatigue has
interfered with your
A. General Activity
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
B. Mood
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
C. Walking Ability
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
D. Normal work (includes both work outside the home and daily chores)
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
E. Relations with other people
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
F. Enjoyment of life
0 1 2 3 4 5 6 7 8 9 10
Does not interfere completely interferes
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4.2 INTERVIEW DEFINED CASE DEFINITION OF CLINICALLY
SIGNIFICANT FATIGUE
The main issue hampering fatigue research is the lack of a commonly accepted
measurement tool. The use of different instruments makes it difficult to compare
studies and make an accurate estimate of prevalence. In addition, from a clinical
perspective it is not clear at what point along these continuous scale measures that
fatigue becomes abnormal or worthy of further assessment or intervention i.e. the
individual becomes a 'case' of clinically significant fatigue. Typically a cancer
patient need only say they are experiencing fatigue to be considered as having cancer
related fatigue, therefore current prevalence estimates may be high and misleading.
Although fatigue questionnaires enable quantitative assessment of a subjective
phenomenon, in clinical practice, they can not be a substitute for talking to patients.
4.2.1 Why we need to define a case of clinically significant fatigue
Although there is an understandable desire amongst researchers and clinicians to
move ahead to treatment of fatigue, we have to have an agreed way of assessing
fatigue in the first place. Applying a case definition of clinically significant fatigue
would provide a homogenous population for research. This would enable a more
accurate prevalence estimation of fatigue that is deserving of extra clinical attention.
Once this case definition is established, it could become a clinical definition which
would have utility for treatment.
4.2.2 Requirements of a case definition
Generally, a 'case' is something that is statistically abnormal and a problem meriting
treatment. An analogy would be blood pressure, we all have it, but when it is
abnormal and a problem, or likely to cause problems in the future, we treat it. Any
case definition is a construction (as is a disease diagnosis) and can be based on
validity or utility (Kendell & Jablensky 2003). Validity assumes a natural boundary
between conditions (such as a histological distinction between bone and muscle
tissue), whereas the point at which the decision is made as to when fatigue is normal/
abnormal is arbitrary and cut-offs are therefore not valid. As validity is not yet
possible with fatigue, any case definition needs to be based on utility instead. A
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diagnostic construct has utility when it provides non trivial information about
prognosis, likely treatment outcomes, and/or testable propositions about biological or
social correlates. As fatigue research is in its early stages, only the latter is currently
applicable.
A case definition of clinically significant fatigue needs to:
(1) Be easy to apply
(2) Make practical sense to clinicians
(3) Describe a level of fatigue that both clinicians and patients would agree
merits attention i.e. is clinically significant
(4) Be reliable
4.2.3 What is offered so far in cancer and other areas
The NCCN definition of cancer related fatigue (see section 1.1.1), though clinically
relevant does not help identify individuals who should be considered to represent a
'case' of clinically significant fatigue. Nor do the continuous scale measures
described earlier. In the past, the assessment of depression raised similar issues and
in addition to measuring depressive symptomatology along a continuum, diagnostic
criteria were proposed for a clinical syndrome of Major Depression (American
Psychiatry Association 1994). Based on that model, valuable initial work by Cella et
al, proposed diagnostic criteria for a clinical syndrome of cancer related fatigue for
the International Classification of Diseases 10th Revision (ICD-10) (Cella et al. 1998)
(see Appendix 1). This is a welcome step forward because they include the DSM IV
(Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) definition of
clinical significance and they have made an attempt at attributing aetiology by
labelling the syndrome as Cancer Related Fatigue.
At the time of embarking on this project there were only two published preliminary
studies using this method: a telephone survey of 379 cancer survivors found the
prevalence of cancer related fatigue to be 17% but they were only able to apply
criteria A and B (Cella et al. 2001); and although another study of 51 blood/bone
marrow transplant recipients appeared to apply all criteria, it was not reported how
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they assessed criterion D, having a comorbid psychiatric disorder (Sadler et al.
2002). In my own experience of applying these criteria I found them to be unwieldy
and time consuming. The latter has since been confirmed by other authors who
reported the structured clinical interview for DSM-IV, Axis 1 (SCID) used for
generating psychiatric diagnoses alone took 45 minutes (for criterion D) (Murphy et
al. 2006) . In addition, when applying these criteria a number of other issues arise
which are described below.
4.2.3.1 Using other symptoms to define a symptom; the overlap with
depression
Fatigue is a symptom associated with cancer. Defining cancer related fatigue as a
syndrome (a collection of symptoms) is not necessarily a step forward. In fact using
other symptoms to describe a symptom is of limited use and may be overly
complicated, especially when a proportion of symptoms overlap with the syndrome
of Depressive Disorder (fatigue, diminished concentration, low motivation, sleep
disturbance and emotional reactivity) (American Psychiatry Association 1994). Some
argue that fatigue is a subset of depression, not a diagnostic entity within itself
(Reuter & Harter 2004). Others have commented that due to overlap of symptoms
between syndromes, the criteria may be useful to diagnose a subset of patients who
have both fatigue and depression and consequently identify those whose fatigue may
respond to antidepressant medication (Jacobsen et al. 2003;Wagner & Cella 2004).
4.2.3.2 Who judges whether fatigue is clinically significant?
The patient, main carer or clinician? Fatigue is subjective, so it should be best judged
by the patient. Most patients and clinicians would agree when fatigue is severe, but
symptoms must be considered in terms of the patient's own expected functional and
activity levels (Monks 1989). For example a keen amateur golf player on
chemotherapy who, because of fatigue can now only play nine holes of golf rather
than 18 may view that as significant impairment of their functioning and quality of
life because they can no longer participate in competitions. Whereas the clinician
may only judge it significant if the patient did not have the energy to walk on the golf
course at all. In addition, many cancer patients are retired and even if they
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experience new difficulty in doing daily tasks due to fatigue (which the clinician
would view as significant) they feel able to put off doing things until the next day
because they have the time. A younger patient who is employed, or looking after
children may find the same level of fatigue a very significant problem. If all these
scenarios were counted as cases it may give misleading impression of prevalence. On
the other hand, not to include them all disregards the patient's perspective, which
after all is what we are aiming to measure. A symptom, by definition is subjective
and only the patients knows how it feels, and how it affects them
4.2.3.3 Premature attribution of fatigue to cancer
There is a tendency in medicine for disease specialists to appropriate fatigue as a
disease specific entity. (Paterson et dl. 2003;Reuter & Harter 2004). Consequently
those in the field of oncology tend to regard the cause of fatigue as being cancer or
its treatment. Attributing cause is inherently difficult and perhaps premature. Just
because a patient has cancer we can not assume that it is the cause. Confusion arises
when taking into account fatigue that has been present before the cancer diagnosis.
For example the patient who had fatigue associated with rheumatoid arthritis before
they were incidentally diagnosed with a small early stage bladder cancer (which most
oncologists would not expect to be biological cause of fatigue). Would she get
classed as a case of cancer related fatigue just because she has a cancer diagnosis? If
she had metastatic liver disease, would we label that as the cause of her fatigue rather
than her rheumatoid arthritis?
In addition, there is so far, little evidence to support the notion that fatigue
experienced in cancer is fundamentally different to that experienced in any other
chronic illness (though the precipitating factors and associations may be different).
Patterson reviewed 35 qualitative studies of fatigue in chronic illness including
cancer and noted there are very few qualitative studies comparing the fatigue
experience across different disease diagnoses (Paterson et al. 2003). One exception
compared the fatigue experience of nine cancer patients on chemotherapy to six
patients with Chronic Obstructive Pulmonary Disease. They found both groups had a
similar fatigue experience. (Ream & Richardson 1997).
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Labelling fatigue as 'cancer related fatigue' does not tell us any more about cause or
treatment approaches. In the clinical situation one accepts that clinical aetiological
judgements are necessary but in the first instance, for research purposes, progress is
more likely if associations are first described rather than judged. A clearer, simpler
approach would be to use the term, 'clinically significant fatigue', meaning fatigue
that interferes with normal functioning, whatever the assumed cause(s).
4.2.4 Proposed case definition of clinically significant fatigue
Measuring the effect of fatigue on activities is more sensitive than simply asking
patients to rate their fatigue (Canadian Multiple Sclerosis Research Group 1987).
Fatigue becomes a problem to patients when it causes them difficulty doing what
they want or need to do. The proposed case definition of clinically significant fatigue
is presented in figure 4.3 and a semi- structured interview in figure 4.4. The
diagnosis should arise from consensus between the clinician and the patient.
4.2.4.1 Inter-rater and test-retest reliability
Initially, all the interviews were conducted by me (DS). Later, Morven Shipway
(MS), an experienced cancer nurse was employed part time between March 2005 and
February 2006. She was trained how to conduct the interview and to apply the case
definition of clinically significant fatigue. In order to broadly assess inter-rater
reliability a convenience sample of 20 cancer inpatients and day case chemotherapy
patients were interviewed. Either DS or MS conducted the interview while the other
observed. Both circled their answers on the interview sheet and the answers were
later compared. There was good inter-rater reliability for the overall rating of CSF
(kappa 0.90). For items 1, 2, 3a, 3b, 3c, respectively kappa was 1.0, 0.80, 0.80, .0.90,
0.86. To assess test-retest reliability 10 patients were then interviewed again by the
same interviewer three days later either in person or by telephone if the patient was




Figure 4.3 Proposed case definition of Clinically Significant Fatigue (CSF)
1) An unpleasant, subjective sense of fatigue/tiredness/ lack of energy/weariness
2) Present every day or nearly every day (for at least 2 weeks)
3) Causing difficulty in usual functioning (daily tasks or social/occupational
activities) attributed to feeling fatigued
All 3 points must be present to be a case
Figure 4.4 Semi-structured interview questions to determine a case of
clinically significant fatigue (CSF)
1) In the last month have you felt fatigued/lack of energy/
weariness/tiredness or a need to rest Yes No
If NO stop here
2) How often have you felt like that?
(every day or nearly every day?) Yes No
3) a) Does fatigue cause you difficulties in doing things
you want or need to do? Yes No
(can you give me an example?)
b) Do you put off doing things because you feel fatigued? ... Yes No
(can you give me an example?)
c) Do you avoid doing things in case you become fatigued?....Yes No
(can you give me an example?)
Case of CSF = 1 and 2 and 3a or 3b or 3c Yes No
Note
Latterly, question 1 and 2 were amalgamated to " over the past month, has there
been at least a 2 week period when you have had significant fatigue, a lack of
energy or a need to rest every day or nearly every day" based on (Sadler et at.
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The four studies presented in this thesis had several methods in common. To prevent
repetition they are described here and unless otherwise stated apply to all. The
different study designs, patient samples and other study specific measures are
presented in their respective chapters.
5.1 DEMOGRAPHIC DATA COLLECTED
5.1.1 Scottish Index of Multiple Deprivation (SIMD 2004).
SIMD scores are derived from the patient's postcode and transformed into
population-weighted quintiles (1 = least deprived; 5 = most deprived). SIMD scores
arise from data derived from the most recent population census including current
income, employment, health, education, skills, training, geographic access,
telecommunications and housing, http://www.scotland.gov.uk/stats/simd2004/. This
data was collected as there is conflicting evidence as to whether fatigue is associated
with social deprivation.
5.1.2 Date of birth and age
Obtained from the medical notes
5.2 CLINICAL DATA COLLECTED
5.2.1 Prostate cancer T (tumour) stage
See section 2.1.2. This data was collected from the medical notes or Urology
computer databases.
5.2.2 Prostate cancer Gleason score




5.2.3 Charlson Comorbidity Index
The presence of other medical comorbidities may influence fatigue scores. This is a
commonly used, well validated measure of comorbidity in oncology patients
(Charlson et al. 1987). Each comorbid medical condition is allotted a score (1-6)
with the total score ranging from 0 to 37. Higher scores indicate more comorbidity.
This information was collected from a combination of reviewing the patient's
hospital medical notes and interviewing the patient. This measure was used in studies
A and B only (see Appendix 2).
5.2.4 Karnofsky Performance Status Scale
This is an 11 point rating scale which ranges from 100 (normal functioning
downwards in decrements of 10 to 0 (dead) (Yates et al. 1980). It is completed by the
observing clinician. This scale is among the most widely used scales for measuring
functional ability in cancer patients. This was used in studies A and B (see Appendix
3) only as studies C and D were postal surveys.
5.3 BIOLOGICAL MEASURES (Studies A and B only)
Blood samples were tested by the Haematology and Biochemistry laboratories at the
Western General Hospital, Edinburgh using standard techniques (full blood count,
urea, electrolytes, albumin, C-reactive protein (CRP), testosterone and prostate
specific antigen). Additional serum samples for cytokine analysis were immediately
put on ice and centrifuged for 10 minutes at lOOOrpm at 4 Celsius. One millilitre
aliquots of supernatant were then put into plastic cryotubes and stored at minus 70
Celsius.
5.3.1 Sensitive CRP testing
Those samples that were beyond the lower limit of the standard CRP assay (<3mg/L)
at the Western General Hospital, Edinburgh were tested by experienced staff at
Glasgow Royal Infirmary Biochemistry Laboratory using a Roche CRP Latex high
sensitivity assay on an Hitachi 917 analyser.
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5.3.2 lnterleukin-6 Enzyme Linked Immunosorbent Assays (IL-6
ELISAs)
Under the supervision of Rhona Aird, Senior Scientific Officer at the University of
Edinburgh Cancer Research Centre the IL-6 assays were performed by myself using
Quantikine High Sensitivity Human IL-6 ELISA Kits from R&D Systems Europe
Ltd, 19 Barton Lane, Abingdon, 0X14 3NB. Catalogue Number HS600B.
5.4 SELF REPORT MEASURES
These were in addition to the Brief Fatigue Inventory described in section 4.1.2.1.
See Appendices 4, 5 and 6 for copies of the questionnaires.
5.4.1 Hospital Anxiety and Depression Scale (HADS)
Fatigue and depression often coexist and it was important to measure both
symptoms. The HADS is a self rated 14 item screening tool with two separate seven
item scales for anxiety and depression (Zigmond & Snaith 1983). Each item can be
answered on a four point scale (0-3) generating a total between 0 and 21 on each
subscale. Higher scores represent more severe symptoms. Patients were asked to
report symptoms over the previous week.
To enable comparisons with other published literature, the mean and median
continuous scores were calculated. For studies C and D when clinical interview was
not possible data were also presented as the proportions with likely clinically
significant levels of depression and anxiety according to recommended cut-off
scores: 9 or more on the anxiety subscale; 8 or more on the depression subscale
(Bjelland et al. 2002).
5.4.2 European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire core 30 Version 3.0 (EORTC QLQ
c30)
This is the most widely used quality of life scale in European cancer patient studies
(Aaronson et al. 1993). It has 30 items consisting of five functional domains
(physical, role, emotional, cognitive and social functioning), three symptom scales
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(pain, fatigue, nausea and vomiting) and a number of single items (dyspnoea, loss of
appetite, insomnia, constipation, diarrhoea and financial difficulties). Each item
relates to the past week and is answered on a four point scale (1-4); not at all, a little,
quite a bit, very much. The two items relating to overall health and quality of life are
rated on a seven point scale (1-7). In accordance with the scoring manual, scores are
then transformed to a 0-100 scale; higher scores represent a better level of
functioning or a worse level of symptoms depending on the parameter measured
(Fayers et al. 2001).
5.4.3 Likert scales for erectile function and how much of a problem it is
Clinicians were interested in the prevalence of erectile dysfunction. These two scales
are routinely used at the Edinburgh Cancer Centre and relate to the past month. The
response to the question, "Did you get erections" was rated on a four point scale (0 to
3 respectively): "No, erection not possible", "Yes, with severely reduced stiffness",
"Yes, with reduced stiffness" and "Yes, with normal stiffness". The second item
asked, "How much of a problem was this for you" and again was scored 0 to 3
respectively: "not a problem", "quite a problem", "a bit of a problem" and "a serious
problem". Lower scores represented worse function and more severe problem
respectively.
5.4.4 International Prostate Symptom Score (IPSS)
Fatigue may have been confounded by urinary symptoms so it was important to
measure these. The IPSS is a seven item scale rated on six points (0-5) to assess
urinary symptoms (Barry et al. 1992). It gives a score 0-35 with a higher score
representing worse symptoms. Mean scores were calculated and the proportion with
moderate to severe urinary symptoms were presented (IPSS > 7) (Fossa et al. 1997).
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5.5 CLINICAL INTERVIEW MEASURES (Studies A and B only)
In addition to the semi structured clinical interview for clinically significant fatigue
described in section 4.2.4, the following measures were also applied (see Appendices
7 and 8).
5.5.1 Structured Clinical Interview for DSM IV - Major depression
section (DSM -IV Axis I Disorders)
This structured psychiatric interview ascertains the presence of the symptoms of
Major Depressive Disorder (MDD) (First et al. 1996). If five or more symptoms
from a list of nine symptoms, at least one of which must be depressed mood or
anhedonia, have been present for two or more weeks the diagnosis ofMDD is made.
In making the diagnosis of MDD, all identified symptoms were counted without
making a judgement about whether they should be attributed to cancer or to
depression. This 'inclusive approach' is the most widely used and was chosen to
maximise the sensitivity and inter-rater reliability of diagnoses (Koenig et al. 1997).
5.5.2 Modified physical activity score
Physical activity was graded for each day of the last week (Morris et al. 1973).
Scores were between 0 (minimal activity) and 4 (very heavy activity). The overall
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6.1 INTRODUCTION
The background to this study has been covered in Chapters 1 and 2. To summarise:
prostate cancer is the most common male cancer and survival for patients with early
localised disease is often beyond 10 years. There is no definitive data with regards to
which treatment gives the best long term survival and so decisions are often made on
the basis of likely side effects such as incontinence, erectile dysfunction and bowel
disturbance. Patients frequently complain of fatigue during radiotherapy and there is
the clinical impression that this persists in a proportion of patients. A small number
of radiotherapy studies have been published prior to October 2003 but the trajectory
of fatigue remains unclear, follow up is short (maximum six weeks), disease stages
are mixed, sample numbers are small and decrease with attrition. None take into
account the possible impact of androgen deprivation therapy prior to radiotherapy or
put fatigue levels in context by comparing to a male non-cancer population.
Commonly fatigue severity has been reported as a continuous fatigue score rather
than the prevalence of fatigue that is of a clinically relevant severity. Additionally,
very few have looked at the biological correlates of fatigue and prostate cancer
beyond haemoglobin and routine biochemistry. There are no published data
regarding fatigue and brachytherapy.
There is consequently a need for larger and longer prospective studies that will
determine the incidence of clinically significant fatigue (CSF) in patients receiving
different treatment regimens. A prospective observational cohort study was therefore
planned to examine the incidence, associations and predictors of CSF in
approximately 200 men with localised prostate cancer receiving either radiotherapy
or brachytherapy. The available numbers would have allowed 80% power to detect a
20% difference between regimens in the incidence of cases of CSF (presumed
clinically relevant as there were no data available to guide sample sizes). It was also
planned to recruit a non-cancer comparison group ofmen of a similar age.
Prior to embarking on a large study, it was necessary to evaluate the feasibility of
recruitment, the patient questionnaire and clinical interview for CSF. It was also
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important to gain information about whether the study design was appropriate and
preliminary indications ofwhat results might be obtained.
6.2 AIMS
(a) To assess likely patient recruitment and attrition
(b) With a view to conducting a larger study of brachytherapy and radiotherapy
patients
(i) Assess the incidence of cases of CSF to aid future sample size
calculations
(ii) Assess whether the three months of neo-adjuvant androgen
deprivation prior to radiotherapy should be included in the
longitudinal assessments
(c) Gain preliminary evidence of associations of cases of CSF and continuous
fatigue scores
(d) Gain preliminary evidence of which biological measures, particularly
inflammatory markers and cytokines changed most with treatment
(e) Pilot the self report patient questionnaire package
(f) Pilot the clinical interview for identifying cases of CSF
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6.3 PROPOSED METHODS
6.3.1 Design
This was a pilot prospective observational cohort study of fatigue in men undergoing
treatment for localised prostate cancer compared to a non-cancer comparison group.
6.3.2 Patient Samples
6.3.2.1 Prostate cancer group sample
A consecutive sample of 45 men with localised prostate cancer was recruited at the
Edinburgh Cancer Centre. All were planned to receive either brachytherapy or
external beam radiotherapy in the near future, or after three months of neo-adjuvant
androgen deprivation therapy. For full treatment details see section 2.1.4.1.
There were three treatment groups:
(a) Brachytherapy (15 patients)
• • 125 • •Patients had radioactive iodine (I ) seeds inserted into the prostate under general
anaesthetic. These remained permanently in situ and a minimum dose of 145Gy was
received over several months. Brachytherapy patients did not routinely receive neo¬
adjuvant androgen deprivation.
(b) External beam radiotherapy (15 patients)
Patients received a dose of 55Gy over 20 fractions (one month, Monday to Friday).
(c) Neo-adjuvant androgen deprivation therapy (15 patients)
Patients received three weeks of biclutamide (Casodex) 50mg daily followed by
monthly injections of LFIRH analogue Goseralin (Zoladex) 3.6mg (for three months
only) prior to receiving radiotherapy.
Justification of prostate cancer patient sample
It is routine practice at the Edinburgh Cancer Centre for patients to receive three
months of neo-adjuvant androgen deprivation therapy prior to radiotherapy.
Androgen deprivation therapy has been noted to be associated with fatigue (Stone et
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al. 2000a) but of the few studies that have examined fatigue prospectively during
radiotherapy, none have included the neo-adjuvant stage of androgen deprivation. In
order to assess the impact of this on fatigue and to inform the recruitment and
assessment strategy for future studies, it was decided to include a third group ofmen
who were starting androgen deprivation therapy prior to radiotherapy.
Patients were not eligible if they had high risk tumours (Stage T3 or Gleason score 8
or above) or were planned to continue with adjuvant androgen deprivation after
radiotherapy (normally for two years). In preparation for future studies, this was to
eliminate the possible confounding factor of prolonged hypogonadism causing
fatigue in addition to the radiotherapy. To eliminate any other major confounding
factors that are recognised to be associated with fatigue, patients were not eligible if
they had another known concurrent cancer diagnosis; anaemia; renal, hepatic or
untreated thyroid dysfunction.
Inclusion criteria
(a) Due to receive brachytherapy or radical external beam radiotherapy
(b) Early localised prostate cancer (clinical rectal examination T1 or T2 or early
radiological T3)
(c) Able to give informed consent
Exclusion criteria
(a) Planned to continue with androgen deprivation after radiotherapy
(b) Clinically T3 on rectal examination
(c) Gleason 8 and above
(d) Another concurrent cancer diagnosis
(e) Haemoglobin less than 100g/l
(f) Untreated thyroid dysfunction
(g) Serum creatinine more than twice the upper limit of normal
(h) Liver function tests more than twice the upper limit of normal
(i) Unable to communicate adequately because of language problems or
cognitive impairment
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6.3.2.2 Non cancer comparison group sample
Justification of non cancer comparison group sample
Fatigue can often be a symptom which many attribute to 'getting older'. In addition,
some men with prostate cancer experience nocturia which could contribute to
disrupted sleep and possible consequent fatigue. In order to assess whether the
severity of fatigue experienced by men with localised prostate cancer was different to
men of a similar age with urinary symptoms it was decided to recruit a sample of 15
men with benign prostatic hypertrophy. These men were consecutively recruited at
the Nurse Urology Clinic at the Western General Hospital, Edinburgh.
Inclusion criteria
(a) Ambulatory patients attending the Nurse Urology Clinic with urinary
symptoms attributed to benign prostatic hypertrophy
(b) Within the age range of the prostate cancer patients
Exclusion criteria
(a) A current diagnosis of cancer
(b) Haemoglobin less than 100g/l
(c) Untreated thyroid dysfunction
(d) Serum creatinine more than twice the upper limit of normal
(e) Liver function tests more than twice the upper limit of normal
(f) Unable to communicate adequately because of language problems or
cognitive impairment
(g) Concurrent chronic disease in which fatigue is recognised to be a prominent
symptom (e.g. multiple sclerosis or severe chronic obstructive airways
disease)
6.3.3 Patient recruitment
Patients were recruited between February and May 2004. A record was kept of those
who declined entry into the study along with their reason for doing so if this
information was volunteered.
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Prostate cancer sample recruitment
Potentially eligible patients planned to receive neo-adjuvant androgen deprivation,
radiotherapy or brachytherapy were identified at the Urology Clinic, Oncology Clinic
and 'Rad Diary' (a computer based appointment system for radiotherapy). They were
introduced to the study and given a patient information sheet by their doctor or
clinical nurse specialist. If the patient agreed to be contacted, they were telephoned
at home by the researcher or seen the next time they were due in hospital. This was
to give them the opportunity to ask any questions about the study and if they chose to
participate, to obtain informed written consent.
Non cancer comparison sample recruitment
These men were identified in the Nurse Urology Clinic and introduced to the study
by their clinic nurse. As they did not routinely return to hospital for several months,
they were given a patient information sheet, questionnaire and consent form to take
home. With their agreement they were telephoned at home by the researcher to give
them the opportunity to ask any questions about the study. If they agreed to
participate they were asked to return the signed consent form and questionnaire in the
post. Once these were received, the patient was telephoned at a time convenient to
them to conduct the clinical interview.
6.3.4 Assessments
6.3.4.1 Baseline data collected
Demographic data
• Date of birth





• T stage (prostate cancer patients only), see section 2.1.2.
• Gleason score (prostate cancer patients only), see section 2.1.3.
• Charlson Comorbidity Index, see section 5.2.3
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6.3.4.2 Content of each assessment
Self rated questionnaire measures
• The Brief Fatigue Inventory (BFI), see section 4.1.2.1
• Hospital Anxiety and Depression Scale (HADS), see section 5.4.1
• European Organisation for the Research and Treatment of Cancer Quality of
Life Questionnaire core 30 version 3.0 (EORTC QLQc30), see section 5.4.2
• Likert scales for erectile function and how much of a problem this is, see
section 5.4.3
• International Prostate Symptom Score (IPSS), see section 5.4.4
• Sleep quality over the last week. Scores 0-20 with higher scores indicating
worse quality sleep (Jenkins et al. 1988).
Interview measures
• Semi structured interview for clinically significant fatigue (CSF), see section
4.2.4
• Structured clinical interview for DSM IV (SCID) - Major depression section,
see section 5.5.1
• Modified activity score, see section 5.5.2
The interviews were performed by me and tape recorded for quality control.
Clinical and biomedical measures
• Body Mass Index
• Concurrent medications were noted
• Karnofsky Performance Status, see section 5.2.4
• blood samples (full blood count, urea and electrolytes, albumin, testosterone,
and markers of systemic inflammatory response: C-reactive protein (CRP)
and interleukin-6 (IL-6), IL-1 receptor antagonist (IL-lra) and sgpl30 (cell
membrane receptor for IL-6). For analysis methods see section 5.3.
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Justification of markers of systemic inflammatory response
The main mediators of CRP production are IL-6, IL-1 and their receptors. I
was advised by Dr Donny McMillan, University of Glasgow, to measure CRP
first and then depending on the results proceed to test the stored samples for
the other cytokines and their receptors.
6.3.4.3 Assessment Intervals
The radiotherapy and brachytherapy groups were assessed three times: baseline (pre-
treatment), one and three months after initial treatment. This was planned to coincide
with anticipated maximum fatigue and routine hospital follow up visits in order to
keep the study burden on the patients to a minimum.
The androgen deprivation group was assessed at baseline and at three months. The
one month assessment was not performed, as these men did not return to hospital as
part of their routine care.
The non cancer comparison group were assessed once only.
6.3.5 Ethical Approval
The study was approved by the Local Research Ethics Committee. Reference number
LREC/2003/8/52.
6.3.6 Statistical Analysis
Data was inspected using histograms and scatter plots. Baseline categorical variables
were described as percentages; continuous variables as means and standard
deviations. The characteristics of the four groups at baseline were compared using
Kruskal Wallis tests, one way analysis of variance (ANOVA) or Chi-squared tests as
appropriate.
Within each treatment group the proportion of cases of CSF at baseline was
compared to one and three months after initial treatment using McNemar's tests;
mean global fatigue scores were compared using Wilcoxon Signed Ranks tests. The
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proportion of cases of CSF in each treatment group at baseline, one and three months
was compared to the non-cancer comparison group using Chi-squared tests; mean
treatment group global fatigue scores were compared using Mann Whitney tests.
To explore the change in cases of CSF between treatment groups whilst adjusting for
any minor differences in baseline prevalence, the number of new cases of CSF
between baseline and one/three months was calculated for each group. These were
then compared using Chi-squared tests. A similar approach was used for fatigue
scores where the mean difference (change) in fatigue scores between baseline and
one/three months was calculated and compared using Student t-tests and one way
analysis of variance (ANOVA) as appropriate.
Associations of cases of CSF at one month were explored using Chi-squared tests for
categorical variables and Student t-tests for the mean changes in continuous variables
between baseline and one month. Pearson product-moment correlation was used for
associations between mean changes in fatigue scores and mean changes in other
variables between baseline and one/three months. F1ADS depression question 8 "I
feel as if I am slowed down" may be construed as referring to fatigue. Hence
associations with depression were performed both including and excluding this item.
This approach has been previously reported (Stone et al. 2000a).
Analyses were performed using SPSS version 12.0 computer software. Pearson Chi-
square test was used for nominal factors, Chi-square test for trend (linear-by-linear
association) was used for ordinal factors and Chi-squared with Yates correction
(continuity correction) was used for 2x2 tables. No correction for multiple testing
was made as these were mainly exploratory and hypotheses generating analyses. A p
value of <0.05 was regarded as statistically significant. This pilot study was designed
to assess feasibility/methodology, and had limited power (could detect approximately
50% difference in proportions). 1 was advised by Dr Rob Elton, PhD and Honorary
Fellow, University of Edinburgh.
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6.4 RESULTS
6.4.1 Recruitment And Attrition
Over three months 49 consecutive men with prostate cancer were eligible for the
study and 45 (92%) agreed to participate (15 in each group). Of the four patients who
declined, two said they "had too much going on", one patient was concerned it would
cause delay with his clinic transport and one patient declined, giving no reason but it
was suspected he may have had literacy difficulties that he did not wish to disclose.
All 15 non-cancer comparison group subjects invited to participate agreed to do so.
The study took eight months to complete and only one of the 45 patients was lost to
follow up when he moved abroad i.e. 98% complete data.
6.4.2 Baseline Characteristics
At baseline the four groups (brachytherapy, radiotherapy, androgen deprivation and
non-cancer comparison group) were similar for all clinical, self report and
biomedical measures. The only statistically significant differences were (a) a smaller
proportion of the brachytherapy group had moderate to severe urinary symptoms
(13% vs. 47%, 60% and 60% respectively p=0.032. This is not surprising as men
with significant urinary symptoms are excluded from receiving brachytherapy as
there is a risk they will develop post-operative urinary retention) (b) serum
testosterone was lower in the radiotherapy group. Again this was expected as they
had already undergone neo-adjuvant androgen deprivation therapy. One man in the
androgen deprivation group was diagnosed as having Major Depressive Disorder.
Other group characteristics are shown in table 6.2.
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Table 6.2 Baseline Clinical Characteristics of patients (p<0.05 in bold)
Treatment Group
Brachy- Radio- Androgen
therapy therapy Deprivation Non-cancer
n=45 n=45 n=45 n=45
% (n) % (n) % (n) % (n) p value
Gleason score 0.345
5 0 0 0 0 7 1 na na
6 73 11 53 8 47 7 na na
7 27 4 47 7 40 6 na na
8 0 0 0 0 7 1 na na
Tumour stage 0.063
1 80 12 40 6 40 6 na na
2 20 3 47 7 60 9 na na




100 87 13 47 7 60 9 67 10
90 13 2 20 3 40 6 20 3
80 0 0 27 4 0 0 7 1
70 0 0 7 1 0 0 7 1
Comorbidity index 0.252
0 80 12 47 7 60 9 40 6
1 7 1 33 5 33 5 47 7
2 13 2 13 2 7 1 7 1
3 0 0 7 1 0 0 7 1
Living with spouse 80 12 66 10 66 10 66 10 0.813*
Living Alone 20 3 33 5 33 5 33 5
Mean age in years (SD) 62.2 (6.3) 65.5 (4.9) 65.5 (7) 67.9 (6.3) 0.101f
Mean body mass index
(SD)
27.6 (3.1) 27.6 (5) 25.9 (4.1) 27.8 (3.5) 0.581 f
Mean activity score (SD) 1.9 (0.7) 1.8 (0.4) 1.8 (0.4) 2.2 (0.6) 0.267f
Not all percentages may add up to 100 as some have been rounded to the nearest whole
number. All comparative tests are Chi-squared tests for trend except * Pearson Chi-squared
and f ANOVA. SD = standard deviation. na=not applicable
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Fatigue results are first presented as cases of CSF then, to enable comparison with
published literature, continuous global fatigue scores are also presented.
6.4.3 CASES OF CLINICALLY SIGNIFICANT FATIGUE (CSF)
6.4.3.1 Incidence of cases of CSF after treatment (See figure 6.1)
6.4.3.1.1 Within treatment group comparisons
Brachytherapy
Cases of CSF significantly increased from 0% (0/15) at baseline to 43% (6/14) at one
month (p= 0.03). By three months there were still 14% cases (3/14) though this was
not statistically different to baseline.
Radiotherapy
Cases of CSF increased from 27% (4/15) at baseline to 46% (7/15) at the end of
radiotherapy (one month) and then decreased to 20% (3/15) by three months after
radiotherapy had started. None of these changes from baseline achieved statistical
significance.
Androgen Deprivation
Cases of CSF decreased from 20% (3/15) at baseline to 13% (2/15) after three
months of treatment. This change was not statistically significant.
6.4.3.1.2 Between treatment group comparisons
In the non-cancer group, 7% (1/15) were cases of CSF. This was not statistically
different to baseline cases of CSF in any of the treatment groups. By one month the
proportion of cases of CSF in both the brachytherapy and radiotherapy groups was
much larger than the non-cancer group (43% and 46% vs. 7% respectively, both
p=0.035) There was a greater incidence of cases between baseline and one month for
the brachytherapy group (43%) than the radiotherapy group (19%) but this did not
achieve statistical significance (p= 0.18). Between baseline and three months, none
of the changes in the proportion of cases between treatment groups were
substantially different.
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Comment
These comparisons were exploratory and the study was not powered to detect
differences between treatment groups as the primary purpose was to assess
feasibility. The absence of a statistically significant difference does not mean there is
not one.
Figure 6.1. Proportions of cases of clinically significant fatigue (CSF) at
baseline, one and three months
6.4.4
baseline 1 month 3 month
■ Brachytherapy ■ Radiotherapy □ Androgen Deprivation
Note the androgen deprivation group were assessed at baseline and 3 months only.
Non cancer comparison group cases of CSF = 7%
dopier 6 66
Study A - Pilot study
6.4.4.1 Associations of cases of CSF after treatment
There were no significant differences between the brachytherapy and radiotherapy
groups, so for the purposes of assessing associations and baseline predictors of cases
of CSF, these two groups have been combined. The prevalence of CSF was highest
one month after initial treatment and in view of the small sample size, analysis was
concentrated on this time point. As the androgen deprivation therapy group could be
considered as being at an earlier treatment stage and did not receive ionising
radiation, they have been described separately.
Brachytherapy and radiotherapy group
Between baseline and one month after initial treatment, cases of CSF at one month
were associated with a statistically significant decrease in role function, white cell
count and basophil count (see table 6.3).
Of the 13 cases of CSF at one month, nine cases were new since baseline. These new
cases of CSF were associated with a larger increase in global fatigue scores (1.0 vs.
0.1, p=0.011) and a decrease in activity scores (-0.5 vs. 0.0, p=0.033) compared to
non-cases.
Despite statistically significant changes from baseline in haemoglobin (145 to 139g/l,
p<0.001) and IL-6 (2.42 to 3.20, p=0.014) there was no association with CSF. There
were no statistically significant changes in CRP and it was not associated with CSF
either.
Androgen Deprivation Group
Those that were cases of CSF at three months (this group were not assessed at one
month) had had a significant decrease in platelets from baseline compared to non
cases (-15 vs. 22.6, p=0.034).
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Table 6.3 Associations of mean changes in continuous variables from
baseline to one month for all cases of CSF (p<0.05 in bold)
(Brachytherapy and radiotherapy)









change SD p value
activity score -0.3 0.7 0.0 0.3 0.130
sleep score 0.3 2.7 1.4 1.8 0.187
Urinary symptoms (IPSS) 8.0 7.3 9.2 3.9 0.584
Erectile function -0.5 1.1 -0.5 0.6 0.904
Fatigue (BFI)
global fatigue 0.7 1.5 0.1 0.6 0.119
HADS
anxiety -1.5 2.0 -1.5 2.5 0.964
depression -0.4 2.1 -0.4 1.5 0.938
depression -Qu8 -0.3 1.8 -0.4 1.1 0.905
EORTC QLQc30
Health related QL -8.3 20.7 0.5 14.1 0.183
Physical Function -4.1 13.5 0.8 6.4 0.205
Role Function -19.2 11.5 -5.2 21.7 0.045
Emotional Function 9.0 20.3 5.7 8.5 0.565
Cognitive Function 1.3 17.3 2.1 13.4 0.889
Social Function -3.8 18.2 -2.1 29.1 0.851
Biological Measures
Haemoglobin -6.9 5.8 -4.4 6.5 0.306
Red Cell Count -0.2 0.2 -0.1 0.2 0.134
White cell count -1.2 1.8 0.2 1.4 0.034
neutrophils -0.5 1.4 0.6 1.5 0.056
lymphocytes -0.6 0.4 -0.5 0.3 0.507
monocytes -0.1 0.2 0.0 0.1 0.318
eosinophils 0.0 0.1 0.1 0.1 0.067
basophils -0.009 0.023 0.008 0.014 0.024
platelets -16.2 34.2 -0.6 25.6 0.178
Albumin -0.5 2.3 -1.0 4.3 0.718
CRP -3.9 11.7 0.4 5.2 0.196
IL-6 0.3 3.1 1.1 2.2 0.432
Testosterone 12.0 15.9 4.6 8.8 0.145
compared using Student t tests
BFI = Brief Fatigue Inventory, CRP = C reactive protein, EORTC QLQc30 = European
Organisation for the treatment of cancer quality of life (QL) questionnaire core 30,
IPSS=lnternational Prostate Symptom Score, HADS -Qu8 = Hospital Anxiety and
Depression Scores minus question 8, IL-6 = Interleukin 6, SD- standard deviation
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6.4.5 THE SYMPTOM OF FATIGUE AS A CONTINOUS VARIABLE
For brachytherapy and androgen deprivation groups, the trajectory of fatigue when
measured by the Brief Fatigue Inventory (giving a continuous global fatigue score)
was different to when cases of CSF were defined by clinical interview. They were
similar for the radiotherapy group.
6.4.5.1 Changes ofglobal fatigue scores from baseline after treatment
6.4.5.1.1 Within treatment group comparisons:
There were no statistically significant changes from baseline in the global fatigue
scores at one or three months for any of the treatment groups separately, or the
combined brachytherapy and radiotherapy group (figure 6.2 and table 6.4)
Brachytherapy
Mean global fatigue scores increased at one month and continued to increase slightly
at three months (whereas cases ofCSF decreased between one and three months).
Radiotherapy
Mean global fatigue scores peaked at the end of radiotherapy (one month) and
decreased to just below baseline levels by three months. This was similar to the CSF
case findings.
Androgen Deprivation
After three months (there was no one month assessment) of androgen deprivation,
mean global fatigue scores increased (but cases of CSF had decreased slightly).
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Figure 6.2. Mean treatment group fatigue scores at baseline, one and three
















androgen deprivation —non cancer comparison
Table 6.4. Mean group fatigue scores at baseline, one and three months
Mean global fatigue score (standard deviation)
n Baseline 1 month 3 months
Brachytherapy 15* 1.53 (1.25) 1.78 (1.47) 2.19 (1.59)
Radiotherapy 15 2.23 (2.09) 2.47 (2.40) 2.05 (1.94)
Androgen Deprivation 15 1.67 (1.08) na na 2.50 (1.74)
Non cancer group 15 1.34 (1.49) na na na na
*
except n=14 at 1 and 3 months, na = not applicable
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Although there were no statistically significant changes within the mean global
fatigue scores over time, further examination of the individual changes revealed that
between 47-60% of subjects rated an increase in their fatigue at one month whilst the
remainder rated a decrease or the same score (see figures 6.3, 6.4 and 6.5). At the
one month assessment I was also aware that some patients would describe
themselves as being more fatigued than before treatment and yet their fatigue scores
were actually lower than baseline (or vice versa). One way to assess this was to ask
the patient to rate their level of fatigue in retrospect (a 'then test'). However, this was
an ad hoc process with a small sample of patients and did not reveal any particular
pattern.
6.4.5.1.2 Between treatment group comparisons
The trajectory of fatigue differed for each treatment group but none of the
comparisons of the mean change between baseline and one month achieved statistical
significance (brachytherapy vs. radiotherapy, 0.46 vs. 0.24 respectively, p= 0.61).
The same was true from baseline to three months although there was a trend for
radiotherapy to decrease from baseline while brachytherapy and androgen
deprivation groups increased (brachytherapy vs. radiotherapy, 0.56 vs. -0.19
respectively, p= 0.07; brachytherapy vs. androgen deprivation, 0.56 vs. 0.83
respectively, p=0.66; radiotherapy vs. androgen deprivation, -0.19 vs. 0.83, p= 0.08).
Comment
It should be remembered that these comparisons were exploratory and the study was
not powered to detect differences between treatment groups.
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Figure 6.3. Individual global fatigue scores for the brachytherapy patients
o 1
months post brachytherapy

























Up %(n) 47(7) 20(3)
Down %(n) 40(6) 66(10)
Same %(n) 13(2) 13(2)
months post radiotherapy
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6.4.5.2 Associations of change in global fatigue scores (see table 6.5)
There were no statistically significant variations between the brachytherapy and
radiotherapy changes in fatigue scores, so these groups have been combined. The
androgen deprivation therapy group did not receive ionising radiation and could be
regarded at as being at an earlier stage of treatment, so they are described separately.
Some of the associations of global fatigue scores were different to cases of CSF.
6.4.5.2.1 Between baseline and one month
Brachytherapy and radiotherapy
From baseline to one month after initial treatment, changes in fatigue scores
inversely correlated with changes in activity levels and role function (same for cases
of CSF), physical function, and cognitive function. Changes in depression scores
correlated with fatigue scores but not once the confounding fatigue question 8 (T feel
slowed down') was removed. Changes in fatigue scores and testosterone also
positively correlated. In common with cases of CSF, despite a statistically significant
drop in haemoglobin (145 to 139g/l, p<0.001), fatigue scores did not correlate with
this, nor was there any relationship to CRP or IL-6.
6.4.5.2.2 Between baseline and three months
Brachytherapy and radiotherapy
From baseline to three months after initial treatment, the only association with an
increase in fatigue was a decrease in monocyte count.
Androgen deprivation therapy
From baseline to three months after commencing treatment, changes in fatigue scores
correlated with change in depression and anxiety and inversely correlated with role
function (cases of CSF were only associated with a decrease in platelets).
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Table 6.5 Associations with change in global fatigue scores and other
measures between baseline and one and three months after initial treatment
(p<0.05 in bold, * indicates p<0.01)
Pearson correlation (r) with global fatigue
score change between baseline and
1 month 3 months
Variable changing
between baseline and









Activity score -0.485* 0.143 0.235
Sleep score 0.325 0.243 0.124
Urinary symptoms (IPSS) 0.319 0.317 -0.128
HADS
anxiety 0.351 -0.127 0.509
depression 0.370 0.084 0.802*
depression - Qu 8 0.284 0.016 0.669*
EORTC QLQc30
health related QL -0.334 -0.177 -0.317
physical function -0.527* 0.116 -0.185
role function -0.378 -0.095 -0.600
emotional function -0.033 0.059 -0.508
cognitive function -0.451 -0.029 -0.260
social function -0.260 0.206 0.080
Biological Measures
Haemoglobin -0.196 0.143 -0.040
White cell count -0.099 0.044 0.341
Neutrophils -0.116 -0.003 0.037
Lymphocytes -0.039 0.177 0.382
Monocytes 0.020 -0.405 -0.209
Eosinophils 0.158 0.330 0.305
Basophils 0.033 -0.012 0.124
Platelets 0.239 0.206 0.075
Albumin 0.149 -0.026 -0.075
CRP 0.139 0.087 na
IL-6 -0.115 -0.080 na
Testosterone 0.525* -0.084 0.403
CRP - C reactive protein, EORTC QLQc30 = European Organisation for the
treatment of cancer quality of life questionnaire core 30, IPSS=lnternational
Prostate Symptom Score, HADS -Qu8 = Hospital Anxiety and Depression
Scores minus question 8, IL-6 = Interleukin 6, na = not applicable
Cohen's (1988) suggested interpretation of strength of relationship for r:
± 0.10 to ± 0.29 = small, ± 0.30 to ± 0.49 = medium, ± 0.50 to ± 1.0 = large
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6.4.6 Changes in biological measures
There was no discernable pattern over time with regards to the relationship between
fatigue and CRP or IL-6 (either measured as cases of CSF or continuous fatigue
scores). In view of the lack of relationship between fatigue and CRP and IL-6,1 was
advised that it would not be worthwhile pursuing further expensive cytokine receptor
assays for IL-lra and sgpl30.
There were some changes in haemoglobin, white cell count, lymphocytes,
eosinophils, platelets and IL-6 between baseline and one/three months indicating that
prostate brachytherapy and radiotherapy may have had a systemic effect. The
changes over time of these parameters are shown in Appendix 9 for completeness.
6.4.7 Patient self report questionnaire package
Patients reported that the content and length of the questionnaire package was
acceptable. As anticipated, some men preferred not to answer questions relating to
erectile function. A small proportion commented that they preferred the scales with
numerical formats rather than ticking boxes with particular phrases, however an
equal proportion expressed the opposite opinion. This was a useful insight into the
limitations of the available validated questionnaire measures and patients seemed to
appreciate the opportunity to discuss their answers in more detail during the clinical
interview.
6.4.8 Clinical interview for identifying cases of CSF
The semi-structured clinical interview for CSF was simple to conduct. The best way
to validate a measure is to see whether it agrees with a 'gold standard' measure
(criterion validity). However with subjective states this is not possible and so the
next best alternative is to assess whether it correlates with other instruments that
purport to measure the same thing or would be expected to correlate with it
(construct validity). For the clinical interview for CSF, construct validity was
assessed by examining whether cases and non cases have significantly different
continuous fatigue scores and quality of life measures. The one month time point was
chosen as this had the greatest numbers of cases of CSF. For the EORTC QLQc30
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functional scales, clinically significant differences have been proposed (moderate =
10 to 20 points, large = more than 20 points) (Osoba et al. 1998). Table 6.6 shows
cases of CSF had significantly higher fatigue scores (both global fatigue measured by
the Brief Fatigue Inventory and the EORTC fatigue subscale) and clinically
significantly poorer health related quality of life, physical, role and social function
than non cases.
Table 6.6 Cases of CSF compared to non cases at one month after
brachytherapy or radiotherapy (compared using Mann Whitney U tests).
P <0.05 in bold




one month variables mean SD mean SD p value
Fatigue measures
global fatigue (BFI) 3.4 1.8 1.1 1.5 0.001
EORTC fatigue subscale 43 19 13 14 <0.001
EORTC QLCc30
Health related QL 61 22 84 18 0.006
Physical Function 78 16 94 7 0.002
Role Function 64 20 94 21 <0.001
Emotional Function 85 14 92 11 0.160
Cognitive Function 85 20 91 12 0.470
Social Function 76 23 92 22 0.006
BFI = Brief Fatigue Inventory, EORTC QLQc30 = European Organisation for the treatment
of cancer Quality of Life (QL) Questionnaire core 30. SD = Standard deviation
Examples of what cases of CSF experienced
One man said, "I feel severely drained when doing things. Mentally and physically
exhausted. Consequently 1 avoid doing things that are not absolutely necessary".
Another had to get up later than usual in the morning. Since treatment he had to
curtail most activities because he felt "a complete lack of energy and no strength".
He therefore no longer did any cooking and bought ready meals instead. He did not
Chapter 6 76
Study A - Pilot study
even feel able to do his favourite hobby, gardening. One patient described having
"very low energy...listless I just don't feel able to do anything I used to I'm
frustrated because I don't even have the energy to complete a task at home (like
hanging the washing out)....I feel guilty because my wife works and she is still
having to do everything". Several expressed that they felt "lifeless" and had to pace
themselves when doing anything. This resulted in those who were employed feeling
unable to return to work at that point.
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6.5 DISCUSSION
6.5.1 Main findings
This study demonstrated that studying prostate cancer patients in the Edinburgh
Cancer Centre was feasible. Recruitment was good and only one patient was lost to
follow up when he moved abroad. The combination of the questionnaire package,
clinical interview and blood test proved acceptable to patients, as did the timing of
assessments.
Not everyone experienced fatigue as a side effect of treatment but there was a
substantial and statistically significant increase in the number of cases of clinically
significant fatigue (CSF) in patients one month after brachytherapy treatment. The
number of cases in the radiotherapy group also increased at one month but not as
much (and this increase was not statistically significant). To put this in context, at
one month after treatment there were 43% and 46% of cases of CSF in the
brachytherapy and radiotherapy groups respectively, compared to only 7% in the
non-cancer group. By three months cases of CSF had decreased in both groups but
there was no substantial change in the androgen deprivation group.
Interestingly changes observed in the continuous measure of fatigue revealed a
somewhat different pattern. There were no statistically significant changes from
baseline in fatigue scores in any of the groups. Possible reasons for this discrepancy
between the self-report continuous measures and clinically rated cases are: (a) the
Brief Fatigue Inventory was not sensitive enough to pick up clinically detectable
changes in fatigue (b) during the course of treatment the patients adapted to the
increased fatigue to the point of regarding the new level as 'normal' (this change in
internalised standard is referred to as response shift (Visser et al. 2000)) (c) the
interviewer (me) was biased and over diagnosed CSF (observer bias). However I
postulate that (d) because approximately half the group increased their fatigue rating
and the rest did not, the mean scores for the group evened out and did not show any
statistical change.
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The discrepancy in results between cases of CSF and continuous scale measures in
fact raises doubt about the validity of the use of scale based questionnaires in fatigue
research as a whole. Therefore further work examining the use of a case definition
approach is warranted.
6.5.2 Subsidiary findings
Some of the radiotherapy group were cases of CSF at baseline. This group also had
higher mean baseline global fatigue scores than the other treatment groups. A
contributory factor may have been that their testosterone levels were low having
completed their neo-adjuvant androgen deprivation therapy. After a rise in fatigue
scores at the end of radiotherapy (one month), most of the scores returned to baseline
levels by three months. Whereas for the brachytherapy group, three months after the
implantation there is a suggestion that fatigue scores may still be increasing. In
addition, CSF cases had not returned to baseline levels. One hypothesis is that the
suggestion of prolonged fatigue after brachytherapy may be due to long term
delivery of low dose radiation that may continue for up to nine months. Further
follow up of the brachytherapy group is justified to determine that trajectory of
fatigue.
In common with another study (Stone et al. 2000a) there was a trend for fatigue
scores to increase in the group undergoing androgen deprivation therapy. In the
present study this was not associated with an increase in cases of CSF so impact on
functioning was minimal.
Fatigue is part of the syndrome of depression and it would be expected that the
symptoms of fatigue and depression would be associated. This was confirmed for the
androgen deprivation group where the increase in fatigue scores from baseline to
three months strongly correlated with changes in depression scores. The relationship
was weaker for the brachytherapy and radiotherapy group. This disparity may be
explained by the clinical impression of differing levels of anxiety of patients who
were at different stages of their 'cancer journey'. Radiotherapy and brachytherapy
patients tended to be less anxious after their treatment was completed whereas those
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on androgen deprivation were about to embark on radiotherapy (which some found a
daunting prospect) and in addition they had had to contend with side effects from
low testosterone such as erectile dysfunction, weight gain and loss of muscle mass;
all ofwhich seemed to impact on their feeling ofwell being.
There were no strong indications that fatigue in the brachy/radiotherapy group was
associated with systemic inflammatory response. There were no statistically
significant changes in CRP during or after treatment and no association with cases of
CSF or fatigue scores. This is similar to findings only published in abstract form so
far (Geinitz et al. 2003). IL-6 did statistically significantly increase after one month
in the brachytherapy group but this was not associated with changes in fatigue scores
or cases. Given the lack of change in CRP and no relationship between fatigue and
IL-6, I was advised there was not sufficient scientific rationale to justify further
expensive assays for IL-lra and sgpl30.
There were some associations between fatigue and biological parameters but no
consistent pattern. In the radiotherapy and brachytherapy group, although there was a
statistically significant fall in haemoglobin one month after initial treatment, this did
not correlate with fatigue scores. This is probably because the drop from a mean of
145g/L to 139g/L was not clinically significant. Two other studies of prostate
radiotherapy patients had similar findings (Windsor et al. 2004;Chander et al. 2005).
It had been expected that the relationship between fatigue and testosterone would be
inverse (more fatigue, less testosterone). The opposite was true but it is unlikely that
fatigue occurs directly as a result of higher testosterone. It is more likely that this
result reflects recovery of testosterone production in the radiotherapy group once
neo-adjuvant androgen deprivation therapy has been stopped.
For the brachytherapy and radiotherapy group, cases of CSF at one month were
associated with a decrease in white cell and basophil count from baseline. Similarly
between baseline and three months, fatigue scores inversely correlated with
monocyte counts. This was the opposite of what was anticipated as it was
hypothesised that fatigue would be associated with a systemic inflammatory response
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to radiotherapy and brachytherapy (and hence raised white cell counts). It is possible
that these results arose from multiple testing. However, these changes may represent
the cytotoxic effects of ionising radiation affecting the bone marrow in the pelvis or
the circulating blood volume through the prostate and surrounding tissues.
Lymphocytes are particularly sensitive to radiation but monocytes and macrophages
(which primarily produce CRP and cytokines) less so. In another study, fatigue has
been found to be predicted by baseline neutrophil and monocyte counts in breast
cancer patients receiving radiotherapy (Wratten et al. 2004).
Fatigue scores and cases of CSF shared the some but not all associations. This may
be because fatigue scores are continuous variables and cases of CSF are categorical.
Using the latter whilst being more clinically meaningful, reduces the statistical power
of detecting a relationship between a variable and an outcome (Altman & Royston
2006).
6.5.3 Limitations
All findings in this preliminary study have to be viewed in the context of the small
sample size. It had power only to detect very large (approximately 50% difference in
proportions) differences between brachytherapy and radiotherapy groups. It cannot
therefore be assumed that the negative findings mean there were no differences in the
incidence of fatigue. It is unlikely however that the absolute size of the difference
would be of clinical significance.
This was a hypothesis generating study and multiple statistical tests were performed.
Some significant results may have arisen by chance and there was no correction
made for this possibility, hence caution must be exercised when interpreting results.
As this was not a randomised study one cannot be sure the patients in each group
were similar and must be cautious making comparisons. In clinical practice there is a
pre-treatment selection bias that may well be present in this sample. For example
brachytherapy patients tend to be younger than radiotherapy patients and have to be
fit enough to undergo a general anaesthetic. In order to address this possible bias, the
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changes in fatigue scores and cases of CSF were compared rather than the absolute
values. However, in order to address this shortcoming in a subsequent study, I looked
into the possibility of performing a subsidiary study of fatigue as part of a national
multicentre randomised controlled trial. The 'ProtecT' study (Prostate Cancer
Testing and Treatment www.epi.bris.ac.uk/protect) is attempting to address questions
regarding which treatment gives best outcome for localised prostate cancer.
However, a subsidiary fatigue study comparing fatigue with different treatments was
not feasible or appropriate because brachytherapy is not included as a treatment
option in the 'ProtecT' study and it is not totally randomised as patients can choose a
treatment if they do not want to be randomly allocated to one.
IL-6 is produced as part of the host's systemic inflammatory response. It is also
produced by prostate cancer cells and acts as an autocrine growth factor (Okamoto et
al. 1997). It is not possible to determine what was the source of the IL-6 in this
study.
6.5.4 Related literature
To my knowledge this is the only study to prospectively examine fatigue in men
receiving prostate brachytherapy so these results can not be directly compared to
other literature.
As mentioned in section 2.2.3.1, there have been a limited number of prospective
studies specifically examining fatigue in prostate cancer during radiotherapy. A study
of 36 patients found fatigue increased by the end of radiotherapy (measured using the
Piper Fatigue Scale) and then decreased by six weeks afterwards, though not quite to
baseline levels (Monga et al. 1999). An abstract examining 105 patients receiving
prostate radiotherapy (some of whom had had surgery as well) also found fatigue
increased with radiotherapy but 8 weeks afterwards had still not reached baseline
(Geinitz et al. 2003).
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Studies published since October 2003
One of the difficulties in comparing previous published work regarding fatigue is the
use of different fatigue measures that are not comparable. Since starting this work,
two studies that used the same fatigue measure as the present study (the Brief Fatigue
Inventory, BFI) have been published.
1) 65 men who received radiotherapy (50Gy in 20 fractions) for prostate cancer were
randomised to participate in an exercise intervention or be in a control group
(Windsor et al. 2004). In common with the findings in the present study, both groups
had an increase in BFI fatigue score by the end of radiotherapy (but this was only
statistically significant in the control group for whom fatigue remained raised four
weeks post radiotherapy). There was no difference in fatigue between the groups at
baseline or after radiotherapy (and the equivalent mean global fatigue scores were
approximately 1.4 and 2.4 respectively, so comparable to the present study values).
Depression was not measured. It should be noted however that although patients had
'localised' prostate cancer, this group was not homogeneous as 19 patients were
receiving androgen deprivation therapy and although 51/65 had Tlor T2 tumours it is
not clear whether the some of the remaining 14 men had T4 disease. In common with
other studies, follow up was short and limited to four weeks after completion of
radiotherapy.
2) A study of 28 patients with prostate cancer who received radiotherapy (74Gy
delivered in 30-37 fractions) showed that mean BFI global fatigue statistically
significantly increased to a maximum at the end of radiotherapy (Truong et al. 2006).
They had similar values to this study (an equivalent mean global fatigue score of
1.27 at baseline, 2.61 at the end of radiotherapy and 1.67 a median of 6.5 weeks post
radiotherapy). They had a longer course of androgen deprivation therapy prior
radiotherapy than the present study (median duration of 12.2 months) and included
patients with more advanced disease (stages T1-T4)
The study with the longest follow up reported 40 out of 62 prostate radiotherapy
patients with complete data between 12-24 months post treatment (Monga et al.
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2005). Results showed fatigue (Piper Fatigue Scale) was still statistically
significantly higher than baseline at 4-8 weeks and at 12-24 months post treatment.
However it should be noted that the follow up intervals were very variable, only two
thirds of the study patients had complete data and it was not clear what proportion
received androgen deprivation therapy.
Overall, these studies suggest that there may be a small proportion of patients who
have fatigue as a longer term side effect of radiotherapy though this was not the case
in the present study.
6.5.5 Conclusions
(1) This study demonstrated that studying prostate cancer patients in the
Edinburgh Cancer Centre was feasible.
(2) The assessment methods were acceptable to patients.
(3) Not everyone experienced fatigue as a side effect of treatment.
(4) There was evidence of a substantial increase in fatigue one month after initial
radiotherapy/ brachytherapy but only with regards to cases of clinically
significant fatigue not fatigue scores. There was an increase in fatigue with
androgen deprivation but this did not have much clinical impact.
(5) Prostate radiotherapy and brachytherapy appeared to have a systemic effect
but there was no strong evidence to suggest fatigue in this population was
associated with a systemic inflammatory response.
(6) Fatigue seemed to be transient in the radiotherapy group and was back to
baseline levels by three months. However, there was the suggestion of
prolonged fatigue in the brachytherapy group which was worthy of future
study.
(7) Given the lack of supportive evidence for prolonged fatigue after
radiotherapy (consistent with some of the existing literature) and lack of any
published fatigue data in relation to brachytherapy, it was decided the
clinically important question to address is what happens to fatigue in the
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7.1 INTRODUCTION
Following analysis of the preliminary study (Study A), it was decided to focus
attention on men with early localised prostate cancer receiving brachytherapy. This
was because (a) there was a suggestion of fatigue still increasing three months after
implantation and (b) to date, there has been no published data relating to fatigue after
brachytherapy so this would generate new information.
7.2 AIMS
To determine the incidence, associations (biological and psychological) and
predictors of cases of clinically significant fatigue (CSF) and continuous fatigue
scores in men with localised prostate cancer up to 12 months after receiving
brachytherapy
To determine whether the prevalence of CSF in men at baseline, one, three, six, nine
or 12 months after brachytherapy is significantly different to a non-cancer
comparison group.
7.3 HYPOTHESES
There would be more cases of CSF/higher global fatigue scores (a) at one, three, six
and nine months after brachytherapy than at baseline (b) in the brachytherapy group
than the non cancer comparison group.
Cases of CSF/higher global fatigue scores at any time point would be associated with
(a) greater depression (b) lower physical activity (c) lower serum testosterone (d)
lower quality of life (e) more severe urinary symptoms and (f) raised C reactive
protein (CRP)
Cases of CSF which persisted twelve months after starting treatment, would be
predicted by (a) higher baseline fatigue (b) higher baseline depression (c) lower
baseline physical activity than non cases.
Chapter 87
Study B - Fatigue After Brachytherapy
7.4 METHODS
7.4.1 Design
A prospective observational cohort study of fatigue in men undergoing
brachytherapy compared to a non-cancer comparison group of men with benign
prostatic hypertrophy.
7.4.2 Patient Samples
Following on from the preliminary study (Study A), the consecutive samples of
brachytherapy and non-cancer comparison group patients were extended from 15 to
50 men in each group.
7.4.2.1 Brachytherapy group sample
Inclusion criteria
(a) Due to receive brachytherapy
(b) Able to give informed consent
Exclusion criteria
(a) Another concurrent cancer diagnosis
(b) Haemoglobin less than 1 OOg/L
(c) Untreated thyroid dysfunction
(d) Serum creatinine more than twice the upper limit of normal
(e) Liver function tests more than twice the upper limit of normal
(f) Unable to communicate adequately because of language problems or
cognitive impairment
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Brachytherapy group sample recruitment
Between January and October 2005 potentially eligible patients planned to receive
brachytherapy were identified at the Oncology Clinic. They were introduced to the
study and given a patient information sheet by their doctor or clinical nurse
specialist. If the patient agreed to be contacted, they were telephoned at home by a
researcher or seen the next time they were due in hospital. This was to give them the
opportunity to ask any questions about the study and if they chose to participate, to
obtain informed written consent. A record was kept of those who declined entry into
the study along with their reason for doing so if this information was volunteered.
7.4.2.2 Non-cancer comparison sample
The inclusion and exclusion criteria remained the same as the pilot (Study A) except
that as this study was focused on brachytherapy patients who were generally younger
and fitter than radiotherapy patients, the age and fitness criteria of the non cancer
comparison group had to be adjusted accordingly.
Inclusion criteria
(a) Ambulatory patients attending Nurse Urology (at the Western General
Hospital) with urinary symptoms attributed to benign prostatic hypertrophy
(b) Within the same age range as the brachytherapy patients
(c) Potentially fit enough for a general anaesthetic
Exclusion criteria
(a) A current diagnosis of cancer
(b) Haemoglobin less than 1 OOg/L
(c) Untreated thyroid dysfunction
(d) Serum creatinine more than twice the upper limit of normal
(e) Liver function tests more than twice the upper limit of normal
(f) Unable to communicate adequately because of language problems or
cognitive impairment
(g) Concurrent chronic disease in which fatigue is recognised to be a prominent
symptom (e.g. multiple sclerosis or severe chronic obstructive airways
disease)
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Non-cancer comparison sample recruitment
These men were identified in the Nurse Urology Clinic and introduced to the study
by their clinic nurse. As they did not routinely return to hospital for several months,
they were given a patient information sheet, questionnaire and consent form to take
home. With their agreement they were telephoned at home by a researcher to give
them the opportunity to ask questions about the study. If they agreed to participate
they were asked to return the signed consent form and questionnaire in the post.
Once these were received, the patient was telephoned at a time convenient to them to
conduct the clinical interview.
7.4.3 Assessments
All methods and measures were identical to Study A except the measure of sleep
quality was eliminated because patients generally had difficulty answering this. It
had not varied significantly between or within treatment groups over time in study A.
7.4.3.1 Baseline data collected
Demographic data
• Date of birth





• T stage (prostate cancer patients only), see section 2.1.2.
• Gleason score (prostate cancer patients only), see section 2.1.3.
• Charlson Comorbidity Index, see section 5.2.3
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7.4.3.2 Content of each assessment
Self rated questionnaire measures:
• The Brief Fatigue Inventory (BFI), see section 4.1.2.1
• Hospital Anxiety and Depression Scale (HADS), see section 5.4.1
• European Organisation for the Research and Treatment of Cancer Quality of
Life Questionnaire core 30 version 3.0 (EORTC QLQc30), see section 5.4.2
• Likert scales for erectile function and how much of a problem this is, see
section 5.4.3
• International Prostate Symptom Score (IPSS), see section 5.4.4
Interview measures:
• Semi structured interview for clinically significant fatigue (CSF), see section
4.2.4
• Additional questions
o Do you feel that fatigue is a problem for you? (Yes/No)
o What do you think causes your fatigue?
• Structured clinical interview for DSM IV (SCID) - Major depression section,
see section 5.5.1
• Modified activity score, see section 5.5.2
Clinical and biomedical measures:
• Body Mass Index
• Concurrent medications were noted
• Karnofsky Performance Status, see section 5.2.4
• blood samples (full blood count, urea and electrolytes, albumin, testosterone,
and C-reactive protein (CRP). For analysis methods see section 5.3.
hapter 91
Study B - Fatigue After Brachytherapy
Until March 2005, all assessments where performed by the author (DS). Between
March 2005 and February 2006, Morven Shipway, a part time NHS research nurse
with previous oncology experience was also trained to conduct the assessments. She
received training in how to administer the clinical interview for clinically significant
fatigue from DS. The SCID interview training was conducted by staff from the
Symptom Management and Research Trials (SMaRT) team based at the University
ofEdinburgh Cancer Research Centre.
7.4.3.3 Assessment Intervals
The assessments were extended over a follow up period of 12 months (baseline, one,
three, six, nine and twelve months) because in Study A there was a suggestion that
fatigue was still increasing at three months post brachytherapy.
The non cancer comparison group were assessed once only.
7.4.4 Ethical Approval
The study was approved by the Lothian Research Ethics Committee. Reference
number LREC/2003/8/52.
7.4.5 Statistical Analysis
Based on preliminary data from Study A, the expected proportion of men
experiencing CSF 12 months post brachytherapy was 0.15. Recruiting a total of 50
brachytherapy patients provided a 95% confidence interval width of +/- 0.10.
Comparing to 50 non-cancer men gave 80% power to detect a 25% difference
(assumed to be clinically significant) in CSF between the two groups, at a
significance level of 0.05.
The data were inspected using histograms and scatter plots. Baseline categorical
variables were described as percentages; continuous variables as means and standard
deviations. The number of baseline cases of CSF in the brachytherapy and non-
cancer groups were compared using Chi-squared tests; Mann Whitney U tests and
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Student t-tests were used for continuous variables as appropriate. C- reactive protein
(CRP) results were heavily skewed so were log. transformed prior to analysis.
Changes in the number of cases of CSF at one, three, six, nine and twelve months
were compared to baseline using McNemars Test; continuous fatigue scores were
compared using Wilcoxon Signed Rank Tests.
Associations of new cases of CSF at one month post brachytherapy were examined
using Chi-squared test for categorical variables and Mann Whitney U Tests for
continuous variables. The mean difference (change) in continuous variables between
baseline and one month were calculated. Correlations between changes in continuous
fatigue scores and other continuous variables were examined using Spearman Rank
Order Correlations. HADS depression question 8 "I feel as if I am slowed down"
may be construed as referring to fatigue. Flence associations with depression were
performed both including and excluding this item. This approach has been previously
reported (Stone et al. 2000a).
The proportion of cases of CSF at each time point was compared to the non cancer
comparison group using Chi-squared tests; continuous fatigue scores were compared
using Mann Whitney U Tests.
Data were analysed using SPSS 13.0 computer software. Pearson Chi- square test
was used for nominal factors, Chi-square test for trend (linear-by-linear association)
was used for ordinal factors and Chi-squared with Yates correction (continuity
correction) was used for 2x2 tables. A p value of <0.05 was regarded as statistically
significant, though those <0.01 have also been highlighted. I was advised by Dr Rob
Elton, PhD and Honorary Fellow, University of Edinburgh.
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7.5 RESULTS
53 men were eligible for the study and the participation rate was 96.2% (51/53). Two
declined participation. One man had a severe needle phobia and did not want to have
the blood tests, the other had previously participated in a number of research studies
because of a relative's medical condition and already felt overburdened.
51 patients entered the study. One patient had his brachytherapy implant and
subsequently did not return for follow up (he moved abroad). One patient was found
to have bone metastases within three months of his brachytherapy implant and was
started on androgen deprivation therapy. This patient was followed up but has been
excluded from the prospective analysis because of the possible confounding effects
of metastatic cancer and androgen deprivation therapy on fatigue. Data was collected
from the 49 remaining patients at all assessment points except the six month interval
(35 patients). The first 15 patients form the preliminary study had already passed this
time point once ethical approval had been obtained for the study extension.
7.5.1 Characteristics of the sample (See tables 7.1 and 7.2)
The mean age of the brachytherapy group was 62.7 years (SD 5.7). There were no
statistically significant differences between the demographic, clinical or self report
measures between the brachytherapy and non-cancer comparison group at baseline
except the brachytherapy patients had less severe urinary symptoms and lower
testosterone levels (11.1 vs. 16.3nmol/L, p>0.001).
Comment
This shows men with benign prostatic hypertrophy were a good comparison group.
One of the original reasons for choosing these men in study A was to be able to
control for urinary symptoms, especially nocturia, which may contribute to disrupted
sleep and fatigue. This was less of an issue for brachytherapy patients because in
order to be eligible, they needed to have good urinary flow. It is therefore not
surprising they had lower IPSS scores than the non-cancer comparison group. There
was however no association between fatigue and urinary symptoms or insomnia, so it
is unlikely that this difference is relevant.
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The lower testosterone levels in the brachytherapy group were due to 14 patients
having undergone neo-adjuvant androgen deprivation to reduce their prostate
volume. This was a larger proportion than originally expected and arose because of
technical differences between referral centres in measuring prostate volumes prior to
formal brachytherapy eligibility assessment.
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Table 7.1. Baseline comparison of continuous variables between the
brachytherapy and non-cancer comparison group (p<0.05 in bold)
Non-cancer group Brachytherapy group
n==51 n= 51 P
Baseline variable mean SD mean SD value
Age (years) 65.0 6.3 62.7 5.7 0.062*
Fatigue (BFI) f
Global fatigue 1.4 1.2 1.8 1.6 0.402
HADS scores §
anxiety 4.2 3.7 4.6 3.4 0.501
depression 3.1 2.2 3.1 3.1 0.429
depression - Qu8 2.1 1.9 2.1 2.6 0.440
EORTC QLQc30 Scores
Health Related QL* 82 13 80 17 0.753
Physical Function* 93 9 91 15 0.625
Role Function* 94 13 91 17 0.596
Cognitive Function* 80 16 85 15 0.098
Social Function* 89 16 88 19 0.875
Pain** 10 18 7 17 0.335
Insomnia** 21 26 25 25 0.281
Constipation** 7 15 6 16 0.469
Diarrhoea** 7 15 7 15 0.804
Activity score 2.3 0.4 2.1 0.6 0.180
Urinary symptoms (IPSS) D 10.7 5.3 6.7 5.2 <0.001
BFI = Brief Fatigue Inventory, EORTC QLQc30= European Organisation for the
Research and Treatment of Cancer Quality of Life core 30, FIADS -Qu8= Hospital
Anxiety and Depression Score minus question 8 ('I feel slowed down'), IPSS =
International prostate symptom score, SD = Standard Deviation
* Higher scores = better function, ** Higher scores - worse symptoms
Non cancer and brachytherapy group respectively:
t Global fatigue > 3 = 10% and 14%;
§ anxiety 29 = 12% for both groups, Depression > 8 = 4% and 6%, Depression > 8 -Qu8
= 4% for both groups
Q IPSS >7 65% and 28%
All comparative tests are Mann Whitney U Tests except j Student t-test
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Table 7.2 Baseline comparison of categorical variables between the







% (n) p value
Case of Clinically Signif. Fatigue 0.647
no 96 (49) 94 48)
yes 4 (2) 6 3)
Employment status 0.232
retired 63 (32) 49 25)
working 37 (19) 51 26)
Marital status 0.991
unmarried 6 (3) 6 3)
married/with partner 78 (40) 80 41)
divorced 12 (6) 10 5)
widowed 4 (2) 4 2)
Deprivation Index (SIMD) 0.437
1 45 (23) 49 24)
2 28 (14) 22 11)
3 22 (11) 10 5)
4 6 (3) 10 5)
5 0 (0) 8 4)
Karnofsky Performance status 0.232
70 0 (0) 2 1)
90 8 (4) 12 6)
100 92 (47) 86 44)
Comorbidities score 0.472
0 65 (33) 77 39)
1 33 (17) 18 9)
2 2 (1) 6 3)
Tumour stage na
1 na na 73 37)












Erectile function a problem na










SIMD = Scottish Index of Multiple Deprivation, na = not applicable (descriptive only).
All comparative tests are Chi-squared tests
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Results are first presented as cases of clinically significant fatigue, then secondly as
mean global fatigue scores (to allow comparison with previously published data).
7.5.2 CASES OF CLINICALLY SIGNIFICANT FATIGUE (CSF)
7.5.2.1 Incidence of CSF cases over 12 months after brachytherapy
There was a statistically significant increase in the number of cases of CSF between
baseline and one month after brachytherapy (6 vs.29%, p=0.001, incidence of 23%).
The prevalence then decreased to 16% at three months, 11% at six months, 12% at
nine months and was 14% at twelve months (see figure 7.1 and table 7.3). There
were three cases of CSF before brachytherapy and all except one remained cases
during the 12 months follow up. Most cases of CSF occurred at one month post
brachytherapy but three of the seven who were cases of CSF at 12 months did not
have CSF at that point. The individual patient profiles of CSF over time did not show
any particular pattern (figure 7.2).
7.5.2.2 CSF in brachytherapy patients vs. non cancer comparison
group
The non-cancer comparison group had a CSF prevalence of 4% (2/51). Post
brachytherapy CSF was significantly higher than the non-cancer comparison group at
one and three months, but not at six, nine or 12 months (see table 7.3).
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Table 7.3. Cases of Clinically Significant Fatigue (CSF) after brachytherapy
months post brachytherapy
0 1 3 6 9 12
Total n 49 49 49 35 49 49
Total cases of CSF % (n) 6(3) 29(14) 16 (8) 11 (4) 12(6) 14(7)
Baseline CSF % (n) 6(3) 6(3) 6(3) 6(2) 4(2) 4(2)
new cases of CSF % (n) na 23 (11) 10(5) 6(2) 8(4) 10(5)
total compared to
baseline CSF. p value*




0.678 0.001 0.049 0.219 0.156 0.089
*Compared using McNemartest, ** compared using Chi-squared test
I
311 1
0 1 2 3 4 5 6 7 8 9 10 11 12
months after brachytherapy
■ baseline cases of CSF □ new cases of CSF post brachytherapy
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Figure 7.2. Individual patient profiles of clinically significant fatigue (CSF) after
brachytherapy
months post brachytherapy
Patient 0 1 3 6 9 12
1 na






























1 case of CSF
H not a case
I na | not assessed
Excluded from analysis
because of metastatic
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7.5.2.3 Associations of new cases of CSF at one month
The highest prevalence of cases of CSF was one month after brachytherapy. As
hypothesised, those who were cases of CSF before brachytherapy tended to remain
so after treatment. It was therefore of interest to examine those who became new
cases of CSF after brachytherapy.
New cases of CSF at one month reported statistically significantly poorer health
related quality of life, physical functioning, role functioning and higher depression
scores compared to non cases. There was also a trend for new cases of CSF to have
poorer social functioning and more pain (see table 7.4). There were no differences in
the severity of anxiety, urinary symptoms, activity levels or any of the blood
parameters.
Comment
Previous published studies have shown a strong association between fatigue and
continuous HADS depression scores. This study confirms that finding however it
should be noted that mean scores were low and decreased from baseline over time
(baseline, 1, 3, 6, 9 and 12 months: 2.98, 2.31, 2.63, 2.37, 2.37, 2.33 respectively ).
There were hardly any patients who had clinically relevant levels of depression (see
table 7.4). Anxiety scores also decreased from baseline (0, 1, 3, 6, 9 and 12 months
respectively 4.61, 3.22, 3.1, 3.29, 3.04, 3.20). In contrast to the hypotheses, CSF was
not associated with lower physical activity, more severe urinary symptoms, or CRP.
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Table 7.4 Associations of new cases of Clinically Significant Fatigue (CSF)
and continuous variables at one month post brachytherapy (p<0.05 in bold)
new case of CSF one month post
brachytherapy
Yes No
One month post n-M n-35
brachytherapy variables Total n mean SD mean SD P-value
Fatigue (BFI)
global fatigue 46 2.6 1.4 1.2 1.6 0.004
HADS scores §
anxiety 46 3.5 2.8 2.7 3.1 0.320
depression 46 3.2 1.9 1.6 2.3 0.007
depression - Qu8 46 1.8 1.5 1.1 2.0 0.049
EORTC QLQc30
Health related QL* 46 65 22 86 14 0.004
Physical function* 46 86 12 95 9 0.009
Role function* 46 73 8 94 12 <0.001
Emotional Function* 46 86 13 90 12 0.234
Cognitive Function* 46 88 11 90 12 0.538
Social function* 46 82 14 90 14 0.067
Pain** 46 17 17 8 14 0.080
Insomnia** 46 18 23 20 25 0.874
Constipation** 46 15 23 8 16 0.253
Diarrhoea** 46 12 17 11 18 0.813
activity score 46 1.8 0.3 2 0.6 0.177
Urinary symptoms (IPSS) 46 15.6 8.4 11.7 7.3 0.146
BFI = Brief Fatigue Inventory, EORTC QLQc30 = European organisation for the research
and treatment of cancer quality of life core 30 scale, FIADS -Qu8= Hospital Anxiety and
Depression Score minus question 8 ('I feel slowed down'), IPSS = International Prostate
Symptom Score, QL quality of life, SD = Standard Deviation,
* Higher scores = better function, ** Higher scores = worse symptoms
For new cases of CSF and non-cases respectively:
§ anxiety ^ 9 = 9% and 6%, Depression s 8 = 0% and 3% (same for Depression > 8-Qu8 )
Compared using the Mann Whitney U Test
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Changes from baseline in new cases of CSF at one month
It was of interest to find out what had changed between baseline and one month post
brachytherapy for those that had become new cases of CSF. As anticipated they had
a statistically significant increase in global fatigue scores. They also had a decrease
in health related quality of life, physical function and role functioning and an
increase in pain scores. Statistically significant results however do not necessarily
translate to clinically significant changes. A change of between 10-20 points on the
EORTC scale has been defined as a moderately large clinically significant change
(Osoba et al. 1998). Changes in quality of life, role function and increase in pain
scores all achieved these criteria. However, there were no substantial differences
between cases and non cases with regards to changes in urinary symptoms, blood
measures, anxiety or depression (see table 7.5).
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Table 7.5 Changes between baseline and one month after brachytherapy for
new cases and non cases of CSF (p<0.05 in bold)
new case of CSF one month after
brachytherapy
Yes No
Variable changing n=11 n=35







global fatigue 46 0.91 1.15 -0.29 1.39 0.011
HADS
anxiety 46 -0.91 1.22 -1.71 2.26 0.263
depression 46 0.09 1.30 -0.97 2.05 0.420
depression -Qu8 46 -0.27 1.10 -0.66 1.64 0.282
EORTC QLQc30
Health related QOL 46 -9.85 21.35 2.14 11.67 0.031
Physical function 46 -5.45 13.27 0.57 6.74 0.025
Role function 46 -19.70 14.56 0.00 11.43 <0.001
Emotional Function 46 1.52 10.42 5.71 11.39 0.254
Cognitive Function 46 1.52 15.73 2.86 13.70 0.746
Social function 46 -1.52 17.41 -3.33 17.53 0.742
Pain 46 12.12 15.08 1.90 15.00 0.035
Insomnia 46 -9.09 26.21 -4.76 21.61 0.522
Constipation 46 6.06 13.48 2.86 12.45 0.470
Diarrhoea 46 0.00 14.91 5.71 22.12 0.428
Activity score 46 -0.39 0.50 -0.11 0.47 0.177
Urinary symptoms (IPSS) 45 8.55 7.49 5.65 5.97 0.272
BFI = Brief Fatigue Inventory, EORTC = European Organisation for the Research and
Treatment of Cancer Quality of Life scale, HADS -Qu8 = Hospital Anxiety and Depression
Score minus question 8 score (' I feel slowed down'), IPSS = International Prostate
Symptom Score, QOL = Quality of life, SD = Standard Deviation
Compared using Mann Whitney U Test
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7.5.2.4 Baseline predictors of new cases of CSF at one month
The only baseline variable that predicted becoming a new case of CSF one month
after brachytherapy was having poorer social functioning (83 vs. 93, p=0.007). There
was no relationship with baseline global fatigue score, depression or activity (new
cases of CSF vs. non cases respectively: global fatigue 1.73 vs. 1.51 p=0.250, HADS
depression 3.09 vs. 2.60 p=0.373, HADS depression minus question 8 'I feel slowed
down' 2.09 vs. 1.77 p=0.320, activity scores 2.2 vs. 2.1 p= 0.392). Similarly there
was no relationship to having neo-adjuvant androgen deprivation therapy (46% vs.
23% p=0.147).
Comment
Analysis focussed on new cases of CSF so it is not surprising that baseline global
fatigue scores did not predict new cases of fatigue (because baseline cases' fatigue
scores were not included). It appears that the development of CSF is quite
unpredictable as virtually no parameters showed any relationship although the
sample numbers were small so statistical power was limited
7.5.2.5 Associations and baseline predictors of CSF at 12 months
There were seven cases of CSF at 12 months post brachytherapy, two of these had
been cases throughout the whole 12 months of follow up but the others had no
particular pattern. In view of the small numbers and inconsistency of CSF over time,
it was decided further analysis of predictors of twelve month CSF would be
inappropriate.
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7.5.3 FATIGUE AS A CONTINUOUS VARIABLE
To allow comparison with published data, fatigue has also been presented as
measured by The Brief Fatigue Inventory. In contrast to the cases of CSF, there were
no significant changes in the global fatigue scores over time. In fact the scores
appeared to decrease slightly (see figure 7.3). There was a trend for the
brachytherapy group to have higher global fatigue scores than the non-cancer group
but this did not achieve statistical significance (see table 7.6).
Comment
Many patients clearly described feeling more fatigued after brachytherapy, yet this
was not reflected in the group global fatigue scores. Closer examination of individual
fatigue scores (figure 7.4) indicated that approximately half the group's scores
increased (52%) at one month post brachytherapy and the other half decreased (38%)
or stayed the same (8%). This may explain why the mean group score did not change
much. In addition, despite some patients saying in the clinical interview that they
were more fatigued, their self rated scores had actually decreased from baseline.
Table 7.6 Mean global fatigue scores over 12 months after brachytherapy
Months after brachytherapy
0 1 3 6 9 12
total n 49 49 49 35 49 49
Mean global fatigue 1.71 1.68 1.72 1.50 1.47 1.48
(SD) (1.61) (1.66) (1.65) (1.53) (1.49) (1.49)
p value compared to baseline 0.752 0.704 0.290 0.700 0.276
p value*. Brachytherapy vs. nor
cancer group, n=51, mean 0.404
global fatigue 1.45 (SD 1.24)
0.811 0.717 0.695 0.641 0.604
SD = standard deviation
Compared using Wilcoxons Signed Rank Test except *Mann Whitney U Test
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Figure 7.4 Individual patient global fatigue scores after brachytherapy
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7.5.3.1 Correlations ofmean change in global fatigue between baseline
and one month (table 7.7)
Changes in global fatigue between baseline and one month correlated with changes
in anxiety, depression, (including when the fatigue item, question 8 was removed),
pain, insomnia, red blood cell count, and eosinophils. Changes in global fatigue
inversely correlated with quality of life, physical, role, emotional and cognitive
function. All other changes were not statistically significant notably, urinary
symptoms, activity and CRP.
Despite statistically significant decreases from baseline in the following blood
measures there was no correlation with fatigue scores: haemoglobin (150 vs,146g/L
at one month, p=0.001) white cell count (6.8 vs. 6.1 xlO9 /L at three months) and
lymphocyte count (1.8 vs., 1.49, 1.37, 1.55, 1.45, 1.49 xlO9 /L at 1, 3, 6, 9 and 12
months respectively, all p<0.001 ).
Chapter 7 108
Study B - Fatigue After Brachytherapy
Table 7.7 Correlation of change in global fatigue from baseline to one month
(p < 0.05 in bold, * indicates p<0.01)
variable changing between Spearman correlation (rho) with change in

















Urinary symptoms (IPSS) 0.303
Blood measures
Haemoglobin 0.241
Red blood cells 0.308










EORTC QLQc30= European Organisation for the Research and Treatment of Cancer
Quality of Life core 30, HADS -Qu8= Hospital Anxiety and Depression Score minus
question 8 ('I feel slowed down'), IPSS = International prostate symptom score
(Cohen 1998) suggested interpretation of strength of relationship for r:
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7.5.3.2 Fatigue and neo-adjuvant androgen deprivation
A larger proportion of patients than expected had received neo-adjuvant androgen
deprivation prior to brachytherapy (14 patients). In case low testosterone levels in
these patients had confounded results, fatigue scores were examined for those who
did and did not receive androgen deprivation therapy. There was an initial trend for
the androgen deprivation therapy group to have higher fatigue scores up to six
months after brachytherapy. By nine months scores were similar to those who had
had brachytherapy alone (see table 7.8). I postulated that this may be due to delayed
testosterone recovery after androgen deprivation which can take a median of four to
nine months (Nejat et al. 2000). However, mean serum testosterone levels were the
same in both groups by one month post brachytherapy so androgen deprivation
therapy is not likely to contribute to longer term fatigue.
Table 7.8 Mean global fatigue scores after brachytherapy for those who did
and did not receive neo-adjuvant androgen deprivation
months post brachytherapy
0 1 3 6 9 12
brachytherapy only group (n) 36 35 35 24 35 35
mean global fatigue 1.55 1.52 1.62 1.28 1.56 1.58
(SD) (1.34) (1.44) (1.47) (1.43) (1.65) (1.63)
androgen deprivation prior to
brachytherapy (n)
14 14 14 11 14 14
mean global fatigue 2.33 2.09 1.96 2.00 1.24 1.23
(SD) (2.20) (2.12) (2.07) (1.67) (0.99) (1.10)
7.5.4 RELATIONSHIP BETWEEN FATIGUE SCALES AND CSF
DEFINITION
Interview rated cases of CSF significantly increased one month after brachytherapy
and gradually decreased over 12 months. However the self-report continuous global
fatigue scores did not change much. The global fatigue score on the Brief Fatigue
Inventory (BFI) was the primary fatigue scale measure but in case these results were
an anomaly of the BFI, EORTC fatigue subscale results were also examined. These
showed a slightly different third pattern and although the scores did not change
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substantially overtime (baseline, 1,3,6,9,12 months: 20.6, 19.0, 17.0, 19.7, 17.0, 17.5
respectively) or achieve the lowest proposed clinically significant change (5 points
(Osoba et al. 1998)), they were statistically significantly lower than baseline three
months after brachytherapy (20.6 vs. 17.0, p=0.047).
The CSF interview appeared to measure the same construct as the fatigue scales
because cases of CSF had higher global fatigue scores than non cases at each time
point (see table 7.9).
Table 7.9 Differences in global fatigue scores between cases of CSF and non




brachytherapy n Mean SD n Mean SD p value
0 3 4.0 2.6 47 1.6 1.5 0.032
1 14 2.8 1.3 35 1.2 1.6 <0.001
3 8 3.5 1.9 41 1.4 1.4 0.001
6 4 3.6 2.1 31 1.2 1.2 0.016
9 6 3.7 1.4 43 1.2 1.2 <0.001
12 7 3.4 0.7 42 1.2 1.3 <0.001
As shown in figure 7.4, the lack of change in mean global fatigue scores could be
because half the group rated an increase and the other half rated a decrease or no
change so there was no overall change in the mean score for the group. Therefore the
relationship between fatigue scores and cases of CSF was examined further.
It appears that the scale measures do not appear to be very good at identifying
interview defined cases of CSF. In figure 7.9 it would be expected there would be
more cases of CSF (in green) than non cases (blue) at the higher end of the fatigue
scores (top right hand side of the graph). Although there is a trend towards this, there
are still some cases who had low fatigue scores and one outlying non-case who had a
high global fatigue score. At first glance the EORTC scale looks marginally better
because the scores seem to be more widely distributed, but this is could be
Chapter 111
Study B Fatigue After Brachytherupy
Figures 7.9 Distribution of fatigue scores for cases and non cases













































Table 7.10 Proportions of cases of CSF and non cases in relation to previously
published 'cut offs' for the Brief Fatigue Inventory (BFI)
cut off
BFI global fatigue > 3
% n
Cases of CSF above 50 7
n=14 below 50 7
non cases above 11 4
n=35 below 89 31
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misleading. The scores are generated in 11 point increments whereas the global
fatigue score is a continuous range making them look more clustered together.
A clinical interview is more rigorous than a questionnaire measure. However it
appears that some patients say different things when talking about how they feel
compared to answers on a questionnaire. For example, there was a case of CSF who
had low fatigue scores ( 0.11 out of 10 on the global BFI and 11 out of 100 on the
EORTC fatigue scale) but in the clinical interview described how since his
brachytherapy implant he had to use an electric buggy to get around the golf course
and could no longer fulfil his responsibilities of doing the gardening or do-it-yourself
(DIY) tasks because of fatigue. Conversely, there was one patient who is not a case
of CSF despite a global BFI of 7.22. Possible reasons for this will be covered in the
discussion section.
A cut off for moderate to severe fatigue has been suggested as scores greater than 3
on a 1 to 10 fatigue scale (Mock 2005). When this was applied to the global fatigue
score 50% of the interview defined cases of CSF in this sample were identified, so
this cut off appears to be slightly high (see table 7.10). However as the sample size
and number of cases of CSF was small, these results must be interpreted with
caution.
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7.6 DISCUSSION
7.6.1 Main findings
Between baseline and one month after brachytherapy the incidence of CSF was 23%.
In total 29% of patients were affected at one month which was significantly higher
than baseline. CSF gradually decreased over 12 months but not quite to baseline
levels and the prevalence of CSF was significantly higher than the non-cancer
comparison group at one and three months after brachytherapy. CSF was associated
with having poorer quality of life and had a significant impact on physical
functioning and patients' ability to fulfil their roles. Those who were fatigued before
brachytherapy tended to remain so afterwards but there were minimal baseline
factors that predicted new cases of CSF. Mean global fatigue scores however showed
a different pattern and did not significantly change over time, nor were they
significantly higher than non-cancer comparison group.
Fatigue was assessed using two different approaches and the results were
inconsistent. There could be several reasons for this: (a) the fatigue scale measures
were not sensitive enough to pick up cases of CSF (b) some patients may have
misunderstood the fatigue questionnaire (c) the researchers may have been biased
and over diagnosed CSF (observer bias) (d) half the group's fatigue scores increased
one month after brachytherapy but the other half decreased or stayed the same
resulting in the mean fatigue score not changing much (e) patients got used to being
fatigued and subconsciously adjusted their internal standards accordingly (known as
response shift). One way this was demonstrated was when some patients who were
nine/twelve months since treatment and feeling well, volunteered the information
that it was only in retrospect that they recognised how fatigued they had been.
Sometimes the internal adjustment of standards was a conscious decision and after
brachytherapy some patients described themselves as 'listening to my body' or
'taking things more easy because my family say I should' as if they now had
permission to do so.
The interview was more rigorous than the questionnaire measures because there was
the opportunity to explore things in more detail. The patients generally filled in the
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questionnaire before the clinical interview and it was noticeable that sometimes
patients said different things on paper to when they were talking to someone. This
demonstrates the shortcomings of questionnaires in general but there may have been
other contributory factors: (a) the interview concentrated on fatigue that had been
present for at least two weeks, whereas the Brief Fatigue Inventory referred to the
last week. It could be that fatigue was truly different from one week to another but it
has been suggested that people tend to answer questionnaires in relation to how they
have felt so far that day, regardless of the timescale mentioned on the questionnaire
(recall bias) (Gendreau et al. 2003) (b) during the interview, on occasions it became
clear that a minority of patients had not wanted to admit the extent of their fatigue on
the questionnaire. There were differing reasons for this. Firstly, some men were keen
to say how effective they believed the brachytherapy was and that it was 'killing the
cancer'. This anxious and slightly forced positive attitude may have contributed to
some patients not wanting to acknowledge their fatigue on paper in case that was an
indication the treatment had not gone well. Secondly, some seemed embarrassed to
admit fatigue because they viewed it as not 'manly'. This sometimes became evident
when their spouse was present at the interview. Some men answered that they were
not fatigued on the questionnaire and said that initially in the interview but their wife
would then disagree and give a very different picture! Thirdly, a small number of
men seemed keen not to be seen as complaining in case they seemed ungrateful for
the treatment they had received for their cancer. This had not been anticipated. It is
possible that because the researchers could have been perceived as part of the
brachytherapy team, then this minority of patients initially did not feel they could be
entirely honest about how they were feeling.
Overall, the impact of fatigue was not severe. Although some individuals' fatigue
scores had increased, they were not classified as a case of CSF because it did not
cause them problems. This may partially be explained by two factors. Firstly,
because many men were retired they could put off doing things without any major
consequences but expressed that had they been in employment, they did not think
they could have gone back to work. Secondly, most men had a female partner and
between them they held traditional household roles. Consequently their spouse would
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continue to do the cooking, cleaning, shopping and take care of them so fatigue did
not have a major impact on the patient's life. In other research, fatigue appears to be
more distressing for female breast cancer patients. This may be because they tend to
be slightly younger and have to continue to care for their families (Woo et al. 1998).
It may also reflect differences in tumour type and treatment.
7.6.2 Subsidiary findings
Fatigue was associated with depressive symptoms (measured by the HADS) in this
population but it is important to recognise that depression scores were on the whole
very low and decreased from baseline. Often the depression scores are similarly low
in the published literature but some reports appear to over emphasise this
relationship. None of the brachytherapy patients developed Major Depressive
Disorder (as diagnosed by the DSM IV SCID interview) over the 12 months of
follow up.
Fatigue after brachytherapy was not associated with testosterone levels or neo¬
adjuvant deprivation therapy.
Fatigue was not associated with CRP in this population. However this should be
interpreted with caution because of (a) the small sample size (b) possible
confounders such as infection (one patient was recovering from a chest infection and
had a raised CRP) or concurrent administration of medications that modulate the host
inflammatory response such as non-steroidal anti inflammatory medications and
steroids (several patients were on aspirin or painkillers such as ibuprofen and two
patients had steroid inhalers for their asthma. However, as numbers were small it was
not possible to account for this in the analysis). Originally the plan was to examine
other cytokines but these tests are very expensive and following results of study A it
was decided there was not sufficient scientific rationale to justify these.
Eosinophils significantly increased and also correlated with fatigue one month after
brachytherapy. It could be that they release substances that mediate fatigue (or this
result may also have arisen from multiple testing). Some research groups have
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examined markers of immune response such as T lymphocytes (Bower et al. 2003)
or genetic polymorphisms that influence interleukin production but so far no
definitive biological correlates of fatigue have emerged.
Haemoglobin, white cell count and lymphocyte count significantly decreased after
brachytherapy but did not correlate with fatigue. The haemoglobin drop could be
explained by bruising after having brachytherapy needles and seeds inserted through
the perineum. However a drop in haemoglobin also occurred in the radiotherapy
patients in study A (who have not undergone an operation) and similar results were
found in a larger study of radiotherapy patients (Windsor et al. 2004). It is possible
that there could have been a systemic effect of ionising radiation from the prostate
brachytherapy seeds affecting the pelvic bone marrow or blood volume circulating
through the prostate. Lymphocytes are known to be sensitive to ionising radiation
and they remained significantly lower than baseline throughout the follow up period.
Having men with benign prostatic hypertrophy (BPH) as the comparison group may
underestimate the difference in fatigue levels compared to the general population. A
paper was published after this study had started showed that men with BPH and
prostate cancer had similar fatigue levels but both were higher than men in the
general Swedish population (Jakobsson et al. 2004).
7.6.3 Other limitations
In addition to above, one of the limitations of this study was the small sample size
and multiple statistical tests. No adjustment was made for this and so results should
be interpreted with caution. There is an increased risk of Type I errors (thinking that
a result is significant when in fact it could have occurred by chance). An alternative
would be to apply Bonferroni's adjustment but some argue that this is not helpful and
merely increases Type II errors (accepting the null hypothesis when there is a real
difference) (Perneger 1998). In this study, a p value of 0.05 was taken to be
statistically significant. When examining results it may be worth paying more
attention to results with a p value <0.01, meaning only one result out 100 could have
arisen by chance (as opposed to one in 20).
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The hypotheses were based on Study A. Inclusion of Study A patients in this cohort
may have biased results, making the hypotheses more likely to be proved positive.
Response shift is a recognised drawback of longitudinal studies of subjective
symptoms (Visser et al. 2000). During some patients' assessments I suspected this
had occurred if their fatigue score had moved in a different direction to what they
described during the interview. One way of addressing possible response shift would
have been to do a 'then test'; asking patients to retrospectively rate their fatigue score
before brachytherapy (not to recall what they put). This was done informally for a
small number of patients once I recognised it might be occurring. It would have been
more rigorous to formally assess everyone but this requires very careful interviewing
and it was important not to make the patient feel they had put the 'wrong' answer.
The case diagnosis of CSF proposed in this thesis was made regardless of supposed
cause. This may have overestimated the prevalence of CSF that is secondary to
brachytherapy. There is a natural tendency to assume that fatigue one month after
brachytherapy may be related to the procedure. It is less clear how to judge fatigue
with no obvious cause that develops for the first time several months after
brachytherapy. Some clinicians may judge it not related to brachytherapy but strictly
speaking we can not exclude the possibility of it being a late effect. In this study one
patient was a case of CSF at the nine month time point only. In the clinical setting I
would have attributed his fatigue to having a lower respiratory chest infection/flu like
illness (i.e. not related to prostate cancer or brachytherapy). However he had to be
classed as a case of CSF regardless. Other authors have proposed that cancer or its
treatment must be considered to be the cause of fatigue when defining 'cancer related
fatigue' (Cella et al. 1998). However this is also unclear and raises other questions.
Where should the line be drawn regarding other medical conditions? Just because a
patient has cancer does that automatically mean their fatigue is related to it? A
parallel situation that has raised similar issues is the assessment of symptoms relating
to the syndrome of Major Depressive Disorder in cancer patients (such as weight loss
which may be due to either cancer or depression). Here, authors have advocated an
inclusive approach rather than to attribute cause (Koenig et al. 1997).
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In any study we can only identify associations, not cause. In clinical practice
however, a judgement about cause tends to take place at some point. Attributing
cause is inherently difficult but is only helpful if it identifies a treatment that may
alleviate the condition. More work needs to be done to clarify a method of fatigue
measurement. It is important to have an agreed measurement tool to enable
consistency with regards to research and future investigations of the efficacy of
treatment.
7.6.4 Other literature
This is the first longitudinal study to specifically examine fatigue after brachytherapy
so there are no others to directly compare to. Obviously, no studies have used the
same case definition, so the next best comparison is to look at those that used the
same fatigue specific measurement tool in men with prostate cancer (the Brief
Fatigue Inventory, BFI). A paper published whilst this study was in progress
examined fatigue in men undergoing external beam radiotherapy. Their population
had similar BFI global fatigue scores to this study (though they reported the sum
global fatigue scores rather than the arithmetic mean) but fatigue scores significantly
increased between baseline and the end of radiotherapy (50-52Gy over four weeks).
They also found that men adhering to a physical exercise intervention had less of an
increase but this was not statistically significantly different (Windsor et al. 2004).
7.6.5 Conclusions and implications
Although almost a third of patients experienced clinically significant fatigue, the
majority did not. However it is difficult to predict who was likely to be affected to
this degree. CSF appears to return back towards baseline levels by six months,
however it may persist for a minority and patients should be warned about it. Those
who are fatigued before brachytherapy are likely to remain so. Further work is
required to ascertain biological correlates of fatigue and identify mechanisms that
may help identify treatments. Perhaps most crucially of all, the issue of how best to
measure fatigue continues to impede further progress and clearly more work is
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Study C - Fatigue in recurrence free prostate cancer survivors
8.1 INTRODUCTION
The background to this study has been covered in Chapter 2. To summarise: the
choice of treatment for localised prostate cancer is primarily determined on the basis
of disease stage, but also with consideration of the patient's age, medical
comorbidities and treatment preferences. There is no conclusive evidence as to which
treatment is best in terms of survival so patient decisions are often made on the basis
of likely side effects. The physical side effects most frequently associated with
prostate cancer are well documented. Generally studies have revealed that
incontinence and sexual difficulties are more common in patients who have received
radical prostatectomy than by those who had radiotherapy or brachytherapy. Bowel
dysfunction however, is more frequent in patients who have received radiotherapy or
brachytherapy. It is increasingly recognised that the impact of these treatments on
quality of life must also be considered in determining the best approach to
management. Fatigue is increasingly recognised as an acute side effect of
radiotherapy, and has been found to be a major determinant of quality of life after
treatment for other cancer survivors (Bower et al. 2000;Fossa et al. 2003;Hjermstad
et al. 2006). Less is known about longer term fatigue after prostate cancer treatment
and this too may be an important consideration in treatment selection.
While this study was being designed, only one publication had specifically addressed
fatigue in prostate cancer patients after treatment (Vordermark et al. 2002). This was
a cross sectional survey of 103 men who had received radiotherapy and found 18.7%
had 'severe fatigue'. Associations between fatigue and factors such as urinary and
bowel symptoms were explored but other issues likely to influence fatigue such as
depression and anxiety were not. This study included men who still had cancer or
were on androgen suppression which may have confounded the findings. At the time,
there was no information about long term fatigue after brachytherapy or radical
prostatectomy.
There is a need for a representative study specifically examining clinically relevant
fatigue and its associations in recurrence free men after different treatments for
prostate cancer.
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8.2 AIMS
To determine the prevalence and associations of Substantial Global Fatigue (Brief
Fatigue Inventory global fatigue >3) in recurrence free men who previously received
treatment for localised prostate cancer more than one year ago.
To determine whether there is any difference in the prevalence of Substantial Global
Fatigue between patients who have undergone radical prostatectomy, radiotherapy or
brachytherapy for localised prostate cancer.
To compare the prevalence of Substantial Global Fatigue to a historical non-cancer
comparison group ofmen with benign prostatic hypertrophy (from Studies A and B).
8.3 HYPOTHESES
Substantial Global Fatigue in recurrence free men would be associated with poorer
quality of life, depression, anxiety, more severe urinary symptoms and adjuvant
androgen deprivation therapy.
The prevalence of Substantial Global Fatigue would be higher in recurrence free men
who have had radiotherapy than brachytherapy or radical prostatectomy.
Recurrence free men previously treated for prostate cancer would have a higher
prevalence of Substantial Global Fatigue than a historical non-cancer comparison
group.
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8.4 METHODS
8.4.1 Design
This was a descriptive, cross sectional, self report postal survey supplemented with
retrospective clinical data.
8.4.2 Patient Sample
The Edinburgh Cancer Centre is a regional, tertiary, cancer centre that is the sole
provider for specialist cancer services to a geographically defined area of
approximately 1.5 million people in the South East of Scotland UK. The
multidisciplinary care of prostate cancer patients occurs in conjunction with the
Urologists at the Western General Hospital which is on the same campus. After
treatment for their localised prostate cancer, patients are followed up for a year in the
outpatient clinic. Thereafter they are routinely put on a postal follow up system
which is led by the Clinical Nurse Specialist. Every six months patients are sent a
postal questionnaire which they are asked to fill in and return. This coincides with a
PSA (prostate specific antigen) test taken by the General Practice Surgery. The
Clinical Nurse Specialist then collates the results and acts accordingly.
This setting provided the ideal opportunity for collecting data from all men
previously treated for localised prostate cancer at the Edinburgh Cancer Centre/
Western General Hospital and who remained recurrence free. In addition they were
used to completing questionnaires. It was assumed that since this was a formal postal
follow up system, patients were able to understand English and did not have
cognitive impairment.
Inclusion criteria
• The patient had received treatment with curative intent for localised prostate
cancer (external beam radiotherapy, brachytherapy or radical prostatectomy)
more than one year previously (seeing as persistent fatigue was the focus of
this study, rather than acute fatigue after treatment).
• Localised (stage Tl- T3) cancer at time of treatment
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Exclusion criteria
• Localised (stage T1-T3) cancer on 'watch and wait' policy (these patients still
have cancer and have not received treatment).
• Localised (stage T1-T3) cancer on primary androgen deprivation therapy
(which is a palliative treatment, not one given with curative intent)
• Stage T4 (too advanced to be cured)
• Suspected relapse of prostate cancer (the specific focus of this study was
recurrence free patients)
• Metastatic prostate cancer (for the reasons above)
• Another concurrent cancer diagnosis (as other cancers can be associated with
fatigue and this may confound the findings).
Recruitment
Between August and November 2005 eligible patients were identified and the CNS
then introduced the survey in a letter which accompanied the patient information
sheet, consent form and survey questionnaire. Patients were invited to participate in
the survey and post back the questionnaire and consent form in a stamped addressed
envelope provided. Potential participants who did not return the questionnaire within
one month, were sent another one by post. Cancer treatment and demographic details
of non responders were noted.
8.4.3 Non-cancer comparison group
This was a historical comparison group which comprised of the 63 men with benign
prostatic hypertrophy recruited for Studies A and B.
8.4.4 Data collected from patient records
• Date of birth
• Postcode, to assess Scottish Index of Multiple Deprivation (SIMD), see
section 5.1.1
• Date and type of previous treatment for prostate cancer (radiotherapy,
brachytherapy or radical prostatectomy)
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• Currently on androgen deprivation therapy or not. The patient was also asked
about this in the questionnaire as sometimes the hospital notes were not
always up to date.
5 Self Rated Questionnaire Measures
The Brief Fatigue Inventory (BFI). As it was not possible to interview
patients, a cut off of global fatigue >3 was used to define fatigue of a
clinically relevant severity (termed Substantial Global Fatigue), see section
4.1.2.1.
Two additional questions which could be answered ,"Yes" or "No"
o "Has fatigue been a problem for you in the last week?" This was asked
because it was found during the preliminary work that although some
patients said they felt fatigued, they did not find it a problem because
they were able to adjust their lives accordingly by for example putting
things off until the next day because they were retired,
o "Have you felt fatigued for longer than one month?" This was to
ascertain whether fatigue was more than an acute problem. A period of
one month was chosen as this corresponded to the work that was done
regarding the case definition of CSF (clinically significant fatigue).
One open question "If yes, to either of the above, what do you think
contributed to it or caused it [fatigue]?"
Hospital Anxiety and Depression Scale (HADS) see section 5.4.1
European Organisation for the Research and Treatment of Cancer
Quality of Life Questionnaire core 30 version 3.0 (EORTC QLQc30), see
section 5.4.2. In order to focus on the most relevant issues for this population,
only the following subscales and items were selected: physical, role, and
social functioning, two symptom scales (pain, fatigue), and single items
(insomnia, constipation, diarrhoea, dyspnoea). This reduced the patient
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questionnaire burden and avoided replication of question themes (i.e. using
both the HADS and the emotional functioning subscale to measure similar
things).
International Prostate Symptom Score (IPSS) see section 5.4.4.
Likert scales for erectile function and how much of a problem this is, see
section 5.4.3.
Likert scales for common prostate cancer treatment side effects, as
fatigue may be associated with symptom burden. These side effects were also
of particular interest to the responsible clinicians. Each item related to the
past week and is answered on a four point scale; not at all, a little, quite a bit,
very much.
o urinary incontinence and dysuria (these are not covered by the IPSS)
o faecal incontinence and rectal bleeding
Other Comorbidities
Patients lived throughout South East Scotland and Dumfries. Although I had
access to Western General Hospital and Edinburgh Cancer Centre medical
records it was not feasible to obtain peripheral hospital notes or to ask the GP
about each patient's past medical history and comorbidities. Instead the
patients were asked about the most common comorbidities that may influence
fatigue (cardiovascular and respiratory problems, diabetes, stroke, depression,
musculoskeletal problems or another cancer diagnosis) and whether they
were taking medication for them. There was also an open question allowing
them to mention any other medical conditions they thought we should know
about. This approach is similar to that employed by other authors (Lilleby et
al. 1999).
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8.4.6 Ethical Approval
The study was approved by the Lothian Local Research Ethics Committee.
Reference number 05/S1104/7.
8.4.7 Statistical Analysis
The data were inspected using histograms and box plots and described using means,
medians and percentages of categories as appropriate. To assess whether the data was
representative of the eligible sample, data from participants and non participants
were compared using Student t-tests and Chi squared tests as appropriate.
Fatigue was described as the global fatigue score and the percentage who had
Substantial Global Fatigue (global fatigue score >3). Prevalence of Substantial
Global Fatigue was compared to the non-cancer group using Chi squared tests
Univariate associations of Substantial Global Fatigue were examined using binary
logistic regression for categorical variables and Student t-tests and Mann Whitney
tests as appropriate for continuous variables. Independent associations of Substantial
Global Fatigue were examined using multivariate analysis with no selection.
Variables such as physical, role and social functioning were not included as these
could be regarded as outcomes of fatigue rather than predictors. HADS depression
question 8 "I feel as if I am slowed down" may be construed as referring to fatigue.
Hence associations between Substantial Global Fatigue and depression were
performed both including and excluding this item. This approach has been previously
reported (Stone et al. 2000a).
A p value of <0.05 was considered statistically significant. I was advised and assisted
with the statistical analysis by Dr Isabella Butcher, Research Fellow, Public health
Sciences, University of Edinburgh using SAS/STAT software. Version 9.1 of the
SAS System for Windows. Copyright © 2002-2003 SAS Institute Inc.
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8.5 RESULTS
Of the 905 patients who were still alive and on postal follow up, 457 fulfilled the
eligibility criteria and were sent the questionnaire package. Seven patients
subsequently transpired to have another concurrent cancer diagnosis, two patients
were found to have had initial treatment less than a year ago and carers informed me
that five patients were demented. These men were deemed ineligible retrospectively
and not included in the analysis. Two patients returned the questionnaire declining
participation, one patient said he did not understand the questionnaire and one
questionnaire was returned as the addressee was unknown. The final eligible patient
participation rate was 91% (402/443). There were no demographic or clinical
differences between those who did and did not participate (see table 8.1).
Table 8.1 Comparison of demographic and clinical characteristics of recurrence




Variable % n % n P-value
SIMD group 0.452
1 39 16 40 159
2 15 6 21 81
3 22 9 19 76
4 15 6 13 51
5 10 4 7 27
Tumour (T) stage at time of
treatment 0.583
1 26 9 36 121
2 60 21 47 160
3 14 5 17 59
Prostate Cancer Treatment 0.730
brachytherapy 5 2 6 25
radiotherapy 56 23 61 244
radical prostatectomy 39 16 33 133
Mean age at time of survey (SD) 72.0 (6.4) 71.7 (6.3) 0.811*
Months since treatment
median (range) 61.0 (21 to 312) 54.0 (13 to 233) 0.085**
SD = standard deviation, SIMD= Scottish Index of Multiple Deprivation
All were compared using Chi squared test except * Student t Test ** Mann Whitney test
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244 (61%) had received radiotherapy, 133 (33%) had undergone radical
prostatectomy and 25 (6%) had had brachytherapy as their initial treatment for
prostate cancer. Due to the small number of brachytherapy patients (this has only
been available in recent years in Edinburgh) the analysis is focussed on the two
largest treatment groups from now on.
The mean age of the sample was 72 years (SD 6.1) and the median time since
treatment was 56 months (range 13-233). Only three men were on adjuvant androgen
deprivation therapy. The radiotherapy group had more medical comorbidities than
the radical prostatectomy group. See tables 8.2 and 8.3
Table 8.2. Continuous variables for the non-cancer group and recurrence free
prostate cancer group according to previous treatment received
Recurrence free prostate
Recurrence cancer group initial treatment Non-cancer
free prostate Radical group
cancer group Radiotherapy Prostatectomy
n=377 n=244 n= 133 n:=63
mean SD mean SD mean SD mean SD
Fatigue
global fatigue (BFI) 2.2 (2.2) 2.4 (2.2) 1.8 (2) 1.8 (1.7)
EORTC fatigue score** 25 (23) 28 (24) 20.8 (21) 21 (15)
Age at time of survey 72 (6.1) 72.8 (5.6) 70.6 (6.7) 66.2 (6.7)
EORTC QLQc30
Global Health related QL* 73 (20) 71 (21) 77 (19) 80 (15)
Physical Function* 81 (21) 78 (22) 86 (18) 89 (15)
Role Function* 83 (26) 79 (28) 89 (22) 91 (18)
Cognitive Function* 79 (19) 78 (20) 81 (16) 80 (16)
Social Function* 80 (27) 78 (29) 83 (24) 86 (22)
Pain** 14 (23) 16 (25) 10 (19) 13 (21)
Dyspnoea** 20 (28) 22 (29) 15 (24) 15 (19)
Insomnia** 24 (29) 23 (30) 24 (29) 21 (26)
Constipation** 13 (23) 13 (22) 12 (25) 8 (16)
Diarrhoea** 9 (19) 10 (20) 6 (16) 6 (15)
BFI= Brief Fatigue Inventory, EORTC QLQc30 = European Organisation for Research and
treatment of cancer core 30, QL = quality of life, SD = standard deviation
* Higher scores = better function, ** Higher scores = worse symptoms
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Table 8.3 Categorical variables for the non-cancer group and recurrence free










n=377 n=244 n= 133 n==63
% n % n % n % n
Fatigue
Substantial Global Fatigue
(BFI global fatigue >3) 29 108 33 79 22 29 16 10
Fatigue is a problem 29 107 34 81 20 26 - -
Fatigue present > 1 month 30 110 35 83 21 27 - -
HADS
Anxiety > 9 13 50 14 34 12 16 13 8
Depression > 8 14 52 16 39 10 13 8 5
Depression -Qu8 > 8 7 27 10 23 3 4 6 4
moderate/severe urinary
symptoms (IPSS > 7) 37 139 41 99 30 40 69 43
Other symptoms
'quite a bit' & 'a lot'
urine incontinence 7 25 5 12 10 13 - -
dysuria 1 4 1 3 1 1 - -
faecal incontinence 3 10 3 7 2 3 - -
rectal bleeding 3 11 5 11 0 0 - -
Erectile Function
not possible/severely reduc 79 287 76 177 85 110 45 28
Serious problem/quite a
problem 30 107 30 69 48 38 46 13
Comorbidities
cardiac problems 31 114 37 86 21 28 46 29
respiratory problems 24 88 27 63 19 25 8 5
diabetes 11 40 15 35 4 5 10 6
cerebrovascular accident 8 29 10 22 5 7 3 2
depression 15 54 16 36 14 18 5 3
musculoskeletal problems 40 147 41 96 39 51 21 13
neurological problems 1 5 1 3 2 2 - -
total comorbidities NONE 29 106 24 59 35 47 40 25
ONE 37 136 34 82 41 54 33 21
TWO + 36 133 42 101 24 32 27 17
BFI= Brief Fatigue Inventory, FIADS - Qu8= Hospital Anxiety and Depression Scale minus
question 8, IPSS= International Prostate Symptom Score, SIMD= Scottish Index of Multiple
Deprivation
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8.5.1 Prevalence and associations of Substantial Global Fatigue
The estimated prevalence of Substantial Global Fatigue was 29% (108/377) for the
whole group. Put in context this is higher than the non-cancer comparison group of
men with benign prostatic hypertrophy from studies A and B (16%, 10/63, p=0.031).
Figure 8.1 Proportions of patients with Substantial Global Fatigue who had









ia post radical prostatectomy s post radiotherapy
There was a significant association between fatigue and treatment received. Patients
who had received radiotherapy were 1.8 times more likely to have Substantial Global
Fatigue than those who had undergone radical prostatectomy (33% vs. 22%, p=
0.024, figure 8.1)
Men with Substantial Global Fatigue had significantly poorer global health related
quality of life, poorer physical, role and social function, more pain and insomnia (see
table 8.4). Substantial Global Fatigue was much more likely in men who had
depression (odds ratio 18.8, but only 40% of those patients had depression, so did not
account for all the fatigue. This dropped to 21% once the confounding fatigue item
from the HADS was excluded). Substantial Global Fatigue was also more likely in
men with anxiety (odds ratio 8), moderate/severe urinary symptoms (odds ratio 4.5)
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having "quite a bit/ a lot" of faecal incontinence (8% vs. 1% p=0.001) and urinary
incontinence (14% vs. 4% p<0.001). Substantial Global Fatigue was not associated
with age, social deprivation category or time since treatment. The majority of men
had erectile dysfunction regardless of their fatigue status however men with
Significant Global Fatigue more frequently said they regarded this as quite a
problem/a serious problem (44.4% vs. 23.5%, p=0.001).
Table 8.4 Univariate associations of continuous variables with Substantial




Variable mean (SD) mean (SD) P-value
Age 71.8 (6.4) 72.1 (6) 0.600*
Months since treatment
median (range) 55 (23,143) 54 (13, 233) 0.515
EORTC QIQc30 scores
Global health status/QL* 53 (20) 81 (14) <.0001
Physical function* 61 (23) 89 (14) <.0001
Role function* 57 (30) 93 (15) <.0001
Social function* 56 (30) 90 (18) <.0001
Pain** 30 (31) 7 (15) <.0001
Insomnia** 43 (35) 16 (23) <.0001
Diarrhoea** 16.0 (25) 5.8 (14) <0.001
Constipation** 20.1 (29) 9.3 (20) <0.001
All compared using Mann Whitney U Tests except * Student t-test
EORTC QLQc30 = European Organisation for Research and treatment of cancer core
30, QL = quality of life
* Higher scores = better function, ** Higher scores = worse symptoms
8.5.2 Independent associations of Substantial Global Fatigue
Treatment received, urinary symptoms, medical comorbidities, anxiety and
depression were entered into a multivariate logistic regression. Treatment received
was no longer associated with Substantial Global Fatigue once the other factors were
controlled for. Depression was the strongest independent predictor with an odds ratio
of 10.9 (see table 8.5). When HADS question 8 was removed the odds ratio was still
10.6 with minimal change in the odds ratios of the other variables.
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8.5.3 Fatigue a problem or not
Of those who had Substantial Global Fatigue, 75% (79/106) said it was a problem.
These patients were slightly younger (71.2 vs. 73.2years) and had more urinary
symptoms (68 vs. 46% moderate/severe urinary symptoms), and a greater proportion
had depression (46 vs. 21%, HADS depression minus question 8, 26% vs. 7%). The
proportions who had received radiotherapy were similar (75% vs. 69%).
76% (80/106) had experienced fatigue for longer than one month. 66% (70/106) said
fatigue was both a problem and had been present for longer than one month.
65/107 patients with Substantial Global Fatigue suggested a possible cause of their
fatigue (shown in table 8.6) only four men attributed it to their previous prostate
cancer treatment.
Table 8.6. Possible causes of fatigue suggested by 65/107 patients with
Substantial Global Fatigue
Frequency Frequency
cardiorespiratory problems 13 diabetes 2
stress 6 blood pressure 2
arthritis 6 age 2
sleep problems 5 weather 1
pain 5 weak legs 1
radiotherapy 4 pernicious anaemia 1
infection 4 neuropathy 1
job 3 medication 1
gardening/DlY 3 feelings of weakness 1
stroke 3 bowel frequency 1
nocturia 3 rectal blood loss 1
parkinsons 2 kidney failure 1
operation (non prostate) 2 overweight 1
numbers do not add up to 65 because some patients suggested more than one reason
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8.6 DISCUSSION
8.6.1 Main findings
Almost one third of recurrence free prostate cancer survivors had fatigue that
interfered with function (Substantial Global Fatigue). Patients who had undergone
radiotherapy were more likely to have Substantial Global Fatigue than radical
prostatectomy patients but this was no longer the case after controlling for urinary
symptoms, depression, anxiety and concurrent comorbidities. Of these, depression
was the most strongly associated, even with the confounding HADS fatigue item 8
removed. This suggests fatigue may be more strongly associated with comorbidities
and psychological variables than the type of prostate cancer treatment received.
Fatigue was more prevalent in men with a history of prostate cancer than the non-
cancer comparison group. This could be because prostate cancer group were older
but as age was not an association or a predictor of fatigue this is unlikely. Urinary
symptoms are known to be associated with fatigue (Jakobsson et al. 2004) but only
37% had moderate to severe urinary symptoms as opposed to 69% in the non-cancer
group. The severity of anxiety and depression was similar but a greater proportion of
the prostate cancer group had concurrent comorbidities. However the non-cancer
group was small so these results must be interpreted with caution.
8.6.2 Limitations
As with all cross sectional studies we can estimate prevalence but not incidence.
Prospective studies are required to fully understand the incidence and trajectory of
fatigue after differing prostate cancer treatments.
The brachytherapy group was too small to allow robust statistical analysis,
consequently any comment can only be limited to patients who have had
radiotherapy or radical prostatectomy.
Patient characteristics confound treatment decisions, consequently the treatment
groups may have been slightly different at baseline. Men who undergo radical
prostatectomy have to be fit enough for a general anaesthetic whereas those who get
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radiotherapy tend to be older, have more comorbidity and therefore could be
expected to have higher levels of fatigue. However attempts were made to address
this by conducting a multivariate analysis.
It should be noted that a small number of men (n=18) in the radical prostatectomy
group also had post operative radiotherapy. As a subgroup these patients were found
to have slightly higher fatigue scores which may have artificially increased the
prevalence of Substantial Global Fatigue in the radical prostatectomy group. It would
not have been statistically meaningful to treat these men as a separate group.
The sample may not be fully representative of the whole population of those treated
for prostate cancer. Although it is routine for all men to go onto the postal follow up
system one year post treatment, patients who are anxious or more symptomatic, or on
two years of adjuvant androgen deprivation therapy may continue to attend out
patient clinics. However, the number of such cases is estimated by the responsible
clinicians to be small.
The historical non-cancer comparison group of Scottish men of a similar age with
urinary symptoms was small and statistical power of comparisons is limited. In
addition they were not recruited specifically as a comparison group for this study.
Ideally I would have compared to a larger group of men without a history of cancer
but it was difficult to identify a representative, accessible population from which to
recruit. The other option would have been to compare to Brief Fatigue Inventory
normative data in men of this age group but there is none available (personal
communication with the authors of the BFI in 2003)
Substantial Global fatigue was defined as global fatigue > 3. Work from Study B
suggests this does not equate with interview defined clinically significant fatigue
(CSF) and this cut off may underestimate the prevalence of CSF in this group.
Ideally I would have interviewed all patients to assess whether they were cases of
CSF. However this was not feasible.
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Using proposed cut offs for continuous variables (such as global fatigue and HADS
anxiety and depression), whilst making the results more clinically meaningful can
reduce the statistical power of detecting a relationship between a variable and
outcome (Altman & Royston 2006). It is appreciated that the HADS cut offs are not
the same as an interview defined case definition of depression or anxiety.
Comorbidities were not assessed using a validated scale. In Studies A and B, the
Charlson Comorbidity Index was used but in this situation it was not a feasible tool
as it depends on reviewing medical case notes. In addition, it was originally devised
to predict the likelihood of a patient dying and so only included potentially life
threatening medical conditions. From earlier work and talking to patients it quickly
became obvious that the Charlson Comorbidity Index did not pick up conditions that
may significantly affect a person's life and possibly fatigue e.g. arthritis and
Parkinson's Disease. Asking about other medical conditions enabled me to account
for these, though relied heavily on the patient's interpretation of the questions and
recall/understanding of their medical history.
8.6.3 Other literature
One of the limitations of comparing any study to the other literature is the
heterogeneity of fatigue scales used, populations studied and the differing criteria for
defining fatigue as being present. Only two studies have specifically examined
fatigue in post treatment prostate cancer patients and one of them used the same
scale, the Brief Fatigue Inventory (Vordermark et al. 2002) . This cross sectional
study examined 103 men who had had radiotherapy a median of 2.1 years previously.
They used a cut off of 7 or greater to represent 'severe fatigue' on the single item of
'worst fatigue' and found the prevalence was 18.7%. They suggested this was due to
late toxicity from radiotherapy however some men still had cancer present and 29%
were receiving androgen suppression, both of which may have confounded the
findings. Applying the same criteria to my data, the corresponding prevalence was
similar in my sample (18.9%). The majority of their remaining analysis focuses on
the mean global fatigue score as a continuous variable (overall mean 2.8+/- 2.3
standard deviation). Correspondingly the radiotherapy patients in the present study
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sample scored 2.4 +1-2.2 and the radical prostatectomy group were significantly
lower at 1.8 +/-2.0 (see table 8.2).
Several papers have compared different prostate cancer treatments using quality of
life measures. The majority do not report fatigue findings. Of those that have, one
examined patients up to 5 years post treatment and found radiotherapy patients had
lower vitality (measured by the SF-36) than radical prostatectomy patients (Bacon et
al. 2001) whereas others found no difference at 2 or 5 years (Potosky et al.
2000;Potosky et al. 2004). Those that compared to control data found fatigue/vitality
scores were similar regardless of type of treatment received (Lilleby et al.
1999;Brandeis et al. 2000;Penson et al. 2003).
Literature published since October 2003
At the time of designing this study there was no information about fatigue after
brachytherapy or radical prostatectomy. Since then, a cross sectional survey has
been published that compared the 'psychological functioning' of 861 men who had
had either radiotherapy, radical prostatectomy or brachytherapy (Hervouet et al.
2005). Fatigue was one of the symptoms assessed and was measured using the
Multidimensional Fatigue Inventory. They applied a cut off for 'clinical fatigue' (but
did not detail the justification for this) and found the prevalence to be 18.5% overall.
Radiotherapy, brachytherapy and radical prostatectomy groups had respective
prevalence of 23.6%, 19.8% and 12.7%. They too found radiotherapy patients had
significantly higher odds than the other treatments of having clinical fatigue (and
depression) but did not compare their findings to a control group. Although a good
sized sample, it only represented 56% of the population invited to participate and
included those who had relapsed local or metastatic cancer. The present study had a
91% participation rate and specifically focussed on men who were recurrence free.
Another study reported a secondary multivariate analysis of prospectively collected
data on 149 patients who under went radiotherapy/brachytherapy (grouped together),
radical prostatectomy or watchful waiting. They found that treatment did not predict
being fatigued at follow up. While this study is the first to attempt to solely examine
predictors of fatigue, it had several shortcomings: fatigue was not measured using a
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fatigue specific instrument and the time since treatment was not clear as the follow
up data was reported as "6-12 months after prostate biopsy" which can predate
treatment by several months (Maliski et al. 2005).
A cross sectional study of 249 patients more than 2 years after radiotherapy showed
EORTC fatigue scores were very similar to over 70s German normal population data
(mean 29.5 vs. 27.8; the mean score for the present study was similar at 25.1).
However in this study 34% had relapsed disease which may have confounded fatigue
findings (Geinitz et al. 2006).
8.6.4 Conclusions
This cross sectional survey is the first study to specifically focus on fatigue in
recurrence free prostate cancer survivors. Fatigue that interferes with function was
present in approximately one third and was more than a non-cancer comparison
group. Fatigue was associated with treatment but not after controlling for depression,
comorbidities and urinary symptoms. Care should be focussed on optimising
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9.1 INTRODUCTION
The background to this study has been covered in Chapter 2 but is summarised here.
Androgen deprivation therapy ('hormone treatment') is the primary therapy for men
with metastatic prostate cancer or those with localised disease who are not suitable
for surgery or radiotherapy. For those with high risk, early localised disease,
adjuvant hormone treatment is also given for two years after radiotherapy or surgery
to reduce the risk of recurrence.
Most commonly long term androgen deprivation is in the form of LHRH (lutinising
hormone releasing hormone) analogue injections given every three months. This
lowers the levels of circulating testosterone, thus preventing prostate tumour growth.
If primary treatment fails, other hormonal treatments can be commenced such as oral
antiandrogens (i.e. biclutamide), stilboestrol and prednisolone. Often the cancer can
be controlled in this way for several years and treatment is continued until either the
disease becomes hormone refractory or the patient dies of other causes.
Androgen deprivation therapy is known to be associated with a number of side
effects, most commonly hot flushes, impotence and loss of libido. Others include
gynaecomastia (breast enlargement) anaemia, muscle wasting, depression, increase
in fat deposition and a decline in cognitive function (Holzbeierlein et al. 2004). In
my clinical experience patients also commonly complain of fatigue. However there is
very little literature that has specifically addressed this symptom in prostate cancer
patients. In common with Study A, the only published study that has, found that
fatigue increased after three months of androgen deprivation (Stone et al. 2000a). To
date there are no published data specifically examining the prevalence of fatigue in
men receiving long term hormone treatment for prostate cancer.
In other cancers, fatigue is common in advanced disease. Hormone treatment is used
to control both localised and metastatic prostate cancer but to my knowledge there
are no data comparing fatigue in prostate cancer patients with different stages of
disease.
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Prostate cancer survival is often in terms of many years and so it is important to
identify symptoms that affect patients' quality of life. There is a clear need for a
representative study specifically exploring the problem of fatigue and its associations
in men with hormone controlled prostate cancer.
9.2 AIMS
To determine the prevalence and associations of Substantial Global Fatigue (Brief
Fatigue Inventory global fatigue > 3) in men with hormone controlled prostate
cancer.
To determine whether there is any difference in the prevalence of Substantial Global
Fatigue between patients who have local or metastatic disease.
To compare the prevalence of Substantial Global Fatigue to a historical non-cancer
comparison group ofmen with benign prostatic hypertrophy (from Studies A and B).
9.3 HYPOTHESES
Substantial Global Fatigue will be associated with poorer quality of life, depression,
anxiety and pain.
The prevalence of Substantial Global Fatigue in men with hormone controlled
prostate cancer will be higher in men with metastatic disease than local disease.
Men with hormone controlled prostate cancer will have a higher prevalence of
Substantial Global Fatigue than a historical non-cancer comparison group.
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9.4 METHODS
9.4.1 Design
A cross sectional postal survey supplemented with retrospective clinical data.
9.4.2 Patient Sample
Men with prostate cancer in the county of Fife receive multidisciplinary care from
the Urologists based in the District General Hospitals (Queen Margaret Hospital
(QMH), Dunfermline and Victoria Hospital, Kirkcaldy) and an Edinburgh Cancer
Centre Oncologist who does a weekly clinic at QMH.
In Fife, all LHRH analogue injections are centrally coordinated and delivered by the
Clinical Nurse Specialists based at QMH. Men on long term androgen deprivation
therapy for prostate cancer receive injections every three months and their PSA
(prostate specific antigen) is checked at the same time. This setting provided the
ideal opportunity for collecting data from a representative sample of men receiving
long term androgen deprivation therapy in a geographically defined area.
Inclusion criteria
• Localised or metastatic prostate cancer
• The patient had been on androgen deprivation therapy for at least three
months
• PSA <0.2pg/L within the last three months (indicating their prostate cancer
was controlled) or if above 0.2pg/L, then stable at nadir for at least two
consecutive readings a minimum three months apart
Exclusion criteria
• On neo-adjuvant androgen deprivation therapy prior to radiotherapy or
brachytherapy (these patients only had treatment for three months)
• Hormone refractory prostate cancer (their cancer would not be controlled and
may have confounded fatigue findings)
• Another concurrent cancer diagnosis (as other cancers can be associated with
fatigue and this may have confounded the findings).
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Recruitment
Between November 2005 and February 2006, The Clinical Nurse Specialist
identified eligible patients and introduced the survey in a letter which accompanied
the patient information sheet, consent form and survey questionnaire. Patients were
invited to participate in the survey and post back the questionnaire and consent form
in a stamped addressed envelope provided. Potential participants who did not return
the questionnaire within one month, were sent another one by post. Demographic and
clinical details of non participants were noted.
9.4.3 Non-cancer comparison group
This was a historical comparison group which comprised of the 63 men with benign
prostatic hypertrophy recruited for Studies A and B.
9.4.4 Demographic and Clinical Data Collected
• Date of birth
• Postcode, to assess Scottish Index ofMultiple Derivation see section 5.1.1.
• Marital status (data from patient questionnaire)
• Most recent PSA result
• Disease status (localised/metastatic) from medical notes or radiological
records
9.4.5 Self Rated Questionnaire Measures
• The Brief Fatigue Inventory (BFI) As it was not possible to interview
patients, a cut off of global fatigue >3 was used to define fatigue of a
clinically relevant severity (termed Substantial Global Fatigue), see section
4.1.2.1.
• Two additional questions which could be answered,"Yes" or "No"
o "Has fatigue been a problem for you in the last week?" This was asked
because in previous work, although some patients said they felt fatigued,
they did not find it a problem because they were able to adjust their lives
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accordingly by for example putting things off until the next day because
they were retired.
o "Have you felt fatigued for longer than one month?" This was to
ascertain whether fatigue was more than an acute problem. A period of
one month was chosen as this corresponded to the work that was done
regarding the case definition of CSF (clinically significant fatigue).
One open question "If yes, to either of the above, what do you think
contributed to it or caused it [fatigue]?"
Hospital Anxiety and Depression Scale (HADS), see section 5.4.1.
European Organisation for the Research and Treatment of Cancer
Quality of Life Questionnaire core 30 version 3.0 (EORTC QLQc30), see
section 5.4.2. In order to focus on the most relevant issues for this population
only the following subscales and items were selected: physical, role, and
social functioning, three symptom scales (fatigue, nausea and vomiting) ,and
single items (dyspnoea, insomnia, constipation, diarrhoea). This reduced the
patient questionnaire burden and avoided replication of question themes (i.e.
using both the HADS and the emotional functioning subscale to measure
similar things).
International Prostate Symptom Score (IPSS), see section 5.4.4, with a
preliminary question asking if they had a urinary catheter. If so, they did not
fill in the IPSS score as the questions were irrelevant.
Likert scales for erectile function and how much of a problem this is, see
section 5.4.3.
Likert scales for common side effects from prostate cancer, androgen
deprivation or previous prostate cancer treatment as fatigue may be
associated with symptom burden. These side effects were also of particular
Chapter 9 147
Study D - Fatigue in hormone controlledprostate cancer
interest to the responsible clinicians. Each item related to the past week and is
answered on a four point scale; not at all, a little, quite a bit, very much.
o urinary incontinence and dysuria as these are not covered by the IPSS.
o faecal incontinence and rectal bleeding
o hot flushes and sore nipples or breasts which are common side effects
of androgen suppression.
• 'Worst pain' item from the Brief Pain Inventory (Cleeland CS 1989) This
cohort included men with metastatic disease so it was decided this symptom
should be investigated. Patients were asked to rate their worst pain in the last
week on an 11 point scale between 0 ('no pain') and 10 ('pain as bad as you
can imagine'). This has been found to be the most sensitive item and is brief
and well validated (Serlin et al. 1995).
• Other Comorbidities
It was not feasible to obtain copies of all peripheral hospital notes or to ask
the GP about each patient's past medical history and comorbidities. Patients
were instead asked about the most common comorbidities that may influence
fatigue (cardiovascular and respiratory problems, diabetes, stroke, depression,
musculoskeletal problems or another cancer diagnosis). There was also an
open question allowing them to mention any other medical conditions they
thought we should know about and medications they were taking. This
approach is similar to that employed by other authors (Lilleby et al. 1999).
9.4.6 Ethical Approval
The study was approved by the Fife and Forth Valley Local Research Ethics
Committee. Reference number 05/S0501/108.
Chapter 9 148
Study D Fatigue in hormone controlled prostate cancer
9.4.7 Statistical Analysis
Data were inspected using histograms and box plots and described using means,
medians and percentages of categories as appropriate. To assess whether the data was
representative of the eligible sample, data from participants and non participants
were compared using Student t-tests and Chi squared tests as appropriate.
Fatigue was described as the global fatigue score and the percentage who had
Substantial Global Fatigue (global fatigue score >3). Prevalence of Substantial
Global Fatigue was compared to the non-cancer group using Chi squared tests
Univariate associations of Substantial Global Fatigue were examined using binary
logistic regression for categorical variables and Student t-tests and Mann Whitney
tests as appropriate for continuous variables. Independent associations of Substantial
Global Fatigue were examined using multivariate analysis with no selection.
Variables such as physical, role and social functioning were not included as these
could be regarded as outcomes of fatigue rather than predictors. HADS depression
question 8 "I feel as if I am slowed down" may be construed as referring to fatigue.
Hence associations between Substantial Global Fatigue and depression were
performed both including and excluding this item. This approach has been previously
reported (Stone et al. 2000a).
A p value of <0.05 was considered statistically significant. I was advised and assisted
with the statistical analysis by Dr Isabella Butcher, Research Fellow, Public health
Sciences, University of Edinburgh using SAS/STAT software, Version 9.1 of the
SAS System for Windows. Copyright © 2002-2003 SAS Institute Inc.
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9.5 RESULTS
There were 298 patients with prostate cancer who were on long term androgen
deprivation therapy, 211 of which had hormone controlled disease. 204 fulfilled the
eligibility criteria and were sent the questionnaire package. Two patients
subsequently transpired to have another concurrent cancer diagnosis and carers
informed me that four patients had severe cognitive impairment and were unable to
fill in the questionnaire. These men were deemed ineligible retrospectively and not
included in the analysis. Two patients sent back the blank questionnaire saying they
were well and did not think the questions were relevant to them. One questionnaire
was returned saying the addressee had moved away. The final eligible patient
participation rate was 81% (160/198). There were no statistically significant
demographic or clinical differences between those who did and did not participate
(see table 9.1).
Table 9.1 Comparison of demographic and clinical details of eligible patients




Variable % n % n p-value
SIMD group 0.801
1 16 6 18 28
2 22 8 31 49
3 19 7 15 24
4 30 11 24 38
5 14 5 12 19
Adjuvant hormones 0.469**
No 97 37 93 148
Yes 3 1 8 12
Disease Status 0.267
local 58 22 70 111
metastatic 42 16 29 47
unknown 0 0 1 2
Mean age in years (SD) 79.1 (8.9) 77.2 (7.5) 0.173*
All were compared using Chi squared test except * Student t test ** Fishers Exact Test
SD = Standard deviation, SIMD= Scottish Index of Multiple Deprivation
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The mean age of the sample was 77.2 years (SD 7.5) and the majority (61%) had
local disease. 88% (140/160) were on first line hormonal treatment and 7.5%
(12/160) were on adjuvant hormonal treatment. 70% were married or cohabiting,
22% were widowed and 8% were unmarried or divorced. Descriptive continuous and
categorical variables are shown in tables 9.2 and 9.3.
Table 9.2 Continuous variables for the non cancer group and hormone
controlled prostate cancer group according to disease extent
Hormone Hormone controlled
controlled prostate cancer
prostate local metastatic Non-cancer
cancer disease disease group
n= 160 n= 111 n=47 n=:63
mean SD mean SD mean SD mean SD
Fatigue
global fatigue (BFI) 3.1 (2.4) 3.3 (2.5) 2.7 (2.2) 1.8 (1.7)
EORTC Fatigue Score 35 (24) 38 (25) 31 (22) 21 (15)
Age in years 77.2 (7.5) 78.1 (7.5) 75.4 (7.0) 66.2 (6.7)
EORTC QLQc30
Global Health Related QL* 65 (23) 63 (25) 70 (20) 80 (15)
Physical Function* 67 (25) 65 (26) 71 (21) 89 (15)
Role Function* 68 (33) 66 (34) 72 (31) 91 (18)
Cognitive Function* 75 (23) 74 (24) 76 (21) 80 (16)
Social Function* 72 (33) 67 (34) 80 (29) 86 (22)
Nausea** 5 (11) 4 (12) 5 (11) 3 (13)
Dyspnoea** 31 (33) 33 (35) 25 (31) 15 (19)
Insomnia** 32 (32) 33 (32) 30 (32) 21 (26)
Constipation** 21 (29) 20 (30) 24 (27) 8 (16)
Diarrhoea** 9 (20) 10 (22) 4 (11) 6 (15)
BFI = Brief Fatigue Inventory, EORTC QLQc30 = European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire core 30. QL = quality of life
* Higher scores = better function, ** Higher scores = worse symptoms
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Table 9.3 Categorical variables for the non-cancer group and the hormone





prostate local metastatic cancer
cancer disease disease group
n= 160 n= 111 n==47 n=63
% n % n % n % n
Fatigue
substantial global fatigue
(BFI global fatigue >3) 43 68 47 52 33 15 16 10
Fatigue is a problem: 45 70 47 50 43 20 - -
Fatigue present > 1 month 44 67 47 50 39 17 - -
Pain
BPI worst pain > 4 28 42 32 34 19 8 - -
HADS
Anxiety ^ 9 19 30 19 21 20 9 13 8
Depression > 8 28 44 28 31 29 13 8 5
Depression -Qu8 ^ 8 12 18 12 13 11 5 6 4
moderate/severe urinary
symptoms (IPSS) 48 74 51 53 46 21 68 43
Other symptoms
'quite a bit' & 'a lot'
urine incontinence 4 6 6 6 0 0 - -
dysuria 1 1 0 0 2 1 - -
faecal incontinence 3 4 3 3 2 1 - -
Hot flushes 35 55 36 39 33 15 - -
Sore breasts 8 13 8 8 11 5 - -
Erectile Function
not possible/severely reduced 97 150 95 102 100 46 45 28
Serious problem/quite a problem 22 34 21 22 24 11 21 13
Comorbidities
cardiac problems 39 61 42 46 30 14 46 29
respiratory problems 37 57 39 43 30 13 8 5
diabetes 13 20 15 16 9 4 10 6
cerebrovascular accident 9 13 10 10 7 3 3 2
depression 17 25 18 18 16 7 5 3
musculoskeletal problems 58 91 59 64 60 27 21 13
neurological problems 2 3 3 3 0 0 0 0
total comorbidities NONE 15 24 16 17 15 7 40 25
ONE 33 53 28 31 43 20 33 21
TWO + 52 82 56 62 43 20 27 17
BFI = Brief Fatigue Inventory, BPI= Brief Pain Inventory, HADS= Hospital Anxiety and
Depression Scale minus question 8, IPSS= International prostate symptom score.
Not all rows add up to 160 because 2 patients' disease status was unclear
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9.5.1 Prevalence and associations of Substantial Global Fatigue
The estimated prevalence of Substantial Global Fatigue in men with hormone
controlled prostate cancer was 43% (68/160). Put in context this is higher than the
non-cancer comparison group ofmen with benign prostatic hypertrophy from studies
A and B (16%, 10/63, p=0.0002). Men with locally advanced prostate cancer had a
higher prevalence of Substantial Global Fatigue than those with metastatic disease
but sample numbers in the latter group were small and this did not achieve statistical
significance (47 vs. 33%, p= 0.10, figure 9.1)
Figure 9.1 Prevalence of Substantial Global Fatigue in men with hormone
controlled metastatic and locally advanced prostate cancer
n metastatic disease ■ local disease
Men with Substantial Global Fatigue had poorer global health related quality of life,
poorer physical, role, and social function and higher insomnia scores (see table 9.4).
It was significantly more likely in men who had depression (odds ratio 9.8, dropping
to 8.4 once HADS question 8 was excluded), anxiety (odds ratio 5.0), worst pain > 4
(odds ratio 9.2), moderate/severe urinary symptoms (odds ratio 3.3) and concurrent
comorbidities (see table 9.5). Substantial Global Fatigue was not associated with age
or deprivation category.
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Table 9.4 Univariate associations of continuous variables with Substantial
Global Fatigue (p<0.05 in bold)
Global Fatigue
Substantial None/mild
Variable n=68 n=91 P-value
mean SD mean SD
Age 77.3 (8.7) 77.1 (6.6) 0.8823 *
EORTC QLQc30 scores
Global health related QL* 52 (21) 74.7 (20) <.0001
Physical function* 50 (21) 79.6 (20) <.0001
Role function* 47 (34) 84.5 (22) <.0001
Social function* 49 (33) 88.6 (22) <.0001
Insomnia** 38 (35) 26.6 (29) 0.0466
All compared using Mann Whitney U test except * Student t-test
EORTC QLQc30 = European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire core 30, QL = quality of life
* Higher scores = better function, ** Higher scores = worse symptoms
9.5.2 Independent associations of Substantial Global Fatigue
Urinary symptoms, comorbidities, anxiety, depression, disease status and 'worst
pain' scores were entered into a multivariate logistic regression. Worst pain > 4 and
depression were the only independent associations of Substantial Global Fatigue
(odds ratios 3.0 and 4.9 respectively) after controlling for the other factors. In case
HADS depression question 8 "I feel slowed down" was confounding the relationship
with fatigue, a second regression was performed excluding this question. This
resulted in worst pain > 4 being the only independent association with Substantial
Global Fatigue (odds ratio 4.4, see table 9.5).
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9.5.3 Fatigue a problem or not
Of those who had Substantial Global Fatigue, 82% (51/62) said it was a problem.
These patients were older (78.1 vs. 73.8years), had more moderate to severe urinary
symptoms (68 vs.54%), more comorbidities (78 vs. 54% had two or more
comorbidities) more pain ('worst pain' > 4, 55 vs.33%) and a greater proportion had
depression (59 vs. 23%).
81% (50/62) had experienced fatigue for longer than one month. 74% (46/62) said
fatigue was both a problem and had been present for longer than one month. 38/68
patients with Substantial Global Fatigue suggested a possible cause of their fatigue
but only four men attributed it to their hormone treatment or prostate cancer. The
other causes suggested by patients are in table 9.6.
Table 9.6 Possible causes of fatigue suggested by 38/68 patients with Substantial
Global Fatigue
Reason for fatique













other health problems 1
caring for relatives 1
diabetes 1
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9.6 DISCUSSION
9.6.1 Main findings
The prevalence of Substantial Global Fatigue in men with hormone controlled
prostate cancer was 43%. Of those that were fatigued, 82% said it was a problem and
had significantly worse quality of life, poorer role, social and physical functioning.
Substantial Global Fatigue was also associated with higher pain scores, depression,
anxiety, concurrent comorbidities and more urinary symptoms. After controlling for
these factors, the only independent associations of Substantial Global Fatigue were
depression and pain. However HADS depression item 8 did confound the
relationship and once this was excluded only pain was independently associated.
These results should be interpreted with caution, because the effect of removing the
contribution of HADS item 8 to the HADS depression score made the definition of
depression more stringent and consequently the depression group became smaller (17
patients). However this would still be an acceptable cut off as other authors have
used case definition thresholds for depression as high as 11 (Bjelland et al. 2002).
The prevalence of Substantial Global Fatigue was higher than a small non-cancer
comparison group of men with benign prostatic hypertrophy. These results must be
interpreted with caution as the latter were younger, had less comorbidities and a
lower prevalence of depression. In addition they were not recruited specifically as a
comparison group for this study. Ideally I would have compared to a group of older
men without a history of cancer but it was difficult to identify a representative,
accessible population from which to recruit. The other option would have been to
compare to Brief Fatigue Inventory normative data in men of this age group but there
is none available (personal communication with the authors of the BFI in 2003). It is
also noteworthy that this hormone controlled group of prostate cancer patients had a
higher prevalence of Substantial Global Fatigue than the recurrence free men in
study C (43 vs. 29%).
There is the clinical impression that patients with greater tumour burden experience
higher levels of fatigue. This was not confirmed by this study as there was no
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statistically significant difference between the prevalence of Substantial Global
Fatigue in men with localised or metastatic disease. This was not surprising as by
definition, cancer is assumed not to be the cause of fatigue because this cohort had
hormone controlled prostate cancer. However, it is interesting to note that there was a
counterintuitive trend for those with local disease to have higher fatigue. They also
had higher pain scores (presumably not cancer related) and lower role, social and
physical functioning. This could be partially explained because they were older and
had more comorbidities than the metastatic group. The severity of anxiety and
depression were similar regardless of disease stage and so appear not to contribute to
the difference in fatigue.
9.6.2 Limitations
The prevalence of Substantial Global Fatigue may be an underestimate. This is
because some of the non participants' addresses were in nursing homes and it is
possible that these men did not participate because they were too ill or fatigued to do
so. However, there was a good response rate to the survey (81%), and no statistical
differences between the demographic and clinical characteristics of those who did
and did not participate.
As with all cross sectional studies we can estimate prevalence but not incidence.
Prospective studies are required to fully understand the incidence and trajectory of
fatigue on long term hormone treatment.
The other limitations relate to the measures: (a) The cut off on the BFI global fatigue
scale of >3 was applied to define Substantial Global Fatigue. Work from Study B
suggests this did not equate to interview defined clinically significant fatigue (CSF)
and so may underestimate this. Ideally I would have interviewed all patients to assess
whether they were cases of CSF, however this was not feasible (b) The HADS could
have also been analysed as a continuous measure but this causes difficulties in
interpreting odds ratios which become less clinically meaningful. It is appreciated
that the cut offs are not the same as an interview defined case definition of
depression or anxiety (c) Comorbidities were not assessed using a validated scale. In
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Studies A and B, the Charlson Comorbidity Index was used but in this situation it
was not a feasible tool as it depends on reviewing medical case notes. In addition, it
was originally devised to predict the likelihood of a patient dying and so only
included potentially life threatening medical conditions. From earlier work and
talking to patients it quickly became obvious that the Charlson Comorbidity Index
did not pick up conditions that may significantly affect a person's life and possibly
fatigue e.g. arthritis and Parkinson's Disease. Asking about other medical conditions
enabled me to account for these though relied heavily on the patient's interpretation
of the questions and recall/understanding of their medical history.
Lastly, some studies found that men on androgen deprivation therapy for three
months had a drop of haemoglobin (Strum et al. 1997;Ornstein et al. 1999). The
patients in this study had been on treatment for longer than that. We were unable to
check the haemoglobin of our sample due to the postal nature of our survey.
However, anaemia is a recognised association of fatigue and should be considered in
future investigations.
9.6.3 Other literature
There are no other studies to compare to that have specifically examined fatigue in
men with long term hormone controlled prostate cancer. The most similar one
prospectively examined fatigue in 62 men receiving androgen deprivation therapy
over three months (Stone et al. 2000a). These men had various stages of disease and
were either receiving hormonal therapy as their primary treatment or as neo-adjuvant
treatment before radiotherapy. The authors used four different fatigue scales, one of
which was also used in this study (the EORTC fatigue subscale). They reported a
significant increase in fatigue scores of three of the scales used but not the EORTC
fatigue subscale. This remained unchanged at median of 22/100 (range 0-89) which
is lower than the men in this study (median 33, range 0-100) who had been on long
term treatment.
Other studies have examined quality of life in men with locally advanced or lymph
node positive prostate cancer comparing men who had hormone treatment vs. no
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treatment. None of these used a fatigue specific instrument but found SF-36 vitality
was lower and EORTC fatigue was statistically significantly higher in those who
had androgen deprivation therapy (Herr & O'Sullivan 2000;Potosky et al. 2002;Van
Andel & Kurth 2003). Fatigue and pain were found to be the most severe symptoms
in men with bone metastases prior to hormone treatment (Jonler et al. 2005) but there
is a lack of studies addressing what happens to fatigue after treatment starts.
9.6.4 Conclusions
To my knowledge this cross sectional study of the first to focus on fatigue in men
with hormone controlled prostate cancer. Almost half this population had fatigue of a
clinically relevant severity that impaired ability to function and quality of life. For
some men with local disease, there is debate about whether they should have
hormone treatment at all or just be on active monitoring in view of the detrimental
effect on quality of life and limited survival benefit.
Most clinicians (and patients) regard fatigue as an inevitable and untreatable side
effect of androgen deprivation therapy. Perhaps this does not have to be the case.
Pain was an independent predictor of fatigue, suggesting attention needs to be paid to
ensure adequate pain management (of presumably non malignant conditions seeing
as their prostate cancer was controlled). In view of the possibility of anaemia
developing during treatment, it may be worthwhile haemoglobin being prospectively
monitored. Finally, it is recognised that androgen deprivation causes muscle wasting.
Exercise may help maintain muscle bulk and has been shown to attenuate fatigue in
cancer patients (Windsor et al. 2003;Courneya et al. 2007). Prospective studies of
men on long term androgen deprivation therapy using a fatigue specific measurement
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10.1 FATIGUE AND PROSTATE CANCER
10.1.1 Why I set out to examine fatigue in prostate cancer
I set out to examine fatigue in prostate cancer patients because there was little
published data regarding fatigue in this population despite it being the commonest
male cancer. In addition, amongst health professionals involved in the care of
prostate cancer patients, there was a difference of opinion about the severity and
trajectory of fatigue during and after treatment. Survival of prostate cancer can be in
terms ofmany years and could be considered to be a chronic disease. Consequently
survivorship issues and long term side effects of treatment are now attracting
increasing recognition and concern amongst oncologists.
10.1.2 What I set out to do
I wanted to explore fatigue in men with prostate cancer from several different
perspectives. These included examining fatigue during and after treatment for
localised disease and also patients on treatment for more advanced and metastatic
disease. Additionally, it was planned to assess fatigue using not only recognised
fatigue specific questionnaire measures but an interview defined case definition of
clinically significant fatigue that would be devised. Finally I wanted to integrate
these subjective assessments with objective biological measures such as cytokines to
assess any possible correlates of fatigue.
10.1.3 What was done
After exploring the feasibility of doing several prospective studies in the time
available, it became clear I would have to focus on specific areas and some studies
would have to be cross sectional.
In total four studies were carried out. Study A was three month pilot prospective
study that concentrated on men having radiotherapy, brachytherapy or neo-adjuvant
androgen deprivation therapy for localised prostate cancer. Results of this led to
Study B which focussed on men having brachytherapy and followed them up for 12
months. Study C was a postal survey examining fatigue in recurrence free survivors
more than a year after having radiotherapy or radical prostatectomy. Finally, men
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with more advanced disease were examined in Study D, a postal survey ofmen with
hormone controlled prostate cancer. Throughout all this work, fatigue was assessed
using a recognised fatigue specific questionnaire. In addition, an interview based
case definition of clinically significant fatigue (CSF) was devised and applied in




The pilot study found that examining fatigue in men with early prostate cancer was
feasible. Preliminary results indicated that CSF increased in both the radiotherapy
and brachytherapy groups one month after treatment but returned to baseline levels
in the radiotherapy group, whilst there was the suggestion of prolonged fatigue in the
brachytherapy group. Fatigue was not associated with changes in markers of
systemic inflammation (CRP and IL-6).
Study B
Following on from the above, Study B focussed on brachytherapy and found that
cases of CSF significantly increased between baseline and one month (6 vs. 29%,
p=0.001). The prevalence at one and three months was significantly greater than that
ofmen without cancer who were of a similar age (29% vs. 4% p=0.001 and 16% vs.
4% p=0.049 respectively). Those who were cases of CSF at baseline tended to
remain so for the 12 months afterwards whereas there were no baseline factors that
predicted who developed CSF at one month. Cases of CSF had poorer health related
quality of life, poorer physical functioning, poorer role functioning and higher
depression scores than non cases. Most cases of CSF had resolved by six months
after treatment but those who were cases at baseline tended to remain so. Fatigue was
not related to CRP.
For both studies A and B, in contrast to cases of CSF, when fatigue was measured as




This postal survey found the prevalence of fatigue (a cut off on the Brief Fatigue
Inventory >3 and called Substantial Global Fatigue in this thesis) was 29% in
recurrence free survivors previously treated for prostate cancer more than one year
ago. Fatigue was associated with poorer quality of life and worse role, social and
physical functioning. Univariate analysis showed a significant association with
treatment received but this was no longer the case after controlling for depression
(with and without HADS item 8), anxiety, urinary symptoms, and medical
comorbidities. Of all these factors, the strongest independent association with fatigue
was depression.
Study D
This postal survey found 43% of men with hormone controlled prostate cancer had
Substantial Global Fatigue. There were no statistically significant differences in the
prevalence for those with metastatic and local disease. Independent associations of
fatigue were worst pain > 4 and depression. However in a second multivariate
analysis when HADS depression item 8 was removed, only worst pain >4 was
independently associated.
Both recurrence free prostate cancer survivors and men with hormone controlled
prostate cancer had a higher prevalence of fatigue than the non-cancer group of men
with benign prostatic hypertrophy (16%).
10.1.5 General Conclusions
This research has produced new information about fatigue and prostate cancer. To
my knowledge it includes the first studies that have specifically examined fatigue (a)
after brachytherapy (b) in recurrence free prostate cancer survivors and (c) in men
with hormone controlled prostate cancer.
Although fatigue was a common side effect of brachytherapy, it did not impair
patients' functioning as much as had been anticipated. Nor did it appear to be related
to markers of systemic inflammatory response such as CRP. The two cross sectional
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surveys found the prevalence of fatigue in recurrence free survivors was higher than
that of a non-cancer comparison group but the relationship with type of treatment
received was not strong. Not surprisingly, men with more advanced hormone
controlled disease had a higher prevalence of fatigue. Fatigue was associated with
depression but generally HADS scores were low in men with prostate cancer and the
association does not appear to be as strong as for women with breast cancer. Fatigue
findings varied according to the assessment tool used (interview or questionnaire)
and this raises doubts about the validity of the use of scale based questionnaires in
fatigue research as a whole (discussed further below).
10.1.6 General Limitations
Fatigue and prostate cancer
The majority of patients studied during this project either had localised prostate
cancer or were recurrence free. There would have probably been a greater proportion
of CSF in men with metastatic hormone refractory prostate cancer. I tried to set up a
study of these men but identifying them was surprisingly difficult. Generally they
were not attending the outpatient clinics, nor were they inpatients in the oncology
wards. The responsible clinicians were under the impression that once patients had
got to that stage they were referred to the palliative care services. Consequently I
went to the two hospices in Edinburgh (St. Columbas and Marie Curie Centre) but in
fact, according to their records they only had one or two such patients a month.
Bearing in mind some of these men would not have been well enough to participate
in a study it was decided on balance this was not feasible.
Although there were some changes after radiotherapy and brachytherapy in
biological measures such as haemoglobin, lymphocyte count, IL-6 and CRP
indicating a systemic effect of localised treatment, there was little evidence that these
changes were associated with fatigue. It had been originally planned to perform more
extensive proinflammatory cytokine testing but the available information did not
justify this and financial resources were limited. Had it been possible to study men
with more advanced prostate cancer in detail, ideally I would have liked to have
assessed biological parameters in those patients.
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There were no data available regarding fatigue scores on the Brief Fatigue Inventory
for the general male population. Instead, a group of men with benign prostatic
hypertrophy were recruited as a non-cancer comparison group. Comparisons with the
prostate cancer group would have been more robust if the non-cancer sample was
larger. It is possible this group ofmen with benign prostatic hypertrophy had a higher
level of fatigue than the general population as has been shown in a Swedish Study
(Jakobsson et al. 2004). I had looked into the possibility of locating a representative
sample of men over 60 years of age without cancer (e.g. recruiting from bowling
clubs) but it was difficult to do this without introducing sampling bias.
The differences in methods of fatigue assessment
Several issues that have hampered fatigue research in the past remain. Firstly, there is
still a problem of defining what fatigue really is. To some extent this is a problem of
colloquial language and the word meaning different things to different people.
Despite the various research definitions of fatigue, patients do not think in
convenient research categories and some authors argue the best definition is similar
to that of pain; it is what the person experiencing it says it is (Cleeland & Wang
1999;Holley 2000a;De Groot et al. 2003). The second issue is measuring fatigue and
defining when it becomes a clinically significant problem. Most clinicians and
patients agree when fatigue is severe. However at other times a patient's
interpretation of fatigue severity can depend on their expectations and can vary from
patient to patient. In turn a clinician's impression may also be different to that of the
patient.
There were some interesting findings with regards to different methods of assessing
fatigue. In studies A and B, fatigue was examined using both a continuous scale
measure and the interview based case definition of CSF which produced different
findings. Possible reasons for this have been discussed in detail in Chapter 7 but in
summary could be partly explained by a combination of factors: (a) some patients
rated an increase in the fatigue scores and others, a decrease, which averaged out the
mean group fatigue score (b) patients adjusted their internal standards and
expectations (response shift) (c) some patients said different things on paper to when
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they were interviewed. The interview was more rigorous and questionnaires should
never be used as a substitute for talking to patients. However, as suggested by the
NCCN, questionnaires may be a useful screening tool to identify who may need
more in depth clinical assessment (Mock 2005).
In addition from a methodological point of view, ideally the CSF criteria would have
been applied to a larger number of fatigued and non fatigued people (such as those
who participated in the postal surveys) to assess its relationship to the Brief Fatigue
Inventory more comprehensively. However due to limitations of time and personnel
this was not feasible.
Since starting this project, further work has been conducted using the ICD 10
proposed definition of the syndrome of Cancer Related Fatigue (Cella et al.
2001;Sadler et al. 2002;Van Belle et al. 2005;Andrykowski et al. 2005;Young &
White 2006;Murphy et al. 2006;Fernandes et al. 2006) but further work is required
because as discussed in Chapter 4, the criteria are impractical to apply in full.
10.2 FATIGUE AND CANCER
Fatigue is a real and serious problem for many cancer patients. There is a natural
tendency to race ahead to investigate possible treatments for this distressing
symptom. Since embarking on this thesis, more evidence for different approaches to
managing fatigue has emerged but none have demonstrated substantially effective
changes in fatigue. Helpful reviews have been published summarising these findings
(Ahlberg et al. 2003;Mustian et al. 2007;Carroll et al. 2007). So far most data relates
to exercise, but this has to be defined carefully according to the fitness of the patient
and it remains unclear what is the most effective prescription. Haematopoetic agents
have shown some benefit in anaemic chemotherapy patients but the effects may be
confounded by disease stage. Pharmacological interventions such as
psychostimulants, antidepressants, corticosteroids and L-carnitine have been
examined in small samples ofmixed cancer samples for times ranging from 7 days to
2 months. However, most studies that have shown benefit to date are open label and
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of the few that have progressed to blinded randomised controlled trials, no
improvement in fatigue has been found. Monoclonal antibodies to block
proinflammatory cytokines have been shown to help fatigue in patients with
Rheumatoid Arthritis (Omdal & Gunnarsson 2005), this may also help cancer
patients. With any of these medications there are side effects and so other
interventions have been attempted such as advising patients to rest, providing
information about the possible development of fatigue, cognitive behavioural
therapy, sleep interventions, or complementary therapies such as acupuncture, yoga
and aromatherapy.
10.2.1 What still needs to be done
Fatigue is a distressing problem for many cancer patients and despite the difficulties
associated with its research, it is an important issue that is deserving ofmore study.
In prostate cancer, further prospective studies of fatigue in men with advanced
prostate cancer who are receiving androgen deprivation therapy or chemotherapy are
required. It may be worthwhile to build on published work and try a gentle exercise
intervention in these men.
With regards to other cancers, more prospective studies of specific clinical groups
receiving similar treatments are required to give clinically meaningful information to
enable clinicians to inform patients of the likelihood of fatigue. In addition,
biological factors should be appropriately measured which may shed light on
potential mechanism or correlates of fatigue. Follow up needs to extend for several
years to assess the trajectory of post treatment fatigue and this will also enable the
identification of pre-treatment risk factors which may help prevent the development
of fatigue in the first place. This is especially important where the aim of treatment is
cure. With a growing number of cancer survivors and given the substantial adverse
physical, psychosocial and economic consequences of post cancer treatment fatigue,




For fatigue research as a whole, further work needs to be done to agree a definition
of clinically significant fatigue and a measurement tool. The evaluation of potential
treatments will remain difficult in view of the lack of these. Fatigue is a symptom of
many other medical conditions and it may be appropriate for a case definition of
clinically significant fatigue to be applied outwith cancer. This would enable
comparisons of prevalence and associations and evaluation of possible shared
mechanisms of fatigue development.
10.3 PERSONAL REFLECTION
I have learned much along the journey of working towards this thesis (amongst other
things, having conducted two small prospective studies I now appreciate why there
are relatively few out there - they are hard work!). I am very grateful to all the
patients who took part for enabling me to gain deeper insight into the issues they
face. That was a privilege for me and I hope in the process, this work has made a
small contribution to the understanding of fatigue in prostate cancer patients. In
general, patients are living longer with cancer and oncologists are increasingly
recognising the adverse impact of fatigue on the patients they treat. Research into
this important symptom is gaining momentum. I hope that in the near future,
advances in the understanding and management of fatigue will mirror progress made
with pain and nausea in previous years. Useful steps forward have been made, but
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1. Proposed ICD-10 Criteria for Cancer Related
Fatigue
A. Six (or more) of the following symptoms have been present every day
or nearly every day during the same 2 week period in the last month,
and at least one of the symptoms is (1) significant fatigue.
1. Significant fatigue, diminished energy,or increased need to rest,
disproportionate to any recent change in activity level.
2. Complaints of generalized weakness or limb heaviness.
3. Diminished concentration or attention
4. Decreased motivation or interest to engage in usual activities
5. Insomnia or hypersomnia.
6. Experience of sleep as unrefreshing or nonrestorative.
7. Perceived need to struggle to overcome inactivity.
8. Marked emotional reactivity (eg sadness,frustration, or irritability) to
feeling fatigued.
9. Difficulty completing daily tasks attributed to feeling fatigued.
10. Perceived problems with short term memory.
11. Post exertional malaise lasting several hours.
B. The symptoms cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning.
C. There is evidence from the history, physical examination, or laboratory
findings that the symptoms are a consequence of cancer or cancer
therapy.
D. The symptoms are not primarily a consequence of co-morbid
psychiatric disorders such as major depression, somatization disorder,
somatoform disorder or delirium.
All criteria (A to D) need to be fulfilled for cancer related fatigue to be
diagnosed
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2. Charlson Comorbidity index
Comorbidity Present Points
Myocardial Infarct 1
Congestive Heart Failure 1
Peripheral Vascular Disease 1
Cerebrovascular Disease 1
Dementia 1
Chronic Pulmonary Disease 1
Connective Tissue Disease 1
Ulcer Disease 1
Mild Liver Disease 1
Diabetes (without Complications) 1
Diabetes with end organ damage 2
Hemiplegia 2
Moderate or severe renal disease 2
2nd solid tumour (non metastatic) 2
Leukeamia 2
Lymphoma, multiple myeloma 2
Moderate or severe liver disease 3
2nd metastatic solid tumour 6
AIDS 6
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3. Karnofsky Performance Status Index
Normal, no complaints 100
Able to carry out normal activities, minor signs of disease 90
Normal activity but with effort 80
Self-caring but unable to carry out normal activity or work 70
Requires occasional assistance but able to care for most needs 60
Requires considerable assistance and frequent medical care 50
Disabled, requires special care and assistance 40
Severely disabled, hospitalization indicated although death not imminent 30




4 Hospital Anxiety and Depression Scale
Patients are asked to tick the box (not shown) for the response that applies best to
them in relation to eth past week. The scores and details ofwhich subscale the items
belong to are shown for completeness
Item Score Scale
(1) I feel tense or'wound up': Anxiety
Most of the time 3
A lot of the time 2
Time to time, occasionally 1
Not at all 0
(2) I still enjoy the things I used to enjoy: Depression
Definitely as much 0
Not quite so much 1
Only a little 2
Hardly at all 3
(3) I get a sort of frightened feeling as if
something awful is about to happen: Anxiety
Very definitely and quite badly 3
Yes, but not too badly 2
A little but it doesn't worry me 1
Not at all 0
(4) I can laugh and see the funny side of things: Depression
As much as I always could 0
Not quite so much now 1
Definitely not so much now 2
Not at all 3
(5) Worrying thoughts go through my mind: Anxiety
A great deal of the time 3
A lot of the time 2
From time to time but not too often 1
Only occasionally 0
(6) I feel cheerful: Depression
Not at all 3
Not often 2
Sometimes 1
Most of the time 0




Not at all 3
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Item Score Scale
(8) I feel as if I am slowed down: Depression
Nearly all the time 3
Very often 2
Sometimes 1
Not at all 0
(9) I get sort of frightened feelings like
'butterflies in the stomach': Anxiety




(10) I have lost interest in my appearance: Depression
Definitely 3
I don't care as much as I should 2
I may not take quite as much care 1
I take just as much care as ever 0
(11) I feel restless as if I had to be on the move: Anxiety
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0
(12) I look forward with enjoyment to things: Depression
As much as I ever did 0
Rather less than I used to 1
Definitely less than I used to 2
Hardly at all 3
(13) I get sudden feelings of panic: Anxiety
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0







5 EORTC QLQc30 version 3.0
Your health in general
1) Do you have any trouble doing strenuous
activities, like carrying a heavy shopping
bag or suitcase?
2) Do you have any trouble taking a long
walk?
3) Do you have any trouble taking a short
walk outside of the house?
4) Do you need to stay in bed or a chair
during the day?
5) Do you need help with eating, dressing,
washing, yourself or using the toilet?
During the past week:
6) Were you limited in doing either your
work or other daily activities?
7) Were you limited in pursuing your
hobbies or other leisure time activities?
8) Were you short of breath?
9) Have you had pain?
10) Did you need to rest?
11) Have you had trouble sleeping?
12) Have you felt weak?
13) Have you lacked appetite?
14) Have you felt nauseated?
15) Have you vomited?
16) Have you been constipated?
17) Have you had diarrhoea?
18) Were you tired?
19) Did pain interfere with your daily
activities?
20) Have you had difficulty in concentrating
on things, like reading a newspaper or
watching television?
Not A Quite Very






















Not A Quite Very
at all little a bit much
21) Did you feel tense?
22) Did you worry?
23) Did you feel irritable?
24) Did you feel depressed?
25) Have you had difficulty remembering
things?
26) Has your physical condition or medical
treatment interfered with your family life?
27) Has your physical condition or medical
treatment interfered with you social
activities?
28) Has your health or medical treatment caused
you financial difficulties?
For the following questions please circle the number between 1 and 7 that best
applies to you
29) How would you rate your overall health during the past week?
1 2 3 4 5 6 7
Very poor Excellent
30) How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Very poor Excellent
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
1 2 3 4
Subscales Items Subscales Items
Symptoms
Global Health status/quality 29,30 Fatigue 10,12,18
of life Nausea and Vomiting 14,15
Pain 9,19
Functional Subscales Dyspnoea 8
Physical function 1-5 Insomnia 11
Role function 6,7 Appetite loss 13
Emotional function 21-24 Constipation 16
Cognitive function 20,25 Diarrhoea 17
Social function 26,27 Financial difficulties 28
Appendices 195
6 International Prostate Symptom Score
Scores are shown in italics



















How often have you had the
sensation of not emptying 0 1 2 3 4 5
your bladder completely after
you finish urinating?
Frequency
How often have you had to
urinate again less than two 0 1 2 3 4 5
hours after you finished
urinating?
Intermittency
How often have you found
you stopped and started again
several times when you
0 1 2 3 4 5
urinated?
Urgency




How often have you had 0 1 2 3 4 5
weak stream?
Straining
How often have you had to
push or strain to begin
urination?
0 1 2 3 4 5
DURING THE PAST
None
1 2 3 4 5 times
MONTH time times times times or more
Nocturia
How many times did you
most typically get up to
urinate overnight?
0 I 2 3 4 5
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7 DSM IV Structured Clinical Interview for Major
Depression
To make a diagnosis ofMDD, five or more of the following criteria must have been
present during the same 2 week period in the past month and represent a
change from previous functioning. At least one of the five symptoms must be
either question 1 or 2 (core symptoms).
CORE SYMPTOMS
1 Depressed mood most of the day, nearly every day
as indicated either by subjective report (feels sad or Y N
empty) or observation (tearful).
2 Markedly diminished interest or pleasure in all, or
almost all activities most of the day, nearly every day, Y N
representing a significant change from previous functioning
3 Significant weight loss when not dieting, or weight
gain (a change ofmore than 5% in 1 month) OR Y N
decrease or increase in appetite nearly every day
4 Insomnia or hypersomnia nearly every day Y N
5 Psychomotor agitation or retardation nearly every
day (must be observable by others) Y N
6 Fatigue OR loss of energy nearly every day Y N
7 Feelings of worthlessness OR excessive or
inappropriate guilt nearly every day Y N
(not merely self-reproach about being sick or
low self-esteem)
8 Diminished ability to think or concentrate or Y N
indecisiveness, nearly every day
9 Recurrent thoughts of death (not just fear of dying)
Recurrent suicidal ideation without a specific plan, Y N
OR a suicide attempt or a specific plan for committing suicide
(Does not need to be present every day)
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8 Modified activity Score
Rate activity over last week. Grade maximum activity each day. Total activity
rating is sum of grade x days/7.Rating for day:
0 = MINIMAL:
1 = MINOR:
i.e. Bed bound with minimal walking
i.e. walking (indoors or out) for less than 1 hour in total
2 = MODERATE: i.e. walking (indoors or out) for 1 - 3 hours in total
3 = HEAVY: i.e. walking (indoors and out) for more than 3 hours in total
Or short period (less than 20 mins) of running / swimming /
cycling or similar vigorous exercise












9 Study A. Changes in biological measures
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non cancer brachytherapy radiotherapy androgen dep non cancer
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10 ASCO Annual Meeting June 2007 abstract
Journal ofClinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol
25, No. 18S (June 20 Supplement), 2007: 9044
Title: Clinically significant fatigue in recurrence free prostate cancer survivors
Authors: D. J. Storey, D. McLaren, M. Shipway, I. Butcher, S. Liggatt, R. O'Dea, J.
F. Smyth, M. Sharpe. University of Edinburgh Cancer Research Centre, Edinburgh,
UNITED KINGDOM.
Background
In the absence of definitive evidence of best disease control, treatment decisions for
early prostate cancer should consider likely long term side effects and quality of life.
Fatigue is an acute side effect of treatment but there are no data about long term
clinically significant fatigue (CSF) in recurrence free prostate cancer survivors. This
study presents the prevalence, associations and predictors of CSF after radical
prostatectomy (RP) or radiotherapy (XRT).
Methods
A postal questionnaire survey of 416 recurrence free men treated at a regional cancer
centre >1 year previously. CSF was defined as global Brief Fatigue Inventory score
>3. Other measures: Elospital Anxiety and Depression Scale (HADS), International
Prostate Symptom Score (IPSS), European Organisation for Research and Treatment
of Cancer Quality of Life Questionnaire, clinical and demographic information.
Relationships between these factors and CSF were explored in univariate and then
multivariate logistic regression analyses.
Results
91% (377/416) of questionnaires were analyzable. Mean age was 72 years (SD 6.1)
and median time since treatment was 56 months (range 13-233). The prevalence of
CSF was 29% (108/377) overall; 22% (29/133) post RP and 33% (79/244) post XRT.
Univariate and multivariate associations of CSF predictors are shown below. Patients
with CSF also had poorer quality of life, physical, role, and social function (all














IPSS>7 (moderate or worse










HADS anxiety >9 8(4.1,15.4) <.0001 2.9(1.3,6.6) 0.0109
HADS depression >8 18.8(8.7,40.6) <.0001 10.9(4.6,25.9) <.0001
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Conclusions
Almost a third of recurrence free prostate cancer survivors have CSF. RP is
associated with less CSF post treatment than XRT but treatment type did not remain
statistically significant in a multivariate analysis controlling for other factors.
Depression at outcome had the strongest association with CSF. Other associated
variables were IPSS>7, comorbid medical conditions and anxiety. Care should focus
on optimising the identification and management of these conditions to improve
fatigue.
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